A. E. Berezin, V. A. Vizir, O. V. Demidenko

RHEUMATOLOGY

(«Internal Medicine». Modul 2)

UDC 616-002.77(075.8)

B45

Reviewers:

V. V. Syvolap - MD, PhD, professor, head of department of propaedeutics of internal medicine, radiation diagnostics and radiation therapy, Zaporizhzhia State Medical University

O. V. Kraydashenko - MD, PhD, professor, Head of Department of Clinical Pharmacology, Pharmacy and Pharmacotherapy with the Course of Cosmetology, Zaporizhzhia State Medical University.

Author:

A. E. Berezin - MD, PhD, professor, department of internal diseases 2;

V. A. Vizir - MD, PhD, professor, department of internal diseases 2;

O. V. Demidenko -MD, PhD, head of department of internal diseases 2.

Berezin A. E.

B45   Textbook of rheumatology / A. E. Berezin, V.A. Vizir, O. V. Demidenko. – Zaporizhzhia : ZSMU, 2021. – 142 p.

The executive task force is provided for students of 5th courses of medical faculties for helping to study of some topics in the fields of rheumatology diseases incorporated into the discipline «Internal Medicine». There is the information about the most important topics regarding diagnosis of rheumatology diseases.

The textbook is addressed to students of 5th courses of medical university for helping to study of internal medicine in the field of rheumatic diseases.

UDC 616-002.77(075.8)

CONTENT

Index of abbreviations

aCL   anticardiolipin antibody
ACR   American College of Rheumatology
ADM   adenosine monophosphate
ADM   amyopathic dermatomyositis
ANA   autoantibodies to nuclear antigens
ANAs   antinuclear antibodies
ANC   absolute neutrophil count
Anti–Jo-1   antihistidyl transfer RNA [t-RNA] synthetase
anti–Scl-70   antibodies versus topoisomerase
aPL   antiphospholipid antibodies
APS   antiphospholipid syndrome
aPTT   activated partial thromboplastin time
AS   ankylosing spondylitis
AST   aspartate aminotransferase
ATP   adenosine triphosphate
BD   Behçet disease
BMI   body mass index
CASPAR   classification criteria for psoriatic arthritis
CBC   complete blood cell
CFS   cerebral spinal fluid
CHCC   Chapel Hill Consensus Conference
CHF   congestive heart failure
CK   creatine kinase
COX   cyclooxygenase
CRP   C-reactive protein
CSS   Churg-Strauss syndrome
CT   computed tomography
CTDs   connective-tissue diseases
CVA   cerebrovascular accident
CY   cyclophosphamide

DEXA   dual-energy X-ray absorptiometry
DILS   diffuse infiltrative lymphocytic syndrome
DIP   distal interphalangeal
DM   dermatomyositis
DMARD   disease-modifying antirheumatic drug
DRVVT   dilute Russell viper venom test
DVT   deep venous thrombosis
EMG   electromyelogram
ESR   erythrocyte sedimentation rate
ESR   erythrocyte sedimentation rate
FDA   Food and Drug Administration
GCs   glucocorticoids
G-CSF   granulocyte colony-stimulating factor
GERD   gastroesophageal reflux disease
GFR   glomerular filtration rate
GI   gastrointestinal
HBV   hepatis B virus
HCV   hepatitis C virus
HIV   human immunodeficiency virus
HLA   human leucocytes antigen
HSPs   heat shock proteins
IBD   inflammatory bowel disease
ICU   intensive care unit
IFN   interferon
Ig   immunoglobulin
IIM   idiopathic inflammatory myopathy
IL   interleukin
iv   intravenously

IVIG   intravenous immunoglobulin
JIA   juvenile inflammatory arthritis
LCV   leukocytoclastic vasculitis
LDH   lactic dehydrogenase
LMWH   low–molecular-weight heparin
MCP   metacarpophalangeal
MCTD   mixed connective-tissue disease
MI   myocardial infarction
MPA   microscopic polyangiitis
MRA   magnetic resonance angiography
MSAs   myositis-specific antibodies
MTP   metatarsophalangeal
MTX   methotrexate
NO   nitric oxide
NO   nitric oxide
NSAIDs non-steroid anti-imflammatory drugs
NSAIDs nonsteroidal anti-inflammatory drugs
OA   osteoarthritis
PAN   polyarteritis nodosa
p-ANCA perinuclear antineutrophil cytoplasmic antibody
PE   pulmonary embolism
PIP   proximal interphalangeal
PM   polymyositis
PMN   polymorphonuclear leukocyte
PMR   polymyalgia rheumatic
PsA   psoriatic arthritis
RA   rheumatoid arthritis
ReA   reactive arthritis
RFs   rheumatoid factors
RS   Reiter syndrome
RTA   renal tubular acidosis.
sc   subcutaneous

SEA syndrome   seronegativity, enthesopathy, and arthropathy
SLE   systemic lupus erythematosus
SpAs   spondyloarthropathies
SPECT   single-photon emission computed tomography
SS   Sjögren syndrome
SSZ   sulfasalazine
TAB   temporal artery biopsy
TIA   transient ischemic attack
TIMP   tissue inhibitors of metalloproteinases
TLR   Toll-like receptor
TNF   tumor necrosis factor
UCTD   undifferentiated connective-tissue disease
USpA   undifferentiated spondyloarthropathy
WBC   white blood cell

PART 1: ANKYLOSING SPONDYLITIS

Definition of spondyloarthropathies

The spondyloarthropathies (SpAs) are a family of related disorders that includes ankylosing spondylitis (AS), Reiter syndrome (RS), reactive arthritis (ReA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease.

Ankylosing spondylitis

Ankylosing spondylitis is the prototypical SpA and its name means "inflamed spine growing together." It has been designated by various names, including rheumatoid spondylitis in the American literature, *spondyloarthrite rhizomegalique* in the French literature, and the eponyms Marie-Strümpell disease and von Bechterew disease. The SpAs are linked by common genetics (human leukocyte antigen [HLA] class-I gene, *HLA-B27*) and a common pathology (enthesitis). Ankylosing spondylitis was the first disease to be linked with an HLA gene (1973). The first documented ankylosing spondylitis case was reported in 1691, although it may have been present in ancient Egyptians.

Pathophysiology

The SpAs are chronic inflammatory diseases involving the sacroiliac joints, axial skeleton, and to a lesser degree, peripheral joints and certain extra-articular organs, including the eyes, skin, and cardiovascular system. The etiology is unknown but involves the interaction of genetic and environmental factors.

The SpAs are associated strongly with *HLA-B27,* an HLA class-I gene. Several genotypic subtypes of *HLA-B27* are associated with the SpAs, with HLA-B*2705 having the strongest association. HLA-B*2702, *2703, *2704, and *2707 also are associated with ankylosing spondylitis. HLA-B27–restricted CD8[+] (cytotoxic) T cells may play an important role in bacterial-related SpAs such as ReA and RS.

Table 1.

Association of SpAs With *HLA-B27*

Population or Disease Entity	HLA-B27–Positive (%)
Healthy whites	8
Healthy African Americans	4
Ankylosing spondylitis (whites)	92

Ankylosing spondylitis (African Americans)	50
ReA/RS	60-80
Psoriasis associated with spondylitis	60
IBD associated with spondylitis	60
Isolated acute anterior uveitis	50
USpA	20-25

The shared amino acid sequence between the antigen-binding region of HLA-B27 and nitrogenase from *Klebsiella pneumoniae* supports molecular mimicry as a possible mechanism for the induction of SpAs in genetically susceptible hosts by an environmental stimulus, including bacteria in the gastrointestinal tract. In the presence of bacteria, *HLA-B27* transgenic rats develop an illness similar to the SpAs, with sacroiliitis, enthesitis, arthritis, skin and nail lesions, ocular involvement, and gastrointestinal tract involvement. Other genetic factors associated with ankylosing spondylitis include *HLA-B60* in both HLA-B27–positive and HLA-B27–negative individuals and *HLA-B39* in HLA-B27 negative individuals. The primary pathology of the SpAs is enthesitis with chronic inflammation, including CD4$^+$ and CD8$^+$ T lymphocytes and macrophages. Cytokines, in particular tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-b), also are important in the inflammatory process by leading to fibrosis and ossification at sites of enthesitis.

Frequency

Ankylosing spondylitis is the most prevalent of the classic SpAs. Prevalence varies with the prevalence of the *HLA-B27* gene, which increases with distance from the equator. Ankylosing spondylitis is more common in whites than in nonwhites. Prevalence is 0.1-1% of the general population, with the highest prevalence in northern European countries and the lowest in sub-Saharan Africa. Approximately 1-2% of all people who are positive for *HLA-B27* develop ankylosing spondylitis. This increases to 15-20% if they have a first-degree relative with ankylosing spondylitis. Prevalence data for undifferentiated spondylitis are scarce, although this disorder appears to be at least as common as ankylosing spondylitis, if not more so. Its actual prevalence may be as high as 1-2% of the general population. The prevalence of ankylosing spondylitis in US is 0.1-0.2% overall but is higher in certain Native American populations and lower in African Americans.

Mortality and Morbidity

The outcome in patients with SpAs, including ankylosing spondylitis, is generally good when compared to a disease such as rheumatoid arthritis. Many

patients have few, if any, symptoms. A small minority of patients with chronic progressive disease develops disability due to spinal fusion, often with thoracic kyphosis or erosive disease involving peripheral joints, especially the hips and shoulders. Patients with spinal fusion are prone to spinal fractures that may result in neurologic deficits. Most functional loss in ankylosing spondylitis occurs during the first 10 years of illness. Patients with severe long-standing ankylosing spondylitis rarely may develop significant extra-articular manifestations such as cardiovascular disease, including cardiac conduction defects and aortic regurgitation; pulmonary fibrosis; neurologic sequelae (eg, cauda equina syndrome); or amyloidosis. Patients with severe long-standing ankylosing spondylitis have increased mortality compared to the general population. USpA appears to have a good-to-excellent prognosis, although some patients have chronic symptoms associated with functional disability. Erosive arthritis is very uncommon. Uveitis occasionally occurs and may be recurrent or chronic. Patients who develop sacroiliitis and spondylitis, by definition, have ankylosing spondylitis.

Race

Prevalence of ankylosing spondylitis parallels the prevalence of *HLA-B27* in the general population. Prevalence of *HLA-B27* and ankylosing spondylitis is higher in whites and certain Native Americans when compared to African Americans, Asians, and other nonwhite ethnic groups. USpA is not associated as strongly with *HLA-B27,* although it is more prevalent in whites than in nonwhite ethnic groups.

Sex and age particularities

Ankylosing spondylitis, in general, is diagnosed more frequently in males. Females, however, may have milder or subclinical disease. The male-to-female ratio of ankylosing spondylitis is 3:1. The male-to-female ratio of USpA is 1:3. The age of onset of ankylosing spondylitis usually is from the late teens to age 40 years. Approximately 10-20% of all patients have onset of symptoms before age 16 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Age of onset of disease symptoms is 25 years in HLA-B27 positive and 28 years in HLA-B27 negative patients with a delay in diagnosis of 8.5 years in HLA-B27 positive and 11.4 years in HLA-B27 negative patients. USpA generally is found in young to middle-aged adults but can develop from late childhood into the fifth decade of life.

History of USpA

General symptoms

Symptoms include those related to inflammatory back pain, peripheral enthesitis, arthropathy, and constitutional and organ-specific extra-articular

manifestations. Because ankylosing spondylitis is a systemic inflammatory disease, systemic features are common. Morning stiffness is characteristic, and fatigue is common. Fever and weight loss may occur during periods of active disease.

Inflammatory back pain

This is the most common symptom and the first manifestation in approximately 75% of patients. Symptoms associated with an inflammatory process include insidious onset occurring over months or years, generally with at least 3 months of symptoms before presentation. Symptoms include morning stiffness lasting at least 30 minutes, improvement of symptoms with moderate physical activity, and diffuse nonspecific radiation of pain into both buttocks. Patients often experience stiffness and pain that awakens them in the early morning hours, a distinctive symptom not generally found in patients with mechanical back pain. New criteria to define inflammatory back pain have been proposed; when all features are present, they have a sensitivity of 70.3% and specificity of 81.2%. These criteria include the following:

- Morning stiffness that lasts more than 30 minutes
- Improvement of back pain with exercise but not rest
- Nocturnal back pain during second half of the night only
- Alternating buttock pain

Acute onset of pain, exacerbation of symptoms with activity, and radicular radiation of pain suggest a mechanical or degenerative process such as disc disease. The spinal disease starts in the sacroiliac joints (bilateral lumbosacral region). Most patients have mild chronic disease or intermittent flares with periods of remission. The spinal disease rarely is active persistently. Progression occurs from the lumbosacral region proximally, with ossification of the annulus fibrosus that results in fusion of the spine (bamboo spine).

Peripheral enthesitis and arthropathy

Peripheral musculoskeletal involvement occurs in 30-50% of all patients. Peripheral enthesitis is the basic pathologic process, involving inflammation at the site of insertion of ligaments and tendons on to bone. This often progresses from erosion and osteitis to ossification, resulting in telltale radiological signs of periosteal new bone formation. Sites commonly involved are the Achilles tendon insertion, the insertion of the plantar fascia on the calcaneus or the metatarsal heads, the base of the fifth metatarsal head, the tibial tuberosity, the superior and inferior poles of the patella, and the iliac crest. Other sites of involvement are the greater trochanter, ischial tuberosity, costochondral junctions, distal scapula, lateral epicondyle, and distal ulna. Enthesopathic lesions tend to be quite painful (eg, the plantar fascia when getting out of bed), especially in the morning. Some of the

peripheral arthritis occurs at sites in which the major component is local enthesitis as suggested by MRI. Joint involvement tends to occur most commonly in the hips, shoulders, and joints of the chest wall, including the acromioclavicular and sternoclavicular joints, and often occurs in the first 10 years of disease. Involvement of the hips and shoulders may result in joint damage with radiographic changes. Other peripheral joints are involved less frequently and to a milder degree, usually as an asymmetric oligoarthritis predominantly involving the lower extremities. Temporomandibular joints occasionally may be involved.

Physical examination

Articular manifestations

Spine

Stiffness of the spine and kyphosis resulting in a stooped posture are characteristic of ankylosing spondylitis at advanced stages. Earlier in the course of the disease, indirect evidence of sacroiliitis and spondylitis may be observed, including tenderness of the sacroiliac joints (elicited by either direct pressure or indirect compression) or a limited range of spine motion. Some patients may have a deformity of the spine, most commonly with a loss of lumbar lordosis and accentuated thoracic kyphosis. The range of motion of the lumbar spine can be assessed using various methods, of which the Schober test is the most popular. This test is not specific for ankylosing spondylitis. Perform the Schober test by marking a 10-cm length of the lumbar spine (with patient in the erect position), starting at the fifth lumbar spinous process. Instruct the patient to maximally flex his or her spine. Remeasure the distance between the marks. Normal flexion increases the distance by at least 5 cm. Loss of chest expansion (<3-cm difference between minimum and maximum chest diameter) usually is found only in patients with late-stage disease and, generally, is not helpful in making a diagnosis.

Peripheral entheses and joints

Peripheral enthesitis occurs in approximately 33% of patients. These lesions are painful and tender upon examination and may be associated with swelling of the tendon or ligament insertion. The most common and characteristic peripheral sites of enthesitis are the insertion of the Achilles tendon on the calcaneus and the insertion of the plantar fascia on the calcaneus. Certain anatomic areas may be more prone to enthesitis due to biomechanical stress. Carefully examine patients for tenderness upon palpation. Enthesitis and synovitis account for some of the peripheral joint involvement. Peripheral joint disease occurs in 33% of patients, most commonly in the hips. Hip involvement usually occurs in the first 10 years of the disease course and typically is bilateral. Other joints may be involved, including the shoulder girdle (glenohumeral, acromioclavicular, sternoclavicular

joints), costovertebral joints, costosternal junctions, manubriosternal joints, symphysis pubis, and temporal mandibular joints. Other peripheral joints uncommonly are involved and, if so, in an asymmetric oligoarticular pattern. Dactylitis (sausage digit) is very uncommon in patients with ankylosing spondylitis. Isolated small-joint involvement of the hands, feet, or dactylitis strongly suggests Reiter syndrome (RS), reactive arthritis (ReA), psoriatic arthritis (PsA), or undifferentiated spondyloarthropathy (USpA). Destructive arthropathy may affect the hips or shoulder girdle, which may result in limited range of motion and flexion deformities.

Extraarticular manifestations

Uveitis (also called iritis or iridocyclitis)

Uveitis is the most common extra-articular manifestation, occurring in 20-30% of patients with ankylosing spondylitis. Of all patients with acute anterior uveitis, 30-50% have or will develop ankylosing spondylitis. The incidence is much higher in individuals who are HLA-B27–positive (84-90%). Patients with uveitis may also have or develop other spondyloarthropathies (SpAs), although less commonly, including RS (5-10%), USpA (2-5%), and PsA (<1%). Isolated inflammatory bowel disease (IBD) is also associated with uveitis. The uveitis associated with ankylosing spondylitis is usually acute in presentation and unilateral, with symptoms that include a painful red eye with photophobia, increased lacrimation, and blurred vision. The involvement is usually anterior, rarely involving posterior elements. Attacks usually resolve over 2-3 months with treatment and without residual visual impairment unless treatment is inadequate or delayed. Recurrences are common. Uveitis that develops in RS is similar to the uveitis that develops in ankylosing spondylitis, while uveitis that develops in PsA and SpA associated with IBD tends to be more chronic and bilateral and often involves posterior elements.

Cardiovascular involvement

Cardiovascular involvement of clinical significance occurs in fewer than 10% of patients, typically those with severe long-standing disease. However, subclinical disease can be detected in many patients and may occur as an isolated clinical entity in association with *HLA-B27*. Aortitis of the ascending aorta may lead to distortion of the aortic ring, resulting in aortic valve insufficiency. Mitral valve insufficiency rarely occurs. Fibrosis of the conduction system may result in various degrees of atrioventricular block, including complete heart block.

Pulmonary involvement

Restrictive lung disease may occur in patients with late-stage ankylosing spondylitis, with costovertebral and costosternal involvement causing limited chest

expansion. Bilateral apical pulmonary fibrosis rarely occurs in the setting of severe disease. These lesions may cavitate and become colonized by bacteria or fungi (eg, *Aspergillus*), resulting in cough, dyspnea, and hemoptysis.

Renal involvement

Amyloidosis is a very rare complication of ankylosing spondylitis in patients with severe, active, and long-standing disease. These patients generally have active spondylitis, active peripheral joint involvement, and an elevated erythrocyte sedimentation rate (ESR) and C-reactive protein level. This may result in renal dysfunction with proteinuria and renal insufficiency or failure. Immunoglobulin A (IgA) nephropathy has been reported in association with ankylosing spondylitis.

Neurologic involvement

Neurologic complications may occur secondarily to fractures of a fused spine, which may be very difficult to detect with standard radiographs. Patients also are prone to atlantoaxial subluxation, which may result in cervical myelopathy. Cauda equina syndrome also may occur in patients with severe long-standing disease.

Gastrointestinal involvement

Asymptomatic inflammation of the proximal colon and terminal ileum has been observed in as many as 60% of patients with ankylosing spondylitis and USpA. Patients with established ankylosing spondylitis develop Crohn disease or ulcerative colitis only rarely.

Metabolic bone disease

Although ankylosing spondylitis is associated with new bone formation at sites of spinal and peripheral enthesitis, osteopenia and osteoporosis have been documented in patients with long-standing spondylitis, resulting in an increased risk of fracture. Reevaluate patients with ankylosing spondylitis who have severe spondylitis and who present with acute exacerbations of back or neck pain for possible fracture, especially in the setting of trauma. Standard radiographs may not be revealing; CT scan or MRI may be required to aid in diagnosis. Heterotopic bone formation may occur after total hip replacement.

Ankylosing spondylitis in women

Clinical ankylosing spondylitis is more common in men than in women, with a male-to-female ratio of approximately 3:1. Based on radiographic survey studies, prevalence rates of ankylosing spondylitis are approximately equal in men and women. Studies of clinical manifestations of ankylosing spondylitis in men and women show similar clinical manifestations, although men have more severe radiographic changes in the spine and hips than women.

Juvenile ankylosing spondylitis

Juvenile ankylosing spondylitis is clinically similar to adult ankylosing spondylitis. Approximately 10-20% of all cases have onset of symptoms before age 16 years. The male-to-female ratio of 3:1 is similar to that of adults. Enthesitis is prominent early in the course of the disease, while spinal symptoms and limitation of motion may not be present until several years later. Peripheral arthritis, especially in the lower extremities, and dactylitis are more common in children than in adults. Systemic manifestations (eg, fever, weight loss, anemia, leukocytosis) occur at the onset of disease in children more frequently than at the onset of disease in adults. Initial radiographs of the sacroiliac regions and spine often are normal or difficult to interpret in children. These factors make a definitive diagnosis of ankylosing spondylitis difficult in children. In such cases, the presence of *HLA-B27* would be supportive of the diagnosis of an SpA. Researchers describe a syndrome of seronegativity, enthesopathy, and arthropathy (SEA) in children that is clinically similar to USpA. These children often develop ankylosing spondylitis over time, with typical radiographic changes, usually by early adulthood. A variant, ankylosing tarsitis, is described in children who present with enthesitis in the tarsal region. This can lead to ossification, which results in a characteristic radiographic appearance. When tarsal inflammation is part of the clinical picture in a child or adult, strongly consider one of the SpAs.

Undifferentiated spondyloarthropathy

USpA is a syndrome with features consistent with the SpAs, but the patients do not fulfill criteria for any specific SpA (Table 2). USpA may represent an early phase or incomplete form of ankylosing spondylitis or another SpA. In fact, several studies of USpA included many patients who probably should have been diagnosed with ankylosing spondylitis, RS, ReA, or IBD-associated SpA, which made the clinical description very ambiguous. However, more recent data suggest that these patients may represent a distinct disease entity based on demographic and clinical criteria. Although no specific criteria are identified, using modified Amor criteria can be helpful in confirming a clinical diagnosis.

Table 2.

Diagnostic Criteria for USpA Using Modified Amor Criteria

Inclusion Criteria	Points	Exclusion Criteria
Inflammatory back pain	1	Diagnosis of specific SpA
Unilateral buttock pain	1	Sacroiliitis on radiograph ☐grade 2
Alternating buttock pain	2	Precipitating genitourinary/GI infection

Enthesitis	2	Psoriasis	
Peripheral arthritis	2	Keratoderma blennorrhagicum	
Dactylitis (sausage digit)	2	IBD (Crohn disease or ulcerative colitis)	
Acute anterior uveitis	2	Positive rheumatoid factor	
HLA-B27–positive or family history of SpA	2	Positive antinuclear antibody, titer >1:80	
Good response to nonsteroidal anti-inflammatory drugs	2		
Diagnosis of SpA with 6 or more points			

Distinguishing features of USpA

The age of onset has a very wide range, with the peak onset at approximately age 50 years. The male-to-female ratio is 1:3. The onset usually is insidious and, even after years of active disease, sacroiliitis and spondylitis are either absent or appear very mild on routine radiographs. Clinical manifestations include inflammatory back pain (90%), buttock pain (80%), enthesitis (85%), peripheral arthritis (35%), dactylitis (17%), and fatigue (55%). Extraarticular manifestations are uncommon, occurring in fewer than 10% of patients, and include acute anterior uveitis (1-2%), oral ulcers, rash, nonspecific IBD, pleuritis, and pericarditis. Laboratory studies generally are unremarkable except for the presence of an elevated ESR or C-reactive protein (36%). HLA-B27 antigen is positive only in approximately 20-25% of patients.

These factors, especially the late age of onset, female predominance, and low *HLA-B27* positivity, suggest that USpA is distinct from ankylosing spondylitis and the other classic SpAs. In addition, when these patients are observed over long periods, they rarely develop clinical manifestations or radiographic changes that result in a change of diagnosis. Occasionally, radiographs show evidence of periosteal new bone formation at sites of enthesitis, especially at the insertion of the Achilles tendon or plantar fascia on the calcaneus, or early syndesmophytes on the lumbar spine without bridging.

Table 3.

Clinical and Laboratory Features of USpA

Clinical Feature of USpA	Frequency (%)
Inflammatory back pain	90
Unilateral buttock pain	80
Fatigue	55
Enthesitis	75

Peripheral arthritis	40
Dactylitis (sausage digit)	20
Acute anterior uveitis	1-2
HLA-B27–positive or family history of SpA	25
Elevated ESR	32

Although most patients with USpA have chronic, active disease and require long-term therapy, some patients with USpA have mild and intermittent symptoms that require intermittent symptomatic therapy. These episodes may last from 1-2 weeks to several months, with long asymptomatic periods that do not require therapy. Most patients (>75%) require long-term therapy for ongoing symptomatic disease. Most patients respond well to nonsteroidal anti-inflammatory drugs (NSAIDs). Most patients maintain good function without progressive disease or clinically significant radiographic changes. A small minority of patients does not respond well to or tolerate NSAIDs. In these patients, treatment progression is similar to patients with ankylosing spondylitis, including the use of sulfasalazine, methotrexate, and TNF-a, although no well-designed clinical trials have been conducted on the treatment of USpA.

The main causes of USpA

The cause of ankylosing spondylitis is unknown, but a combination of genetic and environmental factors work in concert to produce clinical disease.

Genetic predisposition

The strong association of ankylosing spondylitis with *HLA-B27* and a lesser association with *HLA-B60* and *HLA-B39* is direct evidence of the importance of genetic predisposition. The shared amino acid sequence between several *HLA-B27* genotypic subtypes and K. pneumoniae nitrogenase, especially HLA-B*2705, suggests a link between these enteric bacteria and the induction of ankylosing spondylitis that has yet to be proven. People who are homozygous for HLA-B27 are at an increased risk for ankylosing spondylitis compared with those who are heterozygous. The amino acid sequence of the *HLA-B27* molecule is located in the antigen-binding region. Thus, molecular mimicry may be the mechanism by which an environmental trigger (eg, Klebsiella) initiates immunologic and then pathologic changes in a genetically predisposed individual.

Immunologic mechanisms

Another possible mechanism in the induction of ankylosing spondylitis is presentation of an arthritogenic peptide from enteric bacteria by specific HLA molecules. Many patients with ankylosing spondylitis have subclinical gastrointestinal tract inflammation and elevated IgA antibodies directed against

Klebsiella. The bacteria may invade the gastrointestinal tract of a genetically susceptible host, leading to chronic inflammation and increased permeability. Over time, bacterial antigens containing arthritogenic peptides enter the organism via the blood stream. Localization of pathology to certain types of connective tissues (eg, entheses) may be explained by affinity of bacterial antigens to these specific sites. Biomechanical stress, such as that which occurs at entheses in the spine and feet, may predispose to clinical enthesitis at these sites. The SpAs are the only known autoimmune diseases linked to a class-I and not a class-II HLA marker. The cytotoxic $CD8^+$ T-cell response appears to be important; it would respond to antigen presented by HLA class-I molecules on the surface of cells. The association of SpAs (eg, RS) with HIV infection in certain areas of the world supports the relative importance of the $CD8^+$ cytotoxic T-cell responses compared to the $CD4^+$ helper cells in these conditions.

Environmental factors

Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) mostly affects the spine. It can cause damage visible on X-ray (ankylosing spondylitis) or damage that doesn't show up on X-rays (nonradiographic axSpA).

There are two types of axSpA:

- Radiographic axSpA (also called ankylosing spondylitis or AS) includes damage to the sacroiliac joints and spine that can be seen on X-rays.
- Nonradiographic axSpA (nr-axSpA) does not include damage you can see on X-rays but it may show up on magnetic resonance images (MRIs).

The disease can occur at any age, but typically begins between ages 20 and 40. AS is more common in men than in women. However, nr-axSpA may be just as common in women as in men. It is less common among African Americans than people of other racial backgrounds.

Causes of axSpA

The exact cause of axSpA is not clear. Researchers believe that people with certain genes develop axSpA when they are exposed to a virus, bacteria or another trigger. Many people with axSpA have a gene called HLA-B27. But most people that have the gene never develop axSpA

Ankylosing spondylitis does not develop in every person who is HLA-B27–positive, indicating that environmental factors are important. Even first-degree relatives who are HLA-B27–positive do not uniformly develop the disease. In fact,

only 15-20% of such individuals develop the disease. HLA-B27–positive transgenic rats develop an illness similar to a SpA, with manifestations that include sacroiliitis, enthesitis, arthritis, skin and nail lesions, ocular inflammation, cardiac inflammation, and inflammation of the gastrointestinal and male genitourinary tracts. The severity of the clinical disease correlates with the number of copies of HLA-B27 expressed in the transgenic animal. If these HLA-B27–positive transgenic rats are raised in a germ-free environment, they do not develop clinical disease. Once introduced into a regular environment (ie, non–germ-free) and exposed to bacteria, the rats develop clinical manifestations of SpA.

Symptoms of axSpA

Low back, buttocks and hip pain are usually the first symptoms. Children, however, may have pain in the hips, knees or heels before the back. Symptoms of axSpA may include the following:

- Pain in the low back, buttocks and hips that develops slowly over weeks or months.
- Pain, swelling, redness and warmth in the toes, heels, ankles, knees, rib cage, upper spine, shoulders and neck.
- Stiffness when first waking up or after long periods of rest.
- Back pain during the night or early morning.
- Fatigue.
- Appetite loss.

Health Effects

Joints. Over time, the joints and bones of the spine may grow together (fuse). This usually happens at the base of the spine first. This causes the back to become stiff and hard to move. The rib cage may also fuse, making chest expansion difficult.

Eyes. Chronic eye inflammation (uveitis) causes dryness, pain, redness, sensitivity to light and vision problems. The white part of the eye may also get inflamed and red (called scleritis).

Digestive Tract. Inflammation may cause abdominal pain and diarrhea.

Heart. Though uncommon, inflammation may affect the largest artery that leads to the heart (aorta). People with axSpA also have an increased risk for heart attack and stroke.

Lungs. Complications affecting the lungs are rare. Inflammation may cause shortness of breath and impaired lung function

Diagnosis of axSpA

It's important to see a doctor early to get an accurate diagnosis. A primary care doctor may be the first person to assess your joint pain. A doctor that specializes in

arthritis (a rheumatologist) should be seen if axSpA is suspected. There is no single test to diagnose axSpA. The doctor will talk with you, perform a physical exam and order a few tests to rule out other causes of back and hip pain.

- Medical history.
  The doctor will ask about symptoms, when they started, if they come and go, current medical conditions, medication use and whether family members have arthritis.
- Physical examination.
  The doctor will look for signs of tenderness, swelling and pain in your spine, pelvis and hips. They will watch how your joints move and may check your eyes.
- Blood tests.
  The doctor may order a test for the HLA-B27 gene. Having this gene doesn't mean you have axSpA, but it can help with diagnosis. Other tests will check for body-wide inflammation.
- Imaging tests.
  The doctor may order X-rays, ultrasound, MRI or CT scans of the pelvis and spine to look for damage.

Lab Studies

No laboratory tests are specific for ankylosing spondylitis. The diagnosis is made by combining clinical criteria of inflammatory back pain and enthesitis or arthritis with radiological findings. Two sets of criteria, which are sensitive and specific, are available for diagnosis of spondyloarthropathies (SpAs) in general: the European Spondyloarthropathy Study Group (ESSG) criteria (Table 4) and the Amor criteria (Table 2). New York and Rome criteria (Table 5) are used widely for the diagnosis of ankylosing spondylitis. Approximately 15% of patients may present with a normochromic normocytic anemia of chronic disease. The ESR or C-reactive protein level is elevated in 75% of patients and may correlate with disease activity in some, but not all, patients.

Table 4

SpA Criteria

ESSG Criteria	Amor Criteria	Points
Inflammatory spinal pain or synovitis and one of the following:	Inflammatory back pain	1
Alternating buttock pain	Unilateral buttock pain	1
Enthesitis	Alternating buttock pain	2
Sacroiliitis	Enthesitis	2
IBD	Peripheral arthritis	2

Positive family history of SpA	Dactylitis (sausage digit)	2
	Acute anterior uveitis	2
	HLA-B27–positive or family history of SpA	2
	Good response to NSAIDs	2

Note: IBD - Inflammatory bowel disease

Alkaline phosphatase is elevated in 50% of patients, which indicates active ossification but does not correlate with disease activity. Creatine kinase (CK) occasionally is elevated but is not associated with muscle weakness. The serum IgA level may be elevated, correlating with elevated acute phase reactants.

HLA-B27

HLA-B27 positivity is present in 92% of white patients with ankylosing spondylitis and is present less commonly in patients of other ethnicities. Determining *HLA-B27* status is not a necessary part of the clinical evaluation. In patients suspected of having a SpA, determining *HLA-B27* status may help support the diagnosis, especially in populations with a low prevalence of HLA-B27.

Table 5.
Criteria for Diagnosis of Ankylosing Spondylitis

New York Criteria (1984)	Rome Criteria (1961)
Low back pain with inflammatory characteristics	Low back pain and stiffness for >3 months that is not relieved by rest
Limitation of lumbar spine motion in sagittal and frontal planes	Pain and stiffness in the thoracic region
Decreased chest expansion	Limited motion in the lumbar spine
Bilateral sacroiliitis grade 2 or higher	Limited chest expansion
Unilateral sacroiliitis grade 3 or higher	History of uveitis
Definite ankylosing spondylitis when the fourth or fifth criterion mentioned presents with any clinical criteria	Diagnosis of ankylosing spondylitis when any clinical criteria present with bilateral sacroiliitis grade 2 or higher

Imaging Studies

Standard radiographs

Radiographic studies are most helpful in establishing a diagnosis. In ankylosing spondylitis, sacroiliitis is usually bilateral, symmetric, and gradually progressive over years. The lesions progress from blurring of the subchondral bone plate to irregular erosions of the margins of the sacroiliac joints (pseudowidening) to sclerosis, narrowing, and finally, fusion. Erosions of the subchondral bone of the sacroiliac joint generally are seen earlier in the lower portion of the joint (because

this portion is lined by synovium) and on the iliac side (due to the thinner cartilage covering this side of the joint). The spondylitis of ankylosing spondylitis starts in the lumbar or thoracolumbar spine and progresses proximally in a continuous fashion. The radiographic signs of ankylosing spondylitis are due to enthesitis, particularly of the annulus fibrosus. Early radiographic signs include squaring of the vertebral bodies caused by erosions of the superior and inferior margins of these bodies, resulting in loss of the normal concave contour of the anterior surface of the vertebral bodies. The inflammatory lesions at vertebral entheses may result in sclerosis of the superior and inferior margins of the vertebral bodies, called shiny corners (Romanus lesion). Ossification of the annulus fibrosus leads to the radiographic appearance of syndesmophytes, which, in ankylosing spondylitis, typically are marginal. Over time, development of continuous (bridging) syndesmophytes may result in a bamboo spine, which, essentially, is fused (Fig.1).

Figura 1

Radiograph of the lumbar spine of a patient with end-stage ankylosing spondylitis, associated with syndesmophytes, resulting in bamboo spine

Spinal disease associated with IBD is similar to ankylosing spondylitis with bilateral symmetric sacroiliitis and gradually ascending spondylitis and marginal syndesmophytes (Fig. 2). On the other hand, RS and PsA typically exhibit asymmetric sacroiliitis and discontinuous spondylitis with nonmarginal syndesmophytes.

Figura 2.
Radiograph of the cervical spine of a patient with ankylosing spondylitis. Fusion of vertebral bodies due to bridging syndesmophytes.

Radiographs of other areas may show evidence of enthesitis with osteitis or arthropathy. Radiographs of the pelvis may show ossification of various entheses, such as the iliac crest, ischial tuberosity, and femoral trochanter, which is termed whiskering (Fig.3).

Figura 3. Radiographs of the pelvis. Ossification of various entheses, such as the iliac crest, ischial tuberosity, and femoral trochanter

Occasionally, the symphysis pubis develops erosive changes (osteitis pubis). Peripheral entheses may develop radiographic changes, including erosion, periosteal new bone formation, and finally, ossification, especially in the feet at the insertion of the Achilles tendon and the plantar fascia on the calcaneus. Peripheral joint involvement is most common in the hips and shoulders and may result in uniform joint-space narrowing, cystic or erosive changes, and subchondral sclerosis without osteopenia. Heterotopic bone formation may occur after total joint replacement, especially in the hip. Ultimately, peripheral joints may undergo ankylosis.

Magnetic resonance imaging and computed tomography scan

Due to the insensitivity of standard radiographs in the clinical setting of acute back pain in advanced ankylosing spondylitis, an MRI and a CT scan may be useful in making the diagnosis of a spinal fracture in patients with late-stage spinal disease. MRI or CT scan of the sacroiliac and peripheral joints may reveal evidence of early sacroiliitis, erosions, and enthesitis that are not apparent on standard radiographs. MRI using fat-saturating techniques such as short tau inversion recovery (STIR) or MRI with gadolinium are sensitive for inflammatory lesions of enthesitis. However, they are not part of the routine evaluation of patients due to the expense of these studies.


Figura 4.

Magnetic resonance imaging shows increased sinal intensity in the right sacroiliac joint, revealing sacroiliitis.

Histologic Findings

Histopathologic evaluation generally is not part of the diagnostic workup of patients with ankylosing spondylitis. The basic pathologic lesion is inflammation at the enthesis (enthesitis), which occurs at the site of insertion of ligaments and tendons into bone. The histologic picture is that of chronic inflammation with $CD4^+$ and $CD8^+$ T lymphocytes and macrophages. Over time, fibrosis and ossification occur, which can be seen radiographically as periostitis and ossification at sites of enthesitis, particularly the sacroiliac joints, spine, and heels.

Quality of life assessment

Ankylosing spondylitis is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). Disease activity is one of the most powerful predictors of QoL, however latest advances in pharmacological treatment (namely, anti-TNF-α) along with physical exercise can minimize the effects of SpA on QoL. Psychological distress symptoms contribute to impaired QoL both directly and indirectly by influencing disease activity. The impact of other psychosocial variables, however, is less studied and more

prospective investigations are necessary, which could eventually lead to the development of psychosocial interventions that are personalized to this patient population.

There are some scores with high validity of the quality of life assessement, i.e. Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and patient global visual analogue scale (VAS) scores.

Medical Care

Treatment of ankylosing spondylitis is divided into medical care, physical therapy, and surgical care. The goal of pharmacotherapy is to reduce morbidity and prevent complications.Patient education is important in the management of any chronic disease so that the patient is familiar with the symptoms, course, and treatment of the disease. No drugs have been proven to modify the course of the disease, although TNF-alpha antagonists have potential as disease-modifying agents (see additional materials).

Nonsteroidal anti-inflammatory drugs

NSAIDs improve the symptoms of the disease. Indomethacin may be more effective than other NSAIDs, although this has not been proven. Salicylates seldom give adequate relief. Cyclooxygenase-2 (COX-2) inhibitors appear to be as effective as nonselective NSAIDs. Give NSAIDs in full anti-inflammatory doses. Continuous treatment with NSAIDs appears to reduce radiographic progression in ankylosing spondylitis. Common toxicities involve the gastrointestinal (nausea, dyspepsia, ulceration, bleeding), renal, and central nervous systems.

Sulfasalazine

Sulfasalazine is often used in the treatment of ankylosing spondylitis and other spondyloarthropathies (SpAs), especially for peripheral joint involvement, for which it has demonstrated efficacy. Sulfasalazine has been shown to be effective in ankylosing spondylitis, particularly in reducing spinal stiffness, peripheral arthritis, and reducing the ESR, but no evidence shows that spinal mobility, enthesitis, or physical function is benefited. Toxicities include rash, nausea, diarrhea, and agranulocytosis (rarely).

Corticosteroids

Oral corticosteroids occasionally are helpful in controlling symptoms; however, use them only for short-term management. No evidence exists that corticosteroids alter the outcome of the disease, and they increase the tendency towards spinal osteoporosis. Local corticosteroid injections are useful for

symptomatic sacroiliitis, peripheral enthesitis, and arthritis, although the response typically is not as rapid as in patients with rheumatoid arthritis.

Treatment of extra-articular manifestations

Treat extra-articular manifestations as dictated by the clinical setting. Acute anterior uveitis presents as a painful, red eye that is associated with photophobia and often recurs. Untreated uveitis may lead to vision loss. Evaluation and treatment of uveitis should be delivered under the guidance of an ophthalmologist. Generally, patients respond well to topical corticosteroids, mydriatics, and artificial tears, with resolution of the attack over 2-3 months. Treatment may occasionally require topical NSAIDs, retrobulbar corticosteroid injections, or immunosuppressive drugs. TNF-alpha antagonists may be helpful in selected cases.

Disease-modifying anti-rheumatic drugs (DMARDs)

Conventional xenobiotic DMARDs are not usually used in people with axSpA that affects just the back, while they can be helpful in the treatment of ankylosing spondylitis, including methotrexate, azathioprine, cyclophosphamide, and cyclosporine. Methotrexate may have some benefit in ankylosing spondylitis, although various studies have shown conflicting results. Sulfasalazine, however, may be used for joints other than those in the back and pelvis.

Biological-active drugs

A type of DMARD, biologics target certain proteins and processes in the body to control disease. Biologics are self-injected or given by infusion at a doctor's office. The ones that work best for axSpA are tumor necrosis factor (TNF) inhibitors and interleukin (IL-17) inhibitors. The TNF-alpha antagonists have been shown to be effective in the treatment of ankylosing spondylitis, and etanercept, infliximab, and adalimumab are approved therapies. The TNF- alpha antagonists are biologic agents and include etanercept (fusion protein of the extracellular portion of the p75 TNF- alpha receptor and Fc portion of IgG), infliximab (chimeric anti–TNF-alpha monoclonal antibody [mab]), and adalimumab (humanized TNF- alpha mab). These agents inhibit TNF- alpha and have been shown to improve symptoms and function in patients with ankylosing spondylitis in clinical trials. All have been approved for the treatment of ankylosing spondylitis. These agents are also all approved for the treatment of rheumatoid arthritis (RA) and PsA (see additional materials). These agents are very effective with fairly rapid onset of action (2 weeks) and have been shown to reduce inflammatory activity of spinal disease as assessed with MRI. Anakinra, a recombinant human interleukin 1 (IL-1) receptor antagonist, may be effective in treatment-resistant ankylosing spondylitis.

Bisphosphonates

Bisphosphonates may modestly affect clinical disease activity in ankylosing spondylitis.

Surgical Care

Surgery occasionally is useful to correct spinal deformities or repair damaged peripheral joints. Vertebral osteotomy may be performed to correct spinal deformities, but significant morbidity is related to neurologic complications of this procedure. This procedure should be performed only by surgeons specializing in spine surgery who have experience with this procedure, as the risk of major neurologic morbidity is significant. Patients may need total hip replacement and, occasionally, total shoulder replacement. These procedures may be very useful to reduce pain and improve function when the hip and shoulder joints become severely damaged. Heterotopic bone formation may occur after total joint replacement, especially around the hip. Heterotopic bone formation can be reduced by using postoperative NSAIDs (eg, diclophenac, ibupropfen). In general, outcomes of total joint replacement in patients have been satisfactory.

Consultations

- Rheumatologist
- Physical medicine and rehabilitation specialist
- Orthopedic surgeon
- Neurosurgeon

Diet and physical therapy

No special diet is required. Physical therapy, including an exercise program and postural training, is important to maintain function. Spinal extension and deep-breathing exercises help maintain spinal mobility, encourage erect posture, and promote chest expansion. Maintaining an erect posture during daily activities and sleeping on a firm mattress with a thin pillow also tend to reduce the tendency towards thoracic kyphosis. Water therapy and swimming are excellent activities to maintain mobility and fitness.

Complications

Complications may occur from spinal and articular disease or extra-articular manifestations. A small minority of patients develop spinal fusion, which may result in severe kyphosis and limited motion of the spine, including the cervical region. The fused spine is more susceptible to fracture, even with relatively minor trauma. Occasionally, the hip and shoulder joints develop severe arthropathy, requiring total joint replacement. Extraarticular manifestations (eg, recurrent uveitis, cardiovascular involvement, pulmonary involvement, amyloidosis) rarely result in significant morbidity or mortality.

Prognosis for ankylosing spondylitis

Prognosis generally is good for ankylosing spondylitis and undifferentiated spondyloarthropathy (USpA). Patients often require long-term anti-inflammatory therapy. Morbidity can occur related to spinal and peripheral joint involvement or, rarely, extra-articular manifestations. Poor prognostic indicators include peripheral joint involvement, young age of onset, elevated ESR, and poor response to NSAIDs. Mortality is increased in patients with ankylosing spondylitis who have severe long-standing disease and significant extra-articular manifestations.

Patient Education with ankylosing spondylitis

Teach patients about the long-term nature of the illness, the use and toxicities of medications, and the importance of a well-balanced exercise program. Because of the joint involvement in the chest wall and the potential for pulmonary complications, include smoking cessation in recommendations.

PART 2: PSORIATIC ARTHRITIS

In 1964, the American Rheumatism Association listed psoriatic arthritis as a clinical entity. However, diagnostic criteria have not been agreed on, and several proposed definitions have stressed separate features of this multifaceted disease. The high frequency of distal joint involvement in psoriatic arthritis compared with rheumatoid arthritis (RA) and arthritis mutilans (as an unusual but characteristic manifestation) has received special attention. The great variety of clinical manifestations was framed in the definition suggested by Moll and Wright in 1973, ie, "An inflammatory arthritis associated with psoriasis, usually with a negative sheep cell agglutination (SCA) test, ie, rheumatoid factor." Other more detailed criteria have been suggested. Psoriatic arthritis, a term used by the American Rheumatism Association, is widely accepted.

Pathophysiology

Psoriatic arthritis is an autoimmune disease with known human leukocyte antigen (HLA)–associated risk factors. Psoriatic arthritis affects the ligaments, tendons, fascia, and joints and occasionally develops in the absence of detectable psoriasis. Psoriatic arthritis may occur at higher frequencies when skin involvement is more severe, especially when pustular psoriasis is present; however, recent studies suggest that this may not be valid.

Frequency

Estimated rates of the frequency of psoriatic arthritis in persons with all types of psoriasis vary widely according to the nature of the diagnostic criteria and ascertainment used, but most fall into the range of 5-8%. Considering the rate of

psoriasis to be 1-3%, the rate of psoriatic arthritis in the general white population ranges from 0.05-0.24%, a value approaching half that for seropositive RA. Psoriasis affects 2.5% of the white population of North America but is less prevalent in the African American and Native American populations. Psoriatic arthritis affects 5-8% of patients with psoriasis. Recent survey results indicate approximately 1 million US adults have psoriatic arthritis. This figure is significantly higher than researchers had previously believed and suggests many people with psoriasis, a related skin disease, may not be aware that they have psoriatic arthritis.

Mortality and Morbidity

The course of psoriatic arthritis is usually characterized by flares and remissions. Arthritis mutilans is recognized as a typical but unusual form of psoriatic arthritis. Earlier studies have reported that psoriatic arthritis results in joint destruction and severe disability in a large proportion of patients. Of patients observed in a large outpatient psoriatic arthritis clinic, 7% required musculoskeletal surgery.

Race, sex and age particularities

Psoriatic arthritis is more common in white persons than in persons of other races. Men and women are affected equally; however, if the subsets of psoriatic arthritis are considered, male predominance occurs in the spondylitic form, whereas female predominance occurs in the rheumatoid form. Psoriatic arthritis characteristically develops in persons aged 35-55 years, but it can occur in persons of almost any age.

History of Psoriatic arthritis

Psoriatic arthritis may be present with or without obvious skin lesions, with minimal skin involvement (eg, scalp, umbilicus, intergluteal cleft), or with only nail malformations. Psoriasis usually precedes arthritis (occasionally by as many as 20 y); however, in as many as 15-20% of patients, arthritis appears before the psoriasis. If the latter is the case, a family history of psoriasis may reveal a hereditary pattern. Initial symptoms may be acute. When localized to the foot or toe, symptoms may be mistaken for gout. Alternatively, patients may experience only stiffness and pain with few objective findings.

The following list details the 5 patterns of psoriatic arthritis involvement:
- Asymmetrical oligoarticular arthritis
  - Until recently, this was thought to be the most common type.
  - Usually, the digits of the hands and feet are affected first, with inflammation of the flexor tendon and synovium occurring

simultaneously, leading to the typical "sausage" appearance (dactylitis).
- Usually, fewer than 5 joints are affected at any one time.

- Symmetrical polyarthritis
  - Recently, this rheumatoidlike pattern has been recognized as one of the most common types. The hands, wrists, ankles, and feet may be involved.
  - It is differentiated from rheumatoid arthritis (RA) by the presence of distal interphalangeal (DIP) joint involvement, the relative asymmetry, the absence of subcutaneous nodules, and a negative test result for rheumatoid factor (RF). This condition generally is milder than RA, with less deformity.

- Distal interphalangeal arthropathy
  - Although DIP joint involvement is considered classic and unique to psoriatic arthritis, it occurs in only 5-10% of patients, primarily men.
  - Involvement of the nail with significant inflammation of the paronychia and swelling of the digital tuft may be prominent, occasionally making appreciation of the arthropathy more difficult.

- Arthritis mutilans
  - Resorption of bone (osteolysis) with dissolution of the joint, observed as the "pencil-in-cup" radiographic finding, leads to redundant overlying skin with a telescoping motion of the digit.
  - This "opera-glass hand" is more common in men than in women and is more frequent in early-onset disease.

- Spondylitis with or without sacroiliitis
  - This occurs in approximately 5% of patients with psoriatic arthritis and has a male predominance.
  - Clinical evidence of spondylitis, sacroiliitis, or both can occur in conjunction with other subgroups of psoriatic arthritis.
  - Spondylitis may occur without radiologic evidence of sacroiliitis, which frequently tends to be asymmetric, or it may appear radiologically without the classic symptoms of morning stiffness in the lower back. Thus, the correlation between symptoms and radiologic signs of sacroiliitis can be poor.

- Vertebral involvement differs from that observed in ankylosing spondylitis. Vertebrae are affected asymmetrically, and the atlantoaxial joint may be involved with erosion of the odontoid and subluxation.
- Unusual radiologic features may be present, such as nonmarginal asymmetric syndesmophytes (characteristic), paravertebral ossification, and, less commonly, vertebral fusion with disk calcification.

- Juvenile psoriatic arthritis
  - Juvenile psoriatic arthritis accounts for 8-20% of childhood arthritis and is monoarticular at onset.
  - The mean age of onset is 9-10 years, with a female predominance. The disease is usually mild, although occasionally it may be severe and destructive, progressing into adulthood.
  - In 50% of children, the arthritis is monoarticular; DIP joint involvement occurs at a similar rate.
  - Tenosynovitis is present in 30% of children, and nail involvement is present in 71%, with pitting being the most common but least specific finding.
  - In 47% of children, disordered bone growth with resultant shortening may result from involvement of the unfused epiphyseal growth plate by the inflammatory process.
  - Sacroiliitis occurs in 28% of children and is usually associated with HLA-B27 positivity.
  - Although the presence of HLA-B8 may be a marker of more severe disease, HLA-B17 is usually associated with a mild form of psoriatic arthritis.
  - Children have a higher frequency of simultaneous onset of psoriasis and arthritis than adults, with arthritis preceding psoriasis in 52% of children.

Physical

Recognition of the patterns of joint involvement is essential to the diagnosis of psoriatic arthritis.
- Recently, the possibility that less joint tenderness occurs with psoriatic arthritis than with RA has been emphasized.

- The condition termed enthesopathy or enthesitis, reflecting inflammation at tendon or ligament insertions into bone, may be seen in psoriatic arthritis as in other spondyloarthropathies. This is observed more often at the attachment of the Achilles tendon and the plantar fascia to the calcaneus with the development of insertional spurs.
- Dactylitis with sausage digits is seen in as many as 35% of patients.
- Skin involvement includes the following:
    - Arthritis generally is not considered to correlate strongly to any particular type of psoriasis or to the severity of the skin disease. However, in one study, arthritis was noted more frequently in patients with severe skin disease, whereas in another, pustular psoriasis was associated with more severe psoriatic arthritis.
    - In patients presenting with an undefined seronegative polyarthritis, looking for psoriasis in hidden sites such as the scalp (where psoriasis frequently is mistaken for dandruff), perineum, intergluteal cleft, and umbilicus is extremely important.
    - A diagnosis of psoriatic arthritis may be missed because of an inadequate physical examination.

- Nail involvement includes the following:
    - Onycholysis, transverse ridging, and uniform nail pitting are 3 features of nail involvement that should be noted. A direct correlation exists between the number of pits and the diagnostic significance. When skin and joint disease begin simultaneously, nail involvement is frequently present at the onset.
    - Involvement of DIP joints correlates moderately well with psoriasis in adjacent nails, although this is not an invariable association.
    - Nails are involved in 80% of patients with psoriatic arthritis but in only 20% of patients with uncomplicated psoriasis.
    - Severe deforming arthritis of the hands and feet is frequently associated with extensive nail involvement.
    - Fungal infection of the nails is the main consideration in the differential diagnosis in a patient with a seronegative polyarthritis.

- Extra-articular features include the following:
    - Extra-articular features are observed less frequently in patients with psoriatic arthritis than in those with RA. Patients with psoriatic arthritis have a predilection for synovitis to affect flexor tendon

sheaths with sparing of the extensor tendon sheath; both are commonly involved in persons with RA. Subcutaneous nodules are rare in patients with psoriatic arthritis. If nodules are present in a patient who has psoriasis and arthritis, particularly if the RF titer is positive, they suggest the coincidental occurrence of psoriasis and RA.

- Ocular involvement may occur in 30% of patients with psoriatic arthritis, including conjunctivitis in 20% and acute anterior uveitis in 7%. In patients with uveitis, 43% have sacroiliitis and 40% are HLA-B27–positive. Scleritis and keratoconjunctivitis sicca are rare.
- Inflammation of the aortic valve root, which may lead to insufficiency, has been described in 6 patients with psoriatic arthritis and is similar to that observed more frequently in persons with ankylosing spondylitis or Reiter syndrome. Occasionally, patients may develop secondary amyloidosis.

- A large international study group recently developed a simple and highly specific classification known as CASPAR (classification criteria for psoriatic arthritis). These criteria were more specific (98.7% vs 96%) but less sensitive (91.4% vs 97.2%) than those of Vasey and Espinoza classification. The CASPAR criteria consist of established inflammatory articular disease with at least 3 points from the following features:
  o Current psoriasis (assigned a score of 2)
  o A history of psoriasis (in the absence of current psoriasis; assigned a score of 1)
  o A family history of psoriasis (in the absence of current psoriasis and history of psoriasis; assigned a score of 1)
  o Dactylitis (assigned a score of 1)
  o Juxtaarticular new-bone formation (assigned a score of 1)
  o RF negativity (assigned a score of 1)
  o Nail dystrophy (assigned a score of 1)

Causes

The pathogenesis of psoriatic arthritis remains unknown, but much information has been gathered. In addition to the genetic influences, environmental and immunological factors are thought to be prominent in the development and perpetuation of the disease. The de novo development or exacerbation of psoriasis and psoriatic arthritis in patients with human immunodeficiency virus (HIV) infection and CD4 deficiency remains controversial.

Psoriasis may remit following allogeneic bone marrow transplantation and may exacerbate with interferon-alfa treatment for hepatitis C.

- Genetics
    - Approximately 40% of patients with psoriasis or psoriatic arthritis have a family history of these disorders in first-degree relatives. The exact mechanism of the association between HLA and psoriatic arthritis is not clear.
    - Twin studies indicate a concordance rate among monozygotic twins of 35-70%, compared with 12-20% for dizygotic twins.
    - HLA-B17, -Cw6, -DR4, and -DR7 are found to occur with increased frequency in persons with either psoriasis or psoriatic arthritis when compared with the general population. The HLA-Cw*0602 variant is particularly associated with an early age of onset of psoriasis.
    - Psoriatic arthritis is associated with an increased frequency of HLA-B7 and HLA-B27 and a lower frequency of HLA-DR7 and HLA-Cw7.
    - HLA-B27 in the presence of HLA-DR7, HLA-DQ3 in the absence of HLA-DR7, and HLA-B39 are predictors for disease progression, whereas HLA-B22 is protective.
    - Additional loci that demonstrate association with psoriatic arthritis include the *MICA* (class I MHC chain-related) gene and microsatellite polymorphisms in the tumor necrosis factor (TNF) promoter.
    - In psoriasis, linkages with loci on 17q, 4q, and 6p have been reported in whole genome scans, with the strongest evidence for linkage on 6p.

- Immunologic factors
    - Certain immunoglobulin genes have also been suggested to be associated with psoriatic arthritis. Serum levels of immunoglobulin A and immunoglobulin G are higher in psoriatic arthritis patients, whereas immunoglobulin M levels may be normal or diminished.
    - Autoantibodies against nuclear antigens, cytokeratins, epidermal keratins, and heat-shock proteins have been reported in persons with psoriatic arthritis, indicating a humoral immune component of the disease.
    - The pathologic process of skin and joint lesions in psoriatic arthritis is an inflammatory reaction, and evidence also indicates autoimmunity, perhaps mediated by complement activation. The inflammatory nature of the skin and joint lesions in psoriatic arthritis is demonstrated by

synovial-lining cell hyperplasia and mononuclear infiltration, resembling the histopathologic changes of RA. However, synovial-lining hyperplasia is less, macrophages are fewer, and vascularity is greater in psoriatic arthritis compared with RA synovium.

- o The cytokine profile for psoriatic arthritis reflects a complex interplay between T cells and monocyte macrophages. Type 1 helper T–cell cytokines (eg, TNF-alpha, interleukin [IL]–1 beta, IL-10) are more prevalent in psoriatic arthritis than in RA, suggesting that these 2 disorders may result from a different underlying mechanism.

- o Several studies have shown a significant reduction in the number and percentage of CD4$^+$ T cells in the peripheral blood, whereas they are found throughout the skin lesions and synovium.

- o Dendritic cells have been found in the synovial fluid of patients with psoriatic arthritis and are reactive in the mixed leukocyte reaction; the inference is that the dendritic cells present an unknown antigen to CD4$^+$ cells within the joints and skin of patients with psoriatic arthritis, leading to T-cell activation.

- o Fibroblasts from the skin and synovia of patients with psoriatic arthritis have an increased proliferative activity and the capability to secrete increased amounts of IL-1, IL-6, and platelet-derived growth factors. Several studies suggest that cytokines secreted from activated T cells and other mononuclear proinflammatory cells induce proliferation and activation of synovial and epidermal fibroblasts.

- o Psoriatic plaques in skin have increased levels of leukotriene B4. Injections of leukotriene B4 cause intraepidermal microabscesses, suggesting a role for this compound in the development of psoriasis.

- Infections
  - o The temporal relationship between certain viral or bacterial infections and the development or exacerbation of psoriasis or psoriatic arthritis suggests a possible pathogenetic role for these organisms.
  - o Pustular psoriasis is a well-described sequela of streptococcal infections. However, the response to streptococcal antigens by cells from patients with psoriatic arthritis is not different from that of cells from patients with RA, making the role of Streptococcus species in psoriatic arthritis doubtful.
  - o Psoriasis and psoriatic arthritis have been reported to be associated with HIV infection and to be prevalent in some HIV-endemic areas.

Although the prevalence of psoriasis in patients infected with HIV is similar to that in the general population, patients with HIV infection usually have more extensive erythrodermic psoriasis and patients with psoriasis may present with exacerbation of their skin disease after being infected with HIV.

- Trauma: A few studies have reported the occurrence of arthritis and acroosteolysis after physical trauma in patients with psoriasis.

Lab Studies

No specific diagnostic tests are available for psoriatic arthritis. Diagnosis of the disease is made based on clinical and radiologic criteria in a patient with psoriasis. The most characteristic laboratory abnormalities in patients with psoriatic arthritis are elevations of the erythrocyte sedimentation rate (ESR) and C-reactive protein level. The results from these laboratory tests help track the activity of the disease by measuring inflammation. An elevated ESR is usually found in approximately 40% of patients with psoriatic arthritis. Patients with psoriatic arthritis are typically seronegative for RF, although RF is detected in 5-9% of patients. RF testing is usually associated with a high false-positive rate; thus, RF-positive and RF-negative patients should undergo the same treatment. Antinuclear antibody titers in persons with psoriatic arthritis do not differ from those of age- and sex-matched control populations. In 10-20% of patients with generalized skin disease, the serum uric acid concentration may be increased and, on occasion, may predispose to acute gouty arthritis. Low levels of circulating immune complexes have been detected in 56% of patients with psoriatic arthritis but do not appear to parallel disease activity. Serum immunoglobulin A levels are increased in two thirds of patients with psoriatic arthritis and in one third of patients with psoriasis. Synovial fluid is inflammatory, with cell counts ranging from 5000-15,000/µL and with more than 50% of cells being polymorphonuclear leukocytes. Within the synovium, the infiltrate consists predominantly of T lymphocytes. Synovial fluid complement levels are either within reference ranges or increased, and glucose levels are within reference ranges.

Imaging Studies

Radiological features have helped to distinguish psoriatic arthritis from other causes of polyarthritis. In general, the common subtypes of psoriatic arthritis, such as asymmetric oligoarthritis and symmetric polyarthritis, tend to result in only mild erosive disease. Early bony erosions occur at the cartilaginous edge, and, initially, cartilage is preserved, with maintenance of a normal joint space.

Juxta-articular osteopenia, which is a hallmark of rheumatoid arthritis (RA), is minimal in persons with psoriatic arthritis. Asymmetric erosive changes in the small joints of the hands and feet are typical of psoriatic arthritis and have a predilection (in decreasing order) for DIP, proximal interphalangeal, metatarsophalangeal, and metacarpophalangeal joints (figura 5).

Figura 5

Psoriatic arthritis involving the distal phalangeal joint

Erosive disease frequently occurs in patients with either DIP involvement or progressive deforming arthritis and may lead to subluxation and, less commonly, bony ankylosis of the joint. Erosion of the tuft of the distal phalanx, and even the metacarpals or metatarsals, can progress to complete dissolution of the bone. Although this form of acroosteolysis is not diagnostic, it is highly suggestive of psoriatic arthritis. The pencil-in-cup deformity observed in the hands and feet of patients with severe joint disease usually affects the DIP joints but also may involve the proximal interphalangeal joints (figura 6).

Figura 6

Arthritis mutilans (ie, "pencil-in-cup" deformities).

CT scanning of the sacroiliac joint may be a sensitive method of visualizing involvement in patients with spondylitis or sacroiliitis. Recent studies have indicated that MRI may be a sensitive method for demonstrating the typical enthesopathic pathology of psoriatic arthritis, particularly in the hands and feet.

Other Tests

Traditional methods of monitoring patients with rheumatic conditions include clinical assessment for joint inflammation or damage and radiographic evaluations. The radiologic scoring methods for evaluating peripheral joints in persons with psoriatic arthritis were developed for patients with RA. A study validated the original Steinbrocker method, a modified Steinbrocker method, and the Larsen method for assessment of radiographs in patients with psoriatic arthritis. The latter 2 methods can now be used to assess disease progression in patients with psoriatic arthritis.

Histologic Findings

The histopathology of psoriatic synovitis is similar to that observed in other inflammatory arthritides, with a notable lack of intrasynovial immunoglobulin and RF production and a greater propensity for fibrous ankylosis, osseous resorption, and heterotopic bone formation.

Medical Care

The treatment of psoriatic arthritis is directed at controlling the inflammatory process. Although no clear correlation exists between the skin and joint inflammation in every patient, the skin and joint aspects of the disease often must be treated simultaneously.

Initial treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs) for joint disease and topical therapies for the skin. In many patients, this approach is sufficient to control disease manifestations, although some patients have a

worsening of psoriasis with NSAIDs. In these patients, a drug belonging to a different family of NSAIDs should be used.

Intra-articular injection of entheses or single inflamed joints with corticosteroids may be particularly effective in some patients. Use disease-modifying drugs in individuals whose arthritis is persistent. If the skin disease is well controlled with topical medication, the joint disease can be treated with a variety of second-line or cytotoxic drugs. Intramuscular administration of gold has been used in the past but has been supplanted by newer disease-modifying antirheumatic drugs.

Disease-Modifying Antirheumatic Drugs (DMARDs)

In patients with severe skin inflammation, medications such as methotrexate (MTX), retinoic-acid derivatives, and psoralen plus UV light should be considered. These medications have been shown to work for both skin and joint manifestations. Sulfasalazine and cyclosporine are two second-line agents that have received particular attention in the management of psoriatic arthritis. Although these drugs may control the acute inflammation in persons with psoriatic arthritis, they have not been helpful in arresting the progression of clinical and radiologic damage. Thus, the disease must be treated earlier or better drugs are necessary to prevent the damage that may ensue as a result of psoriatic arthritis. Cyclosporine appears to be an effective agent for the treatment of psoriasis and psoriatic arthritis. The major concern with cyclosporine is its toxicity, especially nephrotoxicity and hypertension. Combination therapy (eg, MTX/sulfasalazine, MTX/cyclosporine) may be more efficacious in some patients.

Biological active drugs

The use of biologic response modifiers that target TNF and other cytokines represents an advance in the treatment of several diseases involving autoimmune mechanisms. Several such agents have been developed, in the form of either soluble fusion proteins (eg, etanercept) or monoclonal antibodies (eg, infliximab, adalimumab), which have shown considerable efficacy in the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.

Etanercept is approved by the US Food and Drug Administration for treating adult patients (age $\geq$18 y) with chronic, moderate-to-severe plaque psoriasis; reducing the symptoms and signs of moderate-to-severe polyarticular-course juvenile RA and ankylosing spondylitis; and reducing the signs and symptoms and inhibiting the progression of structural damage associated with psoriatic arthritis. Therefore, etanercept may be an effective and safe alternative monotherapy for the treatment of psoriatic arthritis.

Infliximab (Remicade) is another TNF-neutralizing agent that has been approved for the treatment of Crohn disease, ulcerative colitis, RA (in combination with MTX), ankylosing spondylitis, and psoriatic arthritis. It has shown successful results in reducing the signs and symptoms of psoriatic arthritis. However, the Food and Drug Administration issued safety warnings for infliximab concerning worsening heart failure in patients with moderate-to-severe congestive heart failure and opportunistic infections such as tuberculosis, histoplasmosis, listeriosis, and pneumocystosis. The effects of new generations of biological DMARDs on psoriasis and psoriatic arthritis are being studied.

Secukinumab (Cosentyx) is recombinant fully human monoclonal antibody against interleukin-17A, which alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous xenobiotic DMARD therapy has been inadequate. Guselcumab (Tremfya) is fully human monoclonal antibody against interleukin-23 that is recommended to use in patients having psoriatic arthritis and those who are intolerated to classic DMARDs.

Other drugs

Several other modalities have been tried in persons with psoriatic arthritis, including vitamin-D3, bromocriptine, peptide T, and fish oils, but their efficacy remains to be proven. Antimalarials, particularly hydroxychloroquine (Plaquenil), are usually avoided in patients with psoriasis for fear of precipitating exfoliative dermatitis or exacerbating psoriasis. Two studies showed that these reactions did not occur in patients treated with hydroxychloroquine; therefore, it is occasionally used to treat psoriatic arthritis. Systemic corticosteroids are usually avoided because of possible rebound of the skin disease upon withdrawal.

Surgical Care

Arthroscopic synovectomy has been effective in treating severe chronic monoarticular synovitis. Because of the enhanced tendency for fibrosis associated with this therapy, anti-inflammatory and physical therapy measures aimed at improving range of motion are important adjuncts to this intervention. Joint replacement and forms of reconstructive therapy are occasionally necessary.

Diet

For people who have morning stiffness, the optimal time for taking an NSAID might be after the evening meal and again upon awakening. Taking NSAIDs with food can reduce stomach discomfort. Any NSAID can damage the mucous layer and cause ulcers and GI bleeding when taken for long periods. Cyclooxygenase (COX)–2 selective inhibitors are associated with a lower prevalence of gastric ulcer formation.

Activity

- Exercise
  - Exercise is an important part of the total treatment to limit the pain and swelling of arthritis, which can make joints stiff and hard to move.
  - A directed exercise program can improve movement, strengthen muscles to stabilize joints, improve sleep, strengthen the heart, increase stamina, reduce weight, and improve physical appearance.
- Rest
  - Generally, a normal amount of rest and sleep is sufficient to decrease fatigue and reduce joint inflammation.
  - In a very few people, psoriatic arthritis may cause extreme fatigue.

Further Outpatient Care

Heat and cold treatments can temporarily relieve pain and reduce joint swelling. Examples of treatments include soaking in a warm tub or placing a warm compress or cold pack on the painful joint.

Deterrence/Prevention

A number of medications cause an exacerbation of psoriasis; therefore, avoidance of these medications may help prevent or minimize flare-ups. Lithium and withdrawal from systemic corticosteroids are well known to cause flares of disease. Beta-blockers, antimalarials, and NSAIDs have also been implicated.

Complications

Until recently, psoriatic arthritis was generally believed to be a mild disease, with severe joint deformity and destruction (called arthritis mutilans) occurring in only approximately 5% of patients. This severe condition usually occurs in the small joints of the hands and feet. Some reports now suggest that arthritis mutilans may occur in as many as 16% of patients and that it may be as severe as rheumatoid arthritis (RA). Atlantoaxial subluxation with attendant neurological complications can occur. Rarely, patients with psoriatic arthritis may develop aortic insufficiency.

Prognosis

- Until recently, psoriatic arthritis generally had been considered a milder disease than RA. The following factors influence the degree of severity:
  - Clinical subset (eg, arthritis mutilans, symmetric polyarthritis)
  - Early age of onset
  - Severity of skin involvement
  - Female sex
  - Family history of arthritis

- o HLA marker: Patients with HLA-B39 and HLA-B27 in the presence of HLA-DR7 are more likely to experience disease progression, while those with HLA-B22 or HLA-DQw3 in the presence of HLA-DR7 may be protected from disease progression.
- o ESR of greater than 15 mm/h, medication use before the first clinical visit, evidence of radiologic damage, and absence of nail lesions: These factors have been associated with increased mortality.

New evidence suggests that psoriatic arthritis may be as disabling and destructive as RA when the appropriate comparisons are made; thus, treatment should be aggressive in those individuals with progressive joint disease.

PART 3: REACTIVE ARTHRITIS

In 1916, Hans Reiter described a triad of nongonococcal urethritis, conjunctivitis, and arthritis in a young German officer who had a bout of bloody dysentery. In 1916, Fiessinger and Leroy described 4 patients with what they called oculo-urethro-synovial syndrome and associated the syndrome with an outbreak of *Shigella* dysentery. Since then, many cases of what is now known as reactive arthritis (ReA) have been described. The older term Reiter's syndrome, used in the past to describe the same clinical presentations, is being used less frequently. This is because Reiter was a physician leader of the Nazi party in Germany during World War II and authorized medical experiments on concentration camp prisoners. The syndrome has been associated with gastrointestinal infections with *Shigella, Salmonella,* and *Campylobacter* species and other microorganisms, along with genitourinary infections (especially with *Chlamydia trachomatis*). Outbreaks of enteric Reiter syndrome have been reported aboard military vessels, cruise ships, and vessels transporting immigrants to the United States. In 1967, the term reactive arthritis was first used in cases associated with *Yersinia* gastroenteritis. A strong association with human leukocyte antigen (HLA)–B27 was found. This finding helped to confirm the concept of an incomplete Reiter syndrome, in which arthritis can occur in the absence of urethritis and conjunctivitis. Because of the association with HLA-B27 and its clinical overlap with ankylosing spondylitis and psoriatic arthritis, reactive arthritis is classified as a type of seronegative spondyloarthropathy. In this article, reactive arthritis encompasses the older concepts of complete and incomplete Reiter syndrome and a clinical syndrome of arthritis with or without extra-articular features following within 1 month of infectious diarrhea or genitourinary infection.

Pathophysiology

Reactive arthritis usually develops 2-4 weeks after a genitourinary or gastrointestinal infection. Recent evidence indicates that a preceding respiratory infection with *Chlamydia* may also trigger the disease. About 10% of patients do not have a preceding symptomatic infection. Inflammation of joints, entheses, axial skeleton, skin, mucous membranes, gastrointestinal tract, and eyes may occur. HLA-B27 is positive in 65-96% of patients (75% on average). Patients who are HLA-B27 positive have about a 50-fold increased chance of developing reactive arthritis, but this syndrome can occur in patients who are HLA-B27 negative. Patients with HLA-B27, as well as those with a strong family clustering of the disease, tend to develop more severe and long-term disease. The frequency of reactive arthritis after enteric infection averages 1-4% but varies greatly, even among outbreaks of the same organism. The mechanism of the interaction of the inciting organism with the host (often HLA-B27 positive) leading to the development of reactive arthritis is not known. Synovial fluid cultures are negative for enteric organisms or *Chlamydia* species. However, a systemic and intrasynovial immune response to the organisms has been found with intra-articular antibody and bacterial reactive T cells. Furthermore, bacterial antigen has been found in the joints. Thus, the elements for an immune-mediated synovitis are present.

Molecular evidence of bacterial DNA (by polymerase chain reaction [PCR]) in synovial fluids has been found only in *Chlamydia*-related reactive arthritis, and one placebo-controlled trial of a tetracycline derivative (ie, lymecycline) showed a reduction in the duration of acute *Chlamydia*-related, but not enteric-related, reactive arthritis. This suggests that persistent infection may play a role, at least in some cases of chlamydial reactive arthritis. In a more recent trial, the combination of doxycycline and rifampin was superior to doxycycline alone in reducing morning stiffness and swollen and tender joints in patients with undifferentiated spondyloarthropathy.

The role of HLA-B27 in this scenario remains to be defined but, as discussed elsewhere ([Ankylosing Spondylitis and Undifferentiated Spondyloarthropathies](#)), molecular mimicry, presentation of pathogenic peptides, or an altered host response to the bacteria are all possible. Reactive arthritis, including classic Reiter syndrome, can occur in patients infected with HIV or who have AIDS. This is likely because both conditions can be sexually acquired rather than being triggered by HIV. The course of the illness tends to be severe, with a generalized rash that resembles psoriasis, profound arthritis, and frank AIDS. The frequency of HLA-B27 is the same of that associated with non–AIDS-related reactive arthritis in a similar demographic group. This association points out the likely importance of

CD8$^+$ cytotoxic T cells compared to CD4$^+$ helper T cells in the pathogenesis of reactive arthritis.

Frequency

In Finland, the annual incidence is about 30-40 cases per 100,000 adults, but this varies greatly among different geographic locations.

Mortality and morbidity

Reactive arthritis typically follows a self-limited course, with resolution of symptoms by 3-12 months, even in patients who are acutely incapacitated. However, the condition has a high tendency to recur, particularly with ocular and urogenital inflammation. Individuals who are HLA-B27 positive have a higher frequency of recurrence. A new infection or other stress factor could cause a reactivation of the disease. About 15% of patients develop a long-term, sometimes destructive, arthritis or enthesitis or spondylitis. In a study by Amor et al (1994), seven factors were analyzed as predictors of long-term outcome in spondyloarthropathies. The number of patients with reactive arthritis in this study was low, and a valid subgroup analysis was impossible. The presence of hip joint involvement, an erythrocyte sedimentation rate (ESR) higher than 30, and unresponsiveness to nonsteroidal anti-inflammatory drugs (NSAIDs) probably are predictive of a severe outcome or chronicity in reactive arthritis.

Race, sex and age particularities

Prevalence of HLA-B27 and reactive arthritis is higher in white people than in black people, as in other spondyloarthropathies. Reactive arthritis following food-borne enteric infections affects males and females with the same frequency. Disease associated with venereally acquired infections occurs in a male-to-female ratio of 9:1. Most patients are aged 20-40 years.

History of Reactive arthritis

Reactive arthritis usually develops 2-4 weeks after a genitourinary or gastrointestinal infection. Recent evidence indicates that a preceding respiratory infection with *Chlamydia pneumoniae* may also trigger the disease. About 10% of patients do not have a preceding symptomatic infection. Nongonococcal urethritis, if present, can be one of the presenting symptoms for both postvenereal and postenteric forms. Mild dysuria, mucopurulent discharge, prostatitis and epididymitis in men, and vaginal discharge and/or cervicitis in women can be observed. The onset is most often acute, with malaise, fatigue, and fever. An asymmetrical predominately lower extremity oligoarthritis is the major presenting symptom. Low back pain occurs in 50% of patients. Heel pain is common because of enthesopathies at the Achilles or plantar aponeurosis insertion on the calcaneus. The complete Reiter triad of urethritis, conjunctivitis, and arthritis may occur.

Physical examination fidings

Joints, axial skeleton, entheses

Peripheral joint involvement is typically asymmetric and most frequently affects the weight-bearing joints (ie, knees, ankles, hips), but the shoulders, wrists, and elbows are also affected. In more chronic and severe cases, the small joints of the hands and feet can also be involved. Dactylitis (ie, sausage digits) can be observed, as in other spondyloarthropathies. While low back pain may be present in 50% of patients, most patients with acute disease have minimal findings on physical examination except for decreased lumbar flexion. Patients with more chronic and severe axial disease may develop physical findings similar to ankylosing spondylitis. As with other spondyloarthropathies, the enthesopathy of reactive arthritis may be associated with findings of inflammation (ie, pain, tenderness, swelling) at the Achilles insertion. Other sites include the plantar fascial insertion on the calcaneus, ischial tuberosities, iliac crests, tibial tuberosities, and ribs.

Skin and nails

Keratoderma blennorrhagica observed in the palms and soles is indistinguishable from pustular psoriasis and is very suggestive of chronic reactive arthritis. Erythema nodosum can be observed but is uncommon. Nails can become thickened and crumble, resembling mycotic infection or psoriatic onychodystrophy, but nail pitting is not observed. Circinate balanitis can also be observed. Other mucosal signs and symptoms: Painless shiny patches in the palate, tongue, and mucosa of the cheeks and lips have been described.

Ocular findings

Conjunctivitis is part of the classic triad of Reiter syndrome, and it can occur before or at the onset of arthritis. Other ocular lesions include acute uveitis (20% of patients), episcleritis, keratitis, and corneal ulcerations. The lesions have a tendency to recur.

Enteric infections

Enteric infections can be the triggering event for reactive arthritis. Pathogens include *Salmonella, Shigella, Yersinia,* and *Campylobacter* species. The frequency of reactive arthritis after these enteric infections is about 1-4%. Some patients continue with intermittent bouts of diarrhea and abdominal pain. Lesions resembling ulcerative colitis or Crohn disease have been described when ileocolonoscopy is performed in patients with established reactive arthritis.

Other manifestations

Other manifestations of the disease include mild renal pathology with proteinuria and microhematuria. In severe chronic cases, amyloid deposits and immunoglobulin A (IgA) nephropathy have been reported. Cardiac conduction

abnormalities can be observed, and aortitis with aortic regurgitation occurs in 1-2% of patients.

Causes

Reactive arthritis is usually triggered by a genitourinary or gastrointestinal infection.

Lab Studies

Acute phase reactants, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are usually elevated markedly but later return to the reference range with subsidence of the inflammation. Other laboratory findings include a normocytic normochromic anemia along with mild leukocytosis and thrombocytosis during the acute phase. IgA antibodies to specific bacterial antigens have been reported. Urinalysis can show aseptic pyuria.

Synovial fluid analysis reveals a high white blood cell count, most often with elevated polymorphonuclear leukocytes acutely. Gram stain and culture results are negative and are necessary to exclude septic arthritis. Microbial components and antigens have been identified in joint fluid using sophisticated laboratory techniques. Throat, stool, or urogenital tract cultures can be performed in an attempt to isolate the causative organism. Other serologic techniques for the detection of *Chlamydia* species, including PCR, could be considered. Test results for rheumatoid factor and antinuclear antibodies are negative.

Imaging Studies

Early in the disease, no abnormalities are found on radiograph. In more advanced or long-term disease, periosteal reaction and proliferation at sites of tendon insertion can be observed. Exuberant plantar spurs are a common sign in long-term cases. In the hands and feet, marginal erosions with adjacent bone proliferation occur. Spinal radiographic findings include sacroiliitis and syndesmophytes. Sacroiliitis occurs in less than 10% of acute cases but may be observed in 50% of those patients with chronic severe disease. Syndesmophytes are usually asymmetrical and are found most commonly in the thoracolumbar region. Severe ankylosing spondylitis occurs in less than 5% of cases.

Other Tests

An ECG should be performed in patients having a prolonged course of the disease to evaluate for conduction disturbances. HLA-B27 testing yields positive results in 65-96% of cases. HLA-B27 testing is not necessary in classic Reiter syndrome but may be helpful to support the diagnosis of reactive arthritis in patients with joint-restricted symptoms.

Procedures

     Needle aspiration of a joint may be necessary to rule out septic or crystalline arthritis.

Medical Care

The treatment of reactive arthritis is modified according to the severity of symptoms.

    Nonsteroidal anti-inflammatory drugs

NSAIDs are the foundation of therapy. These agents should be used on a regular basis to achieve a good anti-inflammatory effect. The choice of a specific agent depends on the individual response to treatment, although the general impression is that indomethacin has greater potency. Physical therapy needs to be implemented to help reduce pain and to avoid muscle wasting in severe cases.

- Corticosteroids

These agents can be used as either intra-articular injection or systemic therapy. Joint injections can produce long-lasting symptomatic improvement and help avoid the use of other systemic therapy. Sacroiliac joints can be injected, usually under fluoroscopic guidance. Systemic corticosteroids can be used, particularly in patients with poor response to NSAIDs or in those who develop adverse effects related to their use. The starting dose is guided by a patient's symptoms and objective evidence of inflammation. Prednisone 0.5-1 mg/kg/d can be used initially and tapered according to response.

    Antibiotics

The current concepts on the pathogenesis of reactive arthritis indicate that an infectious agent is the trigger of the disease, but antibiotic treatment does not change the course of the disease, even when a microorganism is isolated. In these cases, antibiotics are used to treat the underlying infection, but specific treatment for reactive arthritis is lacking. However, in chlamydial-induced reactive arthritis, studies have suggested that appropriate treatment of the acute urogenital infection can prevent reactive arthritis and that treatment of acute reactive arthritis with a 3-month course of tetracycline reduces the duration of illness. No evidence indicates that antibiotic therapy benefits enteric-related reactive arthritis or chronic reactive arthritis of any cause.

    Quinolones have been studied because of their broad coverage, but no beneficial effect has been noted. Lymecycline was studied in a double-blind placebo-controlled study of patients with chronic reactive arthritis for a treatment period of 3 months. Those patients with *Chlamydia*-induced disease had a significant decrease in duration of illness, as opposed to those with disease triggered by enteric infections. More studies are needed before definite

recommendations can be made as to the role of antibiotics in the management of reactive arthritis.

Disease-modifying anti-rheumatic drugs

In patients with chronic symptoms or in patients with persistent inflammation despite the use of the agents mentioned above, other second-line drugs may be used. Clinical experience with xenobiotic DMARDs has been mostly in rheumatoid arthritis and in psoriatic arthritis. DMARDs have also been used in reactive arthritis, although their disease-modifying effects in the reactive arthritis setting are uncertain.

Sulfasalazine can be beneficial in some patients. The use of this drug in reactive arthritis is of interest because of the finding of clinical or subclinical inflammation of the bowel in many patients. Sulfasalazine is more widely used in ankylosing spondylitis.

In patients who present with rheumatoid-like disease, methotrexate can be used. Several reports have shown good response, but controlled studies are lacking. Reports also describe the use of azathioprine and bromocriptine in reactive arthritis, but, again, large studies have not been published. Patients with reactive arthritis and HIV/AIDS should not be placed on methotrexate or other immunosuppressive agents.

Biological active drugs

Although biologic agents such as TNF-blockers have been demonstrated to be beneficial and formally approved for the treatment of psoriatic arthritis and ankylosing spondylitis, double-blind, randomized trials have not been performed to prove clinical benefit in reactive arthritis or in undifferentiated spondyloarthropathy. A recent uncontrolled study in patients with either undifferentiated spondyloarthropathy or reactive arthritis showed potential efficacy in symptom relief. Novel biological active drugs (Secukinumab and Guselcumab) are not indicated for the treatment of reactive arthritis yet.

Surgical Care

No surgical treatment of reactive arthritis is recommended.

Consultations

A rheumatologist should be consulted for confirmation of diagnosis and formulation of management plan. Consultation with a urologist may be necessary if particularly prominent genitourinary manifestations develop. An ophthalmologist may be consulted to confirm the diagnosis and to treat the ophthalmologic manifestations of the syndrome.

Activity

Physical therapy may be instituted to avoid muscle wasting and to reduce pain. Activities should otherwise be as tolerated by the patient.

Further Inpatient Care

Hospitalization of a patient with uncomplicated reactive arthritis is not indicated.

Deterrence and prevention

Even when a causal microorganism is isolated, antibiotic therapy does not change the course of the disease.

PART 4: OSTEOARTHRITIS

Osteoarthritis (OA) is the most common articular disease worldwide, affecting over 20 million individuals in the United Europa. Its high prevalence entails significant costs to society. Direct costs include physician visits, medications, and surgical intervention. Indirect costs include such items as time lost from work. Costs can be particularly significant for the elderly, who face potential loss of independence and who may need help with daily living activities. As the populations of developed nations, age over the next few decades, the need for better understanding of OA and for improved therapeutic alternatives will continue to grow.

Pathophysiology of osteoarthritis

Traditionally, OA has been considered a disease of articular cartilage. The current concept holds that OA involves the entire joint organ, including the subchondral bone and synovium. OA has always been classified as a noninflammatory arthritis; yet, there is increasing evidence for inflammation occurring with cytokine and metalloproteinase release into the joint. Therefore, the term degenerative joint disease is no longer appropriate when referring to OA. The joints predominantly involved are weight bearing and include the knees, hips, cervical and lumbosacral spine, and feet. Other commonly affected joints include the distal interphalangeal (DIP) and proximal interphalangeal (PIP) joints of the hands. Cartilage is grossly affected. Focal ulcerations eventually lead to cartilage loss and eburnation. Subchondral bone formation occurs as well, with development of bony osteophytes.

Frequency of osteoarthritis

OA is the most common articular disease. Estimates vary among different populations.

Mortality and morbidity of osteoarthritis

Disease progression characteristically is slow, occurring over several years or decades. Pain is usually the initial and principal source of morbidity in OA. The patient can become progressively more inactive leading to morbidities related to decreasing physical activity including potential weight gain.

Race, sex and age particularities

Different prevalences have been cited for different ethnic groups. African American women appear to have a greater prevalence of knee OA than other groups. Prevalence increases with age. Equivalent prevalence occurs in men and women aged 45-55 years. After age 55 prevalence becomes greater in women. DIP and PIP joint involvement resulting in Heberden's and Bouchard's nodes is more common in women. OA can be defined epidemiologically (ie, using radiographic criteria) or clinically (eg, radiographs plus clinical symptoms). Radiographic criteria indicate that OA occurs in 30% of affected individuals aged 45-65 years and in more than 80% by their eighth decade of life, although most are asymptomatic.

History of octeoarthritis

- Pain
    1. This is the main reason patients seek medical attention.
    2. Initially, symptomatic patients incur pain during activity, which can be relieved by rest and may respond to simple analgesics.
- Morning stiffness in the joint usually lasts for less than half an hour.
- Stiffness at times of rest (gelling) may develop.
- Joints may become unstable with disease progression; therefore, the pain can become more prominent (even at times of rest) and may not respond to medications.

Physical examination findings

Physical examination findings are mostly limited to the affected joints. Malalignment with a bony enlargement (depending on the disease severity) may occur. In most cases, erythema or warmth over the joint does not occur; however, an effusion may be present. Limitation of joint motion or muscle atrophy around a more severely affected joint may occur.

Sources of pain in OA

- Joint effusion and stretching of the joint capsule
- Increased vascular pressure in subchondral bone
- Torn menisci
- Inflammation of periarticular bursae
- Periarticular muscle spasm
- Psychological factors

- Crepitus (a rough or crunchy sensation) may be palpated during motion of an involved joint.

Causes

Risk factors

- Age
- Obesity
- Female sex
- Trauma
- Infection
- Repetitive occupational trauma
- Genetic factors
- History of inflammatory arthritis
- Neuromuscular disorder
- Metabolic disorder

The etiopathogenesis of OA has been divided into the following 3 stages:

Stage 1: Proteolytic breakdown of the cartilage matrix occurs. Chondrocyte metabolism is affected, leading to an increased production of enzymes, which includes metalloproteinases (eg, collagenase, stromelysin) that destroy the cartilage matrix. Chondrocytes also produce protease inhibitors, including tissue inhibitors of metalloproteinases (TIMP) 1 and 2 but in amounts insufficient to counteract the proteolytic effect.

Stage 2: This stage involves the fibrillation and erosion of the cartilage surface, with a subsequent release of proteoglycan and collagen fragments into the synovial fluid.

Stage 3: The breakdown products of cartilage induce a chronic inflammatory response in the synovium. Synovial macrophage production of cytokines, such as interleukin 1 (IL-1), tumor necrosis factor-alpha, and metalloproteinases, occurs. These can diffuse back into the cartilage and directly destroy tissue or stimulate chondrocytes to produce more metalloproteinases. Other pro-inflammatory molecules (eg, nitric oxide [NO], an inorganic free radical) also may be a factor. Eventually, these events alter the joint architecture, and compensatory bone overgrowth occurs in an attempt to stabilize the joint. As the joint architecture is changed and further mechanical and inflammatory stress occurs on the articular surfaces, the disease progresses unchecked.

Lab Studies

No specific laboratory abnormalities are associated with OA. The acute-phase reactants and erythrocyte sedimentation rate are not elevated. Synovial fluid

analysis usually indicates a white cell count less than 2000 per mm3 with a mononuclear predominance.

Imaging Studies

Radiography

- Conduct imaging studies of the affected joint.
- The presence of osteophytes (ie, spurs at the joint margins) is the most characteristic findings.
- Other findings include asymmetric joint space narrowing, subchondral sclerosis, and subchondral cyst formation.

Roentgenographic findings are often poor predictors of the degree of symptomatology in a particular patient.

Procedures

Arthrocentesis of the affected joint can help exclude inflammatory arthritis, infection, or crystal arthropathy.

Histologic Findings

Histologically, the earliest changes occur in the cartilage. Proteoglycan staining is diminished, and, eventually, irregularity of the articular surface with clefts and erosions occurs.

Medical Care

Nonpharmacologic interventions are the cornerstones of OA therapy and include patient education, temperature modalities, weight loss, exercise, physical therapy, occupational therapy, and joint unloading in certain joints (eg, knee, hip).

Reduction of joint stress

Instruct the patient to avoid aggravating stress to the affected joint. Implement correction procedures if the patient illustrates poor posture. Encourage obese patients to lose weight, thus taking stress off the affected knees or hips. Occupational adjustments may be necessary.

Physical therapy

In OA of the knee, disuse atrophy of the quadriceps may occur. These muscles help protect the articular cartilage from further stress. Instruct the patient to perform aerobic and muscle-strengthening exercises. Hydrotherapy may be beneficial. Some patients find relief with heat and capsaicin cream placed locally over the affected joint, and a minority of patients proclaim relief with ice.

Pharmacologic therapy

The goals of treatment are pain alleviation and improvement of functional status. Presently, no proven practical medication-based disease/structure-modifying intervention exists. Begin treatment with acetaminophen for mild or moderate pain without apparent inflammation. If clinical response to

acetaminophen is not satisfactory or if clinical presentation is inflammatory, consider nonsteroidal anti-inflammatory drug (NSAIDs). Use the lowest effective dose or intermittent dosing if symptoms are present intermittently and then try full doses if the patient's response is insufficient. Options in patients at an elevated risk for GI toxicity due to NSAIDs include the addition of a proton-pump inhibitor or misoprostol to the treatment regimen or the use of a selective cyclooxygenase inhibitor instead of the nonselective NSAID. In patients with highly resistant pain, consider the analgesic tramadol. Muscle relaxants may benefit patients with evidence of muscle spasm. Contemplate intraarticular injections of glucocorticoids to improve symptoms. It is recommended that no more than 4 glucocorticoid injections be administered to a single joint per year because of the concerns with long-term damage to cartilage. Do not use systemic glucocorticoids; they have no role in the management of OA. Intraarticular injections of hyaluronic acid (HA) are approved as symptomatic therapy of OA in the knee. Prescribe as a series of 3 or 5 injections (depending on the product). Each injection is administered 1 week apart. Consider judicious use of narcotics (eg, acetaminophen with codeine) only in patients with severe OA.

Recommendations for the medical management of OA of the hip and knee

In 1995, the American College of Rheumatology (ACR) published recommendations for the medical management of OA of the hip and knee. Those guidelines outlined the use of nonpharmacologic modalities, including patient education and physical and occupational therapy-the foundation of treatment of individuals with OA, as well as the use of pharmacologic agents. Specific recommendations for surgical management of OA, however, were not included. Since that time, several systematic reviews of drug therapy for OA have been published, and many clinical trials have been conducted which have resulted in the approval, or pending review, by the Food and Drug Administration (FDA) of new devices and drug treatments for OA. In 1998, the ACR established an ad hoc subcommittee, comprising several of the American authors of the 1995 recommendations, to review interim developments in the field and update the recommendations. As in the original review, the subcommittee followed the 1905 principles of evidence-based medicine as used in the process of making clinical decisions. As stated by Guyatt, "Physicians practicing [evidence-based medicine] will search for the highest evidence available, integrate this evidence with their clinical experience and judgment, and acknowledge the value judgments implicit in moving from evidence to action"

The goals of the contemporary management of the patient with OA continue to include control of pain and improvement in function and health-related quality of

life, with avoidance, if possible, of toxic effects of therapy. The recommended approach to the medical management of hip or knee OA includes nonpharmacologic modalities and drug therapy. The Subcommittee on OA Guidelines emphasizes that these recommendations are not fixed, rigid mandates, and recognizes that the final decision concerning the therapeutic regimen for an individual patient rests with the treating physician.

Nonpharmacologic modalities

The components of nonpharmacologic therapy are outlined in Table 6. Patient education and, where appropriate, education of the patient's family, friends, or other caregivers are integral parts of the treatment plan for patients with OA. Patients should be encouraged to participate in self-management programs, such as the Arthritis Foundation Self-Management Program. Individuals who participate in these programs report decreases in joint pain and frequency of arthritis-related physician visits, increases in physical activity, and overall improvement in quality of life. Additional educational materials, including videos, pamphlets, and news letters, are available from the Arthritis Foundation and other national voluntary health organizations. Another cost-effective nonpharmacologic approach for patients with OA is provision of personalized social support, either directly or by periodic telephone contact. Studies of the results of monthly telephone calls by trained nonmedical personnel to discuss such issues as joint pain, medications and treatment compliance, drug toxicities, date of next scheduled visit, and barriers to keeping clinic appointments showed moderate-to-large degrees of improvement in pain and functional status without a significant increase in costs. These studies underscore the concept that improved communication and education are important factors in decreasing pain and improving function in patients with OA.

Table 6.

Nonpharmacologic therapy for patients with osteoarthritis

№	Nonpharmacologic therapy
1	Patient education
2	Self-management programs (e.g., Arthritis Foundation Self-Management Program)
3	Personalized social support through telephone contact
4	Weight loss (if overweight)
5	Aerobic exercise programs
6	Physical therapy Range-of-motion exercises
7	Muscle-strengthening exercises
8	Assistive devices for ambulation
9	Patellar taping

10	Appropriate footwear
11	Lateral-wedged insoles (for genu varum) Bracing
12	Occupational therapy
13	Joint protection and energy conservation
14	Assistive devices for activities of daily living

Individuals with OA of the lower extremity may have limitations that impair their ability to perform activities of daily living (ADLs), such as walking, bathing, dressing, use of the toilet, and performing household chores. Physical therapy and occupational therapy play central roles in the management of patients with functional limitations. The physical therapist assesses muscle strength, joint stability, and mobility; recommends the use of modalities such as heat (especially useful just prior to exercise); instructs patients in an exercise program to maintain or improve joint range of motion and periarticular muscle strength; and provides assistive devices, such as canes, crutches, or walkers, to improve ambulation. Similarly, the occupational therapist can be instrumental in directing the patient in proper joint protection and energy conservation, use of splints and other assistive devices, and improving joint function. In addition, the input of a vocational guidance counselor may be important to patients who are still actively employed.

Quadriceps weakness is common among patients with knee OA, in whom it had been believed to be a manifestation of disuse atrophy, which develops because of unloading of the painful extremity. Recent studies, however, have indicated that quadriceps weakness may be present in persons with radiographic changes of OA who have no history of knee pain, and in whom lower extremity muscle mass is increased, rather than decreased; and that quadriceps weakness may be a risk factor for the development of knee OA, presumably by decreasing stability of the knee joint and reducing the shock-attenuating capacity of the muscle.

The beneficial effects of both quadriceps strengthening and aerobic exercise for patients with knee OA, noted in the original recommendations, were confirmed in the Fitness Arthritis and Seniors Trial, in which patients with mild disability due to symptomatic knee OA were randomly assigned to aerobic exercise, resistive (muscle-strengthening) exercise, or an education/attention control group. Patients in both exercise groups had modest but significant improvement compared with the control group; this improvement was sustained over an 18-month followup period. In post hoc analyses, the authors found that the degree of adherence to the exercise regimen was significantly associated with the magnitude of improvement in pain and functional limitation. The ability of elderly subjects to maintain conditioning levels of exercise is noteworthy, since many patients with advanced

hip or knee OA are sedentary, deconditioned, and at increased risk for cardiovascular disease.

Another recent study demonstrated the efficacy of an exercise program in improving muscle strength, mobility, and coordination in patients with OA of either the knee or hip. In this study, patients randomly assigned to the exercise group not only had improvement in pain and observed disability, but also reported taking less acetaminophen and had made fewer physician visits by 12 weeks after entry. The effectiveness of exercise was similar in patients with hip or knee OA. These exercise programs, however, require a commitment of time, and effort on the part of the patient. In addition to quadriceps weakness, sensory dysfunction, reflected by a decrease in proprioception, has been documented in patients with knee OA. The 1995 ACR guidelines also recommended that overweight patients with hip or knee OA lose weight. A randomized open trial of an appetite suppressant and low-calorie diet was completed in 40 overweight patients with knee OA; all patients received instruction in an exercise walking program. Patients randomly assigned to the appetite suppressant group lost a mean of 3.9 kg over the course of 6 weeks, and also had significant improvement in their knee OA, as measured by the Lequesne algofunctional index. Although this study had limitations, it provided the only data from a randomized trial demonstrating a relationship between loss of body fat (rather than loss of body weight) and improvement in symptoms of knee OA. As noted in the 1995 ACR recommendations, proper use of a cane (in the hand contralateral to the affected knee) reduces loading forces on the joint and is associated with a decrease in pain and improvement of function. In addition, patients may benefit from wedged insoles to correct abnormal biomechanics due to varus deformity of the knee. Another useful maneuver for patients with OA of the knee who have symptomatic patellofemoral compartment involvement is medial taping of the patella.

Pharmacologic therapy

All of the pharmacologic agents discussed in this section should be considered additions to nonpharmacologic measures, such as those described above, which are the cornerstone of OA management and should be maintained throughout the treatment period. Drug therapy for pain management is most effective when combined with nonpharmacologic strategies.

For many patients with OA, the relief of mild-to-moderate joint pain afforded by the simple analgesic, acetaminophen, is comparable with that achievable with an NSAID. However, this finding was based on a post hoc analysis with limited statistical power that used a definition of inflammation which included joint-line and soft-tissue tenderness or soft-tissue swelling. Eccles and

colleagues, in a metaanalysis of trials comparing simple analgesics with NSAIDs in patients with knee OA, did note that NSAID-treated patients had significantly greater improvement in both pain at rest and pain on motion.

The daily dose of acetaminophcn should not exceed 4 gm. Although it is one of the safest analgesics, acetaminophen can be associated with clinically important adverse events. Recent reports have highlighted long-recognized conditions in which increased awareness of potential toxicity is important. For example, because acetaminophen can prolong the half-life of warfarin sodium, careful monitoring of the prothrombin time is recommended in patients taking warfarin sodium who subsequently begin high-dose acetaminophen treatment. Hepatic toxicity with acetaminophen is rare with doses of <4 gm/day. Nonetheless, the drug should be used cautiously in patients with existing liver disease and avoided in patients with chronic alcohol abuse because of known increased risk in these settings. Even though acetaminophen was reported to be weakly associated with end-stage renal disease, the Scientific Advisory Committee of the National Kidney Foundation recommends it as the drug of choice for analgesia in patients with impaired renal function.

For those patients who fail to obtain adequate symptomatic relief with the above measures, alternative or additional pharmacologic agents should be considered. The choice should be made after evaluation of risk factors for serious upper gastrointestinal (GI) and renal toxicity. Data from epidemiologic studies show that among persons of age ≥ 65 years, 20-30% of all hospitalizations and deaths due to peptic ulcer disease were attributable to therapy with NSAIDs. Furthermore, in the elderly, the risk of a catastrophic GI event in patients taking NSAIDs is dose dependent. Risk factors for upper GI bleeding in patients treated with NSAIDs include age ≥ 65 years, history of peptic ulcer disease or of upper GI bleeding, concomitant use of oral glucocorticoids or anticoagulants, presence of comorbid conditions, and, possibly, smoking and alcohol consumption (Table 7). Risk factors for reversible renal T2 failure in patients with intrinsic renal disease (usually defined as a serum creatinine concentration of ≥ 2.0 mg/dl) who are treated with NSAIDs include age ≥ 65 years, hypertension and/or congestive heart failure, and concomitant use of diuretics and angiotensin-converting enzyme inhibitors.

Table 7.

Risk factors for upper gastrointestinal adverse events in patients with OA

№	Risk factors
1	Age >=65 years
2	Comorbid medical conditions
3	Oral glucocorticoids

4	History of peptic ulcer disease
5	History of upper gastrointestinal bleeding
6	Anticoagulants

Additional considerations involved in a practitioner's decision to treat the individual OA patient include existing comorbidities and concomitant therapy, as well as the side effects and costs of specific treatments. In individuals with OA of the knee who have mild-to-moderate pain, do not respond to acetaminophen, and do not wish to take systemic therapy, the use of topical analgesics (e.g., methylsalicylate or capsaicin cream) is appropriate as either adjunctive treatment or monotherapy. Capsaicin cream should be applied to the symptomatic joint 4 times daily; a local burning sensation is common, but rarely leads to discontinuation of therapy. A systematic review of topical NSAIDs also demonstrated efficacy in patients with OA; there are no published findings of trials comparing the same NSAID administered orally versus topically. Initiation of treatment in the patient at increased risk for an upper GI adverse event. Of further advantage with respect to upper GI bleeding, neither of the COX-2-specific inhibitors has a clinically significant effect on platelet aggregation or bleeding .time. This is a consideration, especially in preand perioperative management of patients with OA (in whom nonselective NSAIDs have traditionally been discontinued as long as 2 weeks prior to surgery), as well as for patients taking warfarin sodium. Accordingly, these agents appear preferable to currently available nonselective NSAIDs for use in patients at risk for upper GI complications.

Tramadol, a centrally acting oral analgesic, is a synthetic opioid agonist that also inhibits reuptake of norepinephrine and serotonin. It has been approved by the FDA for the treatment of moderate-to-severe pain and can be considered for use in patients who have contraindications to COX-2-specific inhibitors and nonselective NSAIDs, including impaired renal function, or in patients who have not responded to previous oral therapy. Although there are numerous studies of the use of tramadol in general pain, few controlled studies have examined its use in OA. The efficacy of tramadol has been found to be comparable with that of ibuprofen in patients with hip and knee OA, and it has been found to be useful as adjunctive therapy in patients with OA whose symptoms are inadequately controlled with NSAIDs. Mean effective daily doses of tramadol have generally been in the range of 200-300 mg, given in 4 divided doses. Side effects are common and include nausea, constipation, and drowsiness. Despite its opioid pharmacology, a comprehensive surveillance program has failed to demonstrate significant abuse, and tramadol remains an unscheduled agent.

Although the efficacy of therapy with combinations of the above pharmacologic agents has not been established in controlled clinical trials, in general, it is reasonable to use the recommended agents in combination in an individual patient. However, only a single NSAID should be used at any given time, the sole exception being the concomitant use of a cardioprotective dose of aspirin (81-325 mg/day) with other NSAIDs. Even these low doses of aspirin, however, will increase the risk of upper GI bleeding in patients taking NSAIDs. In this regard, it should be noted that the incidence of endoscopically identified ulcers in patients taking a COX-2-specific inhibitor and a cardioprotective dose of aspirin was lower than that in comparator groups taking nonselective NSAIDs with or without concomitant low dose aspirin.

Biological active drugs

Novel biological active drugs (Secukinumab and Guselcumab) are indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

Surgical Care

Closed-needle joint lavage may benefit a small subgroup of patients. Arthroscopy may help patients with OA of the knee that has specific structural damage on imaging (eg, repairing meniscal tears, removing fragments of torn menisci that are producing symptoms). Overall, arthroscopy is not recommended for nonspecific "cleaning of the knee" in OA.

Osteotomy

Consider this procedure for those patients with a malaligned hip or knee joint. The procedure usually is recommended in younger patients with OA. This surgery can lessen pain, although it can lead to more challenging surgery later if the patients require arthroplasty.

Arthroplasty

Perform this procedure if all other modalities are ineffective and osteotomy is not viable or if a patient cannot perform his or her daily activities despite maximal therapy. This procedure alleviates pain and may improve function. Approximately 8-15 years of viability are expected from the joint replacement if there are no complications.

Consultations

A physiatrist may help in formulating a nonpharmacologic management plan. A referral to an orthopedic surgeon may be necessary if a patient fails to respond to a

medical management plan. A nutritionist may help the patient achieve some weight loss.

Diet and activity

A diet to achieve some degree of weight loss may be beneficial. OA may severely hinder the patient's ability to work or even to perform daily living activities, depending on the joints involved and the degree of involvement.

PART 5 : RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause that primarily affects the peripheral joints in a symmetric pattern. Constitutional symptoms, including fatigue, malaise, and morning stiffness, are common. Extra-articular involvement of organs such as the skin, heart, lungs, and eyes can be significant. RA causes joint destruction and thus often leads to considerable morbidity and mortality. The treatment of RA is rapidly advancing with the recent addition of new and innovative therapies.

Pathophysiology

RA has an unknown cause. Although an infectious etiology has been speculated (eg, Mycoplasma organisms, Epstein-Barr virus, parvovirus, rubella), no organism has been proven responsible. RA is associated with a number of autoimmune responses, but whether autoimmunity is a secondary or primary event is still unknown. RA has a significant genetic component, and the so-called shared epitope of the HLA-DR4/DR1 cluster is present in up to 90% of patients with RA, although it is also present in more than 40% of controls. Synovial cell hyperplasia and endothelial cell activation are early events in the pathologic process that progresses to uncontrolled inflammation and consequent cartilage and bone destruction. Genetic factors and immune system abnormalities contribute to disease propagation.

Major cellular roles are played by CD4 T cells, mononuclear phagocytes, fibroblasts, osteoclasts, and neutrophils, while B lymphocytes produce autoantibodies (ie, rheumatoid factors [RFs]). Abnormal production of numerous cytokines, chemokines, and other inflammatory mediators (eg, tumor necrosis factor alpha [TNF-alpha, interleukin (IL)–1, IL-6, transforming growth factor beta, IL-8, fibroblast growth factor, platelet-derived growth factor) have been demonstrated in patients with RA. Ultimately, inflammation and exuberant proliferation of synovium (ie, pannus) leads to destruction of various tissues such

as cartilage, bone, tendons, ligaments, and blood vessels. Although the articular structures are the primary sites, other tissues are also affected.

Frequency

The worldwide incidence of RA is approximately 3 cases per 10,000 population, and the prevalence rate is approximately 1%. RA affects all populations, although a few groups have much higher prevalence rates (eg, 5-6% in some Native American groups) and some have lower rates (eg, black persons from the Caribbean region). First-degree relatives of patients with RA have an increased frequency of disease (approximately 2-3%). Disease concordance in monozygotic twins is approximately 15-20%, suggesting that nongenetic factors play an important role. Because worldwide frequency is relatively constant, a ubiquitous infectious agent has been postulated to play an etiologic role.

Mortality and morbidity of rheumatoid arthritis

RA does not usually follow a benign course. It is associated with significant morbidity, disability, and mortality. Daily living activities are impaired in most patients. Spontaneous clinical remission is uncommon (approximately 5-10%). After 5 years of disease, approximately 33% of patients will not be working; after 10 years, approximately half will have substantial functional disability. Poor prognostic factors include persistent synovitis, early erosive disease, extra-articular findings (including subcutaneous rheumatoid nodules), positive serum RF findings, family history of RA, male sex, and advanced age.

Life expectancy for patients with RA is shortened by 5-10 years, although those who respond to therapy may have lower mortality rates. Increased mortality rates are associated with poor functional status, age, male sex, socioeconomic factors (eg, level of education), positive RF findings, extra-articular disease, elevated acute phase response (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]), and increased clinical severity (eg, more involved joints). Mortality is increased by causes such as infections, cardiovascular disease, renal disease, GI bleeding, and lymphoproliferative disorders; these events may be directly due to the disease and its complications (eg, vasculitis, amyloidosis) or to therapy-induced adverse effects.

Race, sex and age particulaties.

RA affects all populations, although a few groups have much higher prevalence rates (eg, 5-6% in some Native American groups) and some have lower rates (eg, black persons from the Caribbean region). Females are 2-3 times more likely to develop RA than males. The frequency of RA increases with age and peaks in persons aged 35-50 years. Nevertheless, the disease is observed in both elderly persons and children. Juvenile inflammatory arthritis (JIA) has been

classified as polyarticular (multiple joints), pauciarticular (<5 joints), and systemic. Systemic JIA is often associated with fever, rash, and organ involvement; it is also called Still disease. Children with polyarticular RF-positive arthritis generally have a clinical course similar to those with adult RA.

History of RA

Historically, the diagnosis of RA was based on the 1987 American College of Rheumatology (ACR) criteria. These criteria were based on the persistence of arthritic symptoms over time; however, this classification system failed to identify patients with early inflammatory arthritis.

The American College of Rheumatology developed the following criteria for the classification of RA (1987).

- Morning stiffness: This occurs in and around the joints and lasts at least 1 hour before maximal improvement.
- Arthritis of 3 or more joint areas: At least 3 joint areas simultaneously have soft tissue swelling or fluid (not bony overgrowth) observed by a physician. The 14 possible areas are right or left proximal interphalangeal (PIP), metacarpophalangeal (MCP), wrist, elbow, knee, ankle, and metatarsophalangeal (MTP) joints.
- Arthritis of hand joints of at least one area swollen in a wrist, MCP, or PIP joint
- Symmetric arthritis with simultaneous involvement of the same joint areas on both sides of the body: Bilateral involvement of PIPs, MCPs, and MTPs is acceptable without absolute symmetry.
- Rheumatoid nodules: Subcutaneous nodules are present over bony prominences or extensor surfaces or in juxta-articular regions.
- Serum RF: Abnormal amounts of serum RF are demonstrated by any method for which the result has been positive in fewer than 5% of healthy control subjects.
- Radiographic changes typical of RA on posteroanterior hand and wrist radiographs, which must include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints: Osteoarthritic changes alone do not qualify.

A patient can be classified as having RA if 4 of 7 criteria are present. Criteria 1-4 must be present for at least 6 weeks, and a physician must observe criteria 2-5. These criteria are intended as a guideline for classification of patients, often for research purposes. They do not absolutely confirm or exclude a diagnosis of RA in a particular patient, especially in those with early arthritis.

It is now recognized that early therapeutic intervention significantly improves clinical outcomes and reduces irreversible joint damage and disability. With this focus, the ACR and the European League Against Rheumatism (EULAR) devised new classification criteria for early arthritis, which assess joint involvement, autoantibody status, acute-phase response, and symptom duration, as well as revised criteria for classifying RA in newly presenting patients, those with erosive disease typical of RA, and those with inactive disease with or without treatment.

Classification of RA

Classification of RA

The 2010 ACR/EULAR classification criteria for RA are designed to identify patients with unexplained inflammatory arthritis in at least 1 peripheral joint and a short duration of symptoms who would benefit from early therapeutic intervention. They represents a paradigm shift from the 1987 ACR criteria, which lacked the sensitivity to detect early RA. According to the ACR/EULAR criteria, patients who should be tested are those (1) who have at least 1 joint with definite clinical synovitis and (2) whose synovitis is not better explained by another disease (eg, lupus, psoriatic arthritis, or gout).

The ACR/EULAR classification system is a score-based algorithm for RA that incorporates the following 4 factors:

- Joint involvement
- Serology test results
- Acute-phase reactant test results
- Patient self-reporting of the duration of signs and symptoms

The maximum number of points possible is 10. A classification of definitive RA requires a score of 6/10 or higher. Patients with a score lower than 6/10 should be reassessed over time. If patients already have erosive changes characteristic of RA, they meet the definition of RA, and application of this diagnostic algorithm is unnecessary.

Joint involvement consists of swelling or tenderness upon examination. The presence of synovitis may be confirmed on imaging studies. Points are allocated as follows:

- 1 large joint (ie, shoulders, elbows, hips, knees, ankles) = 0 points
- 2-10 large joints = 1 point
- 1-3 small joints (with or without involvement of large joints), such as MCP, PIP, second to fifth MTP, thumb interphalangeal (IP), and wrist joints = 2 points

- 4-10 small joints (with or without involvement of large joints) = 3 points
- More than 10 joints (at least 1 small joint, plus any combination of large and additional small joints or joints such as the temporomandibular, acromioclavicular, or sternoclavicular) = 5 points

At least 1 serology test result is needed for RA classification. Points are allocated as follows:
- Negative rheumatoid factor (RF) *and* negative anti−citrullinated protein antibody (ACPA; in the ACR/EULAR criteria set, tested as anti−cyclic citrullinated peptide [anti-CCP]) = 0 points
- Low-positive RF *or* low-positive ACPA = 2 points
- High-positive RF *or* high-positive ACPA = 3 points

Negative serology test results are defined as international unit (IU) values that do not exceed the upper limit of normal (ULN) for the reporting laboratory or assay. Low-positive results are defined as IU values that exceed the ULN but are no more than 3 times the ULN for the reporting laboratory or assay. High-positive results are IU values that are more than 3 times higher than the ULN for the reporting laboratory or assay. When RF is available only as a positive or negative finding, a positive result should be scored as low-positive RF.

At least 1 test acute-phase reactant test result is needed for classification. Local laboratory standards determine which results are normal and which are abnormal. Points are allocated as follows:
- Normal C-reactive protein (CRP) *and* normal erythrocyte sedimentation rate (ESR) = 0 points
- Abnormal CRP *or* abnormal ESR = 1 point

Points for the patient's self-reporting of the duration of signs or symptoms of synovitis in clinically involved joints are allocated as follows:
- Shorter than 6 weeks = 0 points
- 6 weeks or longer = 1 point

Causes

The cause(s) of RA is unknown. Genetic, environmental, hormonal, immunologic, and infectious factors may play significant roles. Socioeconomic, psychological, and lifestyle factors may influence disease outcome.

Genetic

Approximately 60% of US patients with RA carry the so-called shared epitope of the HLA-DR4 cluster, which constitutes one of the peptide binding sites of certain HLA-DR molecules associated with RA (eg, HLA-DR beta *0401, 0404,

or 0405); in addition, HLA-DR1 (HLA-DR beta *0101) also carries this shared epitope and confers risk, particularly in certain southern European areas.

Other HLA-DR4 molecules (eg, HLA-DR beta *0402) do not share the same epitope and do not confer risk. Genes other than those of the major histocompatibility complex are also involved, and results from sequencing genes of RA families suggest the presence of several susceptibility genes and several resistance genes.

Environmental factors

For many decades, numerous infectious agents have been suggested to induce RA. Among these are Mycoplasma organisms, Epstein-Barr and rubella viruses, and others.

This supposition is further supported indirectly by the following:

- Occasional reports of flulike disorders preceding the start of arthritis
- The inducibility of arthritis in experimental animals with different bacteria or bacterial products (eg, streptococcal cell walls)
- The presence of bacterial products including bacterial RNA in patients' joints
- The activity of several agents that have antimicrobial effects as disease-modifying drugs (eg, gold salts, antimalarials, minocycline)

Hormonal factors

Sex hormones may play a role, as evidenced by the disproportionate number of females with RA, its amelioration during pregnancy, its recurrence in the early postpartum period, and its reduced incidence in women using oral contraceptives.

Hyperprolactinemia may be a risk factor for RA.

Immunologic factors

All of the major immunologic elements play fundamental roles in the initiation, propagation, and maintenance of the autoimmune process of RA. The exact orchestration of the cellular and cytokine events that lead to pathologic consequences, such as synovial proliferation and subsequent joint destruction, is complex. It involves T and B lymphocytes, antigen-presenting cells (eg, B cells, macrophages, dendritic cells), and numerous cytokines. Aberrant production and regulation of both pro- and anti-inflammatory cytokines and cytokine pathways are found in RA.

T cells are assumed to play a pivotal role in the initiation of RA, and the key player in this respect is assumed to be the Th1 CD4 cells. (T helper 1 cells produce IL-2 and interferon gamma.)

These cells may subsequently activate macrophages and other cell populations, including synovial fibroblasts. The latter 2 populations are the main

producers of the proinflammatory cytokines TNF-alpha and IL-1 that appear to be the major driving forces of inflammation.

B cells are important in the pathologic process because they may serve as antigen-presenting cells and activated T cells, produce numerous autoantibodies (eg, RF, to citrullinated proteins), and secrete cytokines. Elimination of populations of B cells with monoclonal antibodies (eg, rituximab) offers another effective therapeutic option.

Experimental models suggest that synovial macrophages and fibroblasts may become autonomous and thus lose responsiveness to T-cell activities in the course of the disease. The hyperactive and hyperplastic synovial membrane is ultimately transformed into pannus tissue and invades cartilage and bone, the latter being degraded by activated osteoclasts. The major difference between RA and other forms of inflammatory arthritis, such as psoriatic arthritis, does not lie in their cytokine patterns but rather in the highly destructive potential of the RA synovial membrane and in the local and systemic autoimmunity. Whether these 2 events are linked is unclear; however, the autoimmune response conceivably leads to the formation of immune complexes activating the inflammatory process to a much higher degree than is otherwise the case. This theory is supported by the much worse prognosis of RA among patients positive for RF. In patients with RA, autoantibodies are not only directed against immunoglobulin G (IgG), ie, RFs, but also against a variety of other antigens such as nuclear antigens (RA 33, EBNA), citrullinated proteins (anti-CCP antibodies), collagen, and glucose-6-phosphate isomerase.

Clinical presentation

The hallmark feature of rheumatoid arthritis (RA) is persistent symmetric polyarthritis (synovitis) that affects the hands and feet, although any joint lined by a synovial membrane may be involved. The severity of RA may fluctuate over time, but chronic RA most commonly results in the progressive development of various degrees of joint destruction, deformity, and a significant decline in functional status. Extra-articular involvement of organs such as the skin, heart, lungs, and eyes can also be significant.

Juvenile idiopathic arthritis (JIA), sometimes referred to as juvenile rheumatoid arthritis (JRA), is the most common form of childhood arthritis. In most patients, the immunogenic associations, clinical pattern, and functional outcome of JIA are different from those of adult-onset RA.

Patients often present with constitutional complaints including malaise, fever, fatigue, weight loss, and myalgias. They may report difficulty performing

activities of daily living (eg, dressing, standing, walking, personal hygiene, using their hands).

Most patients with the disease have an insidious onset. It may begin with systemic features, such as fever, malaise, arthralgias, and weakness, before the appearance of overt joint inflammation and swelling. A small percentage of patients (approximately 10%) have an abrupt onset with the acute development of synovitis and extra-articular manifestations. Spontaneous remission is uncommon, especially after the first 3-6 months.

Patients with RA may report difficulty performing activities of daily living (ADLs), such as dressing, standing, walking, personal hygiene, or use of their hands. In addition to articular deterioration, constitutional symptoms (eg, fatigue, malaise, morning stiffness, weight loss, and low-grade fever) may be present.

In most patients, RA has an insidious onset. It may begin with systemic features (eg, fever, malaise, arthralgias, and weakness) before the appearance of overt joint inflammation and swelling. A small percentage (approximately 10%) of patients with this disease have an abrupt onset with the acute development of synovitis and extra-articular manifestations. Spontaneous remission is uncommon, especially after the first 3-6 months.

Physical examination findings

Joint involvement is the characteristic feature of patients with RA. In general, the small joints of the hands and feet are affected in a relatively symmetric distribution. Those most commonly affected joints, in decreasing frequency, are the MCP, wrist, PIP, knee, MTP, shoulder, ankle, cervical spine, hip, elbow, and temporomandibular. Joints show inflammation with swelling, tenderness, warmth, and decreased range of motion. Atrophy of the interosseous muscles of the hands is a typical early finding. Joint and tendon destruction may lead to deformities such as ulnar deviation, boutonnière and swan-neck deformities, hammer toes, and occasionally joint ankylosis.

Other commonly observed musculoskeletal manifestations are tenosynovitis and associated tendon rupture (due to tendon and ligament involvement, most commonly involving the fourth and fifth digital extensor tendons at the wrist), periarticular osteoporosis due to localized inflammation and generalized osteoporosis due to systemic chronic inflammation, immobilization-related changes or corticosteroid therapy, and carpal tunnel syndrome. Most patients have muscle atrophy from disuse, which is often secondary to joint inflammation.

Effect of RA on organs and organ systems

- **Skin**: Subcutaneous nodules (rheumatoid nodules) occur in many patients with RA whose RF value is abnormal. They are often present over pressure

points (eg, olecranon). Vasculitic lesions of the skin may manifest as palpable purpura or skin ulceration.

- **Cardiac**: The incidence of cardiovascular morbidity and mortality is increased in patients with RA. Nontraditional risk factors appear to play an important role. Myocardial infarction, myocardial dysfunction, and asymptomatic pericardial effusions are common; symptomatic pericarditis and constrictive pericarditis are rare. Myocarditis, coronary vasculitis, valvular disease, and conduction defects are occasionally observed.

- **Pulmonary**: RA involvement of the lungs may take several forms, including pleural effusions, interstitial fibrosis, nodules (Caplan syndrome), and bronchiolitis obliterans-organizing pneumonia.

- **GI**: Intestinal involvement, as with kidney involvement, is often secondary to associated processes such as medication effects, inflammation, and other diseases. The liver is often affected in patients with Felty syndrome (ie, RA, splenomegaly, and neutropenia).

- **Renal**: The kidneys commonly are not affected directly by RA. Secondary involvement is common, including that due to medications (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], gold, cyclosporin), inflammation (eg, amyloidosis), and associated diseases (eg, Sjögren syndrome with renal tubular abnormalities).

- **Vascular**: Vasculitic lesions can occur in any organ but are most commonly found in the skin. Lesions may present as palpable purpura, skin ulcers, or digital infarcts.

- **Hematologic**: Most active patients have an anemia of chronic disease. Several hematologic parameters parallel disease activity, including normochromic-normocytic anemia, thrombocytosis, and eosinophilia, although the latter is uncommon. Leukopenia is a finding in patients with Felty syndrome.

- **Neurologic**: Entrapment of nerves is common, such as with the median nerve in carpal tunnel syndrome. Vasculitic lesions, mononeuritis multiplex, and cervical myelopathy may cause serious neurological consequences.

- **Ocular**: Keratoconjunctivitis sicca is common in RA and is often the initial manifestation of secondary Sjögren syndrome. The eye may also have episcleritis, uveitis, and nodular scleritis that may lead to scleromalacia.

Differencial diagnosis.

Other problems to be considered as the following:

- Infectious arthritis - Bacteria (eg, Lyme disease, fungi, mycobacteria), viruses (eg, hepatitis B, rubella, parvovirus, human T-cell leukemia virus 1). Pyogenic arthritis can be distinguished by chills and fever, demonstration of the causative organism in joint fluid, and the frequent presence of a primary focus elsewhere (eg, gonococcal arthritis).
- Autoimmune connective tissue diseases (eg, systemic lupus erythematosus, progressive systemic sclerosis, mixed connective tissue disease, Sjögren syndrome, vasculitis, cryoglobulinemias) can associated with arthritis, but not with destructive arthritis.
- Polymyalgia rheumatica occasionally causes polyarthritis in patients older than 50 years, but these patients have chiefly proximal muscle pain and stiffness and remain negative for rheumatoid factor
- Hemoglobinopathies and subacute bacterial endocarditis frequently correspond to monoarthritis, but not with polyarthritis with positive RF.
- Gout and other rheumatic diseases (eg, seronegative spondyloarthropathy [eg, ankylosing spondylitis, reactive arthritis])
  During the early years of disease, gouty arthritis is almost always intermittent and monoarticular; in later years, it can become a chronic polyarticular process that mimics RA. Gouty tophi can at times resemble rheumatoid nodules. The early history of intermittent monoarthritis and the presence of synovial urate crystals are distinctive features of gout.
- Rheumatic fever.
  Rheumatic fever is characterized by the migratory nature of the arthritis, an elevated anti-streptolysin O titer, and a more dramatic and prompt response to aspirin. Carditis and erythema marginatus may occur in adults, but chorea and subcutaneous nodules virtually never do.
- Degenerative joint disease is not associated with constitutional manifestations; in contrast to the morning stiffness of RA, the joint pain from DJD is characteristically relieved by rest. Signs of articular inflammation prominent in RA are usually minimal in DJD, and in contrast to RA, osteoarthritis spares the wrist and the MCP joints.
- A variety of cancers and angioimmunoblastic lymphadenopathy produce paraneoplastic syndromes, including polyarthritis. One form is hypertrophic pulmonary osteoarthropathy, which is most often produced by lung and gastrointestinal carcinomas. Hypertrophic pulmonary osteoarthropathy is characterized by a rheumatoidlike arthritis associated with clubbing, periosteal new bone formation, and a negative RF test. Diffuse swelling of

the hands with palmar fasciitis has also been reported with a variety of cancers, especially ovarian carcinoma.

Lab Studies

- No pathognomonic test is available to help confirm the diagnosis of RA; instead, the diagnosis is made using clinical, laboratory, and imaging features.
- Markers of inflammation, such as ESR and CRP, are associated with disease activity; additionally, the CRP value over time correlates with radiographic progression.
- Hematologic parameters include a CBC count and synovial fluid analysis.
- Complete blood cell count
- Anemia of chronic disease is common and correlates with disease activity; it improves with successful therapy.
- Hypochromic anemia suggests blood loss, commonly from the GI tract (associated with NSAIDs).
- Anemia may also be related to disease-modifying antirheumatic drug (DMARD) therapy.
- Thrombocytosis is common and is also associated with disease activity.
- Thrombocytopenia may be a rare adverse event of therapy and may occur in patients with Felty syndrome.
- Leukocytosis may occur but is usually mild.
- Leukopenia may be a consequence of therapy or a component of Felty syndrome, which may then respond to DMARD therapy.

Synovial fluid analysis

- An inflammatory synovial fluid (WBC count >2000/μL) is present with counts generally from 5,000-50,000/μL.
- Usually, neutrophil predominance (60-80%) is observed in the synovial fluid (in contrast with mononuclear cell predominance in the synovium).
- Note that because of a transport defect, the glucose levels of pleural, pericardial, and synovial fluids from patients with RA are often low compared to serum glucose levels.
- Immunologic parameters include RF, antinuclear antibodies, and, possibly, other newer antibodies (anti-RA33, anti-CCP).

Rheumatoid factor

- RF is an immunoglobulin (Ig) M antibody directed against the Fc fragment of IgG that is present in approximately 60-80% of patients with RA over the course of their disease (but in fewer than 40% of patients with early RA). RF

values fluctuate somewhat with disease activity, though titers of RF generally remain high even in patients with drug-induced remissions.

- RF values fluctuate somewhat with disease activity, although high-titered RF generally remains present even in patients with drug-induced remissions.

Antinuclear antibodies

- Antinuclear antibodies: These are present in approximately 40% of patients with RA, but test results for antibodies to most nuclear antibody subsets are negative.
- Newer antibodies (eg, anti-RA33, anti-CCP): Recent studies of anti-CCP antibodies suggest a sensitivity and specificity equal to or better than those of RF, with an increased frequency of positive results in early RA. The presence of both anti-CCP antibodies and RF is highly specific for RA. Additionally, anti-CCP antibodies, as do RF, indicate a worse prognosis and anti-CCP -positive patients may have a more erosive RA disease course than ACPA-negative patients

Other biomarkers

There are novel RA biomarkers panels that were recently found to be improved the diagnosis of early RA in patients who tested negative on conventional tests. The panel of 4 biomarkers—UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21—had 83% specificity for RA. These markers were found in 37% of patients with early RA and 26% of those who were seronegative for rheumatoid factor and anticitrullinated protein antibody. The investigators suggested that in addition to an improved diagnosis in early RA, use of these biomarkers may also have prognostic potential.

Pregnancy and RA

RA often goes into remission during pregnancy. The presence of RF neither helps predict nor correlates with the outcome of arthritis during pregnancy. The ESR cannot be used to assess RA disease activity during pregnancy, because pregnancy alters the normal values. The volume expansion that occurs during pregnancy can result in lower hematocrit values.

Imaging Studies

Radiographs: Note that erosions may be present in the feet, even in the absence of pain and in the absence of erosions in the hands.

Extremities - Hands, wrists, knees, feet, elbows, shoulders, hips, cervical spine. Others when indicated

MRI: This modality is primarily used in patients with abnormalities of the cervical spine; early recognition of erosions based on MRI images has been sufficiently validated.

Sonography: This allows recognition of effusions in joints that are not easily accessible (eg, hip joints, shoulder joints in obese patients) and cysts (Baker cysts). High-resolution ultrasound images may allow visualization of tendon sheaths, changes and degree of vascularization of the synovial membrane, and even erosions; however, this needs further validation. Sonography may be used as an office-based procedure.

Bone scanning: Findings may help to distinguish inflammatory from noninflammatory changes in patients with minimal swelling.

Densitometry: Findings are useful for helping diagnose changes in bone mineral density indicative of osteoporosis.

Other Tests

HLA-DR4 (shared epitope) may constitute a helpful marker in early undifferentiated arthritis.

Procedures

Joint aspiration, diagnostic arthroscopy (histology), and biopsies (eg, skin, nerve, fat, rectum, kidney) may be considered if vasculitis or amyloidosis is suggested.

Histologic Findings

The lymphoplasmacytic infiltration of the synovium with neovascularization seen in RA is similar to that seen in other conditions characterized by inflammatory synovitis. Early rheumatoid nodules are characterized by small vessel vasculitis and later by granulomatous inflammation.

2012 ACR Disease Activity Measures

In 2012 the ACR published new recommendations for the measurement of disease activity for clinical use at the point of care. The scales used included the following 6 recommended measures:

- Patient-driven composite tools – (1) PAS (patient activity scale): scale, 0-10; (2) PAS II: scale, 0-10; (3) RAPID-3 (routine assessment of patient index data with 3 measures): scale, 0-10; these can be completed easily by the patient before they are seen by clinicians
- Patient and provider composite tool – (4) CDAI (clinical disease activity index): scale, 0-76
- Patient, provider, and laboratory composite tools – (5) DAS28 (28-joint disease activity score) (ESR or CRP): scale, 0-9.4; (6) SDAI (simplified disease activity index): scale, 0-86

The 6 measures above result in a single continuous index with defined ranges for low, moderate, or high disease activity or clinical remission. In addition, the data

collected from these measures are not solely dependent on the patient's report, the clinician's assessment, or laboratory measurements.

Activity of RA according to DAS-28 calculation

Activity RA is calculated using special calculator DAS-28 (Scheme 1) by formula:

DAS28 = 0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR) + 0.014*GH

This calculation may be done using free on-line calculator http://www.das-score.nl

Scheme 1: DAS 28

The DAS28 is a measure of disease activity in rheumatoid arthritis (RA). DAS stands for 'disease activity score' and the number 28 refers to the 28 joints that are examined in this assessment.

There are a wide range of measures of disease activity in RA including:-

- examination of your joints for swelling and tenderness,
- global scores of pain and overall status,
- blood markers of inflammation (e.g. ESR and CRP),
- questionnaires (e.g. the HAQ which assesses function),
- X-rays, and newer imaging techniques such as ultrasound and MRI.

The DAS28 is a composite score derived from 4 of these measures. This '28' version is a simplification of the original DAS score, which requires 44 joints to be counted. Other versions of the DAS28 allow the CRP to be used instead of the ESR, or the omission of either. To calculate the DAS28 your rheumatologist or specialist nurse will:-

- count the number of swollen joints (out of the 28),
- count the number of tender joints (out of the 28),
- take blood to measure the erythrocyte sedimentation rate (ESR) or C reactive protein (CRP), ask you (the patient) to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).

These results are then fed into a complex mathematical formula to produce the overall disease activity score. A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission. A sample the received results using DAS-28 is reported on the Scheme 2.

Scheme 2: Principles of interpretation of DAS-28

Measurement of disease progression

In the 2012 ACR-recommended RA disease activity measures, the following indicate disease activity cutoffs for patient-driven composite tools (all 3 scales, 0-10):

- PAS and PAS-II – Low/minimal disease, 0.26-3.70; moderate disease, 3.71 to less than 8.0; high/severe disease, 8.00-10.00
- RAPID-3 – Low/minimal disease, greater than 1.0 to 2.0; moderate disease, greater than 2.0 to 4.0; high/severe disease, greater than 4.0 to 10

For the CDAI patient and provider composite tool (scale, 0-76), low/minimal disease is in the range of greater than 2.8 to 10.00; moderate disease, greater than 10.0 to 22.0; and high/severe disease, greater than 22.0.

The following disease activity cutoffs are for the ACR-recommended RA patient, provider, and laboratory composite tools:

- DAS28 (ESR or CRP) (scale, 0-9.4) – Low/minimal disease, 2.6 or more to less than 3.2; moderate disease, 3.2 or more to 5.1 or less; high/severe disease greater than 5.1
- SDAI (scale, 0-86) – Low/minimal disease, greater than 3.3 to 11.0 or less; moderate disease, greater than 11.0 to 26 or less; high/severe disease, greater than 26

Measurement of disease remission

In 2011, the ACR and the EULAR published a Boolean-based definition of remission in RA, according to which a patient must satisfy all of the following to be considered in remission:

- Tender joint count of 1 or less (if joints are tender and swollen, a 28-joint count may miss actively involved joints, particularly those in the feet and ankles; include the feet and ankles when assessing for remission)
- Swollen joint count of 1 or less (as noted above, include the feet and ankles when assessing for remission)
- CRP level of 1 mg/dL or lower
- Patient global assessment of 1 or less (on a 0-10 scale); suggestions are available for appropriate formatting and wording for global assessment questions to evaluate remission. In addition, the ACR/EULAR index-based definition considers RA patients to be in remission if they have an SDAI score of 3.3 or lower. The SDAI score is defined as the sum of the tender joint count (28 joints), swollen joint count (28 joints), patient global assessment (0-10 scale), and CRP measurement (mg/dL).

Given the cost and potential adverse effects of newer drugs used to treat RA, individualized treatment requires knowledge of poor prognostic factors. A systematic review of prospective studies identified 16 independent clinical, laboratory, and genetic factors predictive of RA remission. Although the predictive value of these factors remains to be confirmed, early aggressive treatment has been shown to improve outcomes regardless of poor prognostic factors.

In the 2012 ACR-recommended RA disease activity measures, the following indicate disease remission cutoffs for patient-driven composite tools (all 3 scales, 0-10):

- PAS and PAS-II – Remission, 0.00-0.25
- RAPID-3 – Remission, 0-1.0

For the CDAI patient and provider composite tool (scale, 0-76), remission is indicated by a measurement of 2.8 or less.

The following disease remission cutoffs are for the ACR-recommended RA patient, provider, and laboratory composite tools:

- DAS28 (ESR or CRP) (scale, 0-9.4) – Remission, less than 2.6
- SDAI (scale, 0-86) – Remission, 3.3 or less

The American College of Rheumatology developed criteria to aid in determining the progression, remission, and functional status of patients with RA. Progression of RA (clinical and radiological staging)

Stage 1 (early RA)

- No destructive changes observed upon roentgenographic examination
- Radiographic evidence of osteoporosis possible

Stage II (moderate progression)

- Radiographic evidence of periarticular osteoporosis with or without slight subchondral bone destruction
- Slight cartilage destruction possible
- Joint mobility possibly limited; no joint deformities observed
- Adjacent muscle atrophy
- Extra-articular soft tissue lesions (eg, nodules, tenosynovitis) possible

Stage III (severe progression)

- Radiographic evidence of cartilage and bone destruction in addition to periarticular osteoporosis
- Joint deformity (eg, subluxation, ulnar deviation, hyperextension) without fibrous or bony ankylosis
- Extensive muscle atrophy
- Extra-articular soft tissue lesions (eg, nodules, tenosynovitis) possible
- Stage IV (terminal progression)

- Fibrous or bony ankylosis

Criteria of stage III
- Remission of RA - Five or more of the following conditions present for at least 2 consecutive months
- Duration of morning stiffness not exceeding 15 minutes
- No fatigue
- No joint pain
- No joint tenderness or pain with motion
- No soft tissue swelling in joints or tendon sheaths
- ESR of less than 30 mm/h for a female or less than 20 mm/h for a male

Functional status of patients with RA
- Class I - Completely able to perform usual activities of daily living
- Class II - Able to perform usual self-care and vocational activities but limited in avocational activities
- Class III - Able to perform usual self-care activities but limited in vocational and avocational activities
- Class IV - Limited in ability to perform usual self-care, vocational, and avocational activities

The HAQ questionnaire assesses function

The DAS score was originally developed by Dutch rheumatologists for the purpose of standardizing and comparing results in clinical trials of new drugs for treating RA . With time the DAS28 has also been applied to routine clinical practice. In the UK a score equal or greater than 5.1 on two occasions is one of the mandatory criteria required to be eligible for NHS funded treatment with biologic (including anti-tumour necrosis factor) therapies.

The DAS-CRP score

The DAS-CRP is a modification of the DAS28 (Disease Activity Score 28). Originally the DAS28 includes the measured erythrocyte sedimentation rate (ESR) value, while the DAS-CRP uses the C-Reactive Protein (CRP) value instead. The DAS-CRP is often used in clinical trials for the development of RA. The DAS-CRP is also referred to as DAS28(CRP).

DAS-CRP values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS-CRP below the value of 2.6 is interpreted as Remission. Studies that compared the DAS-CRP and the DAS28 (ESR) showed that DAS-CRP underestimates disease activity and overestimates the improvement in disease activity compared with DAS28-ESR.

As the original DAS28 the DAS-CRP uses 28 different joints for its calculation:
- proximal interphalangeal joints (10 joints)

- metacarpophalangeal joints (10)
- wrists (2)
- elbows (2)
- shoulders (2)
- knees (2)

When looking at these joints, both the number of joints with tenderness upon touching and swelling are counted. In addition, the erythrocyte sedimentation rate is measured. Also, the patient makes a subjective assessment of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is "no activity" and 100 is "highest activity possible".

With the above mentioned parameters, DAS-CRP is calculated as:

$$DAS\text{-}CRP = 0.56 \times \sqrt{TEN28} + 0.28 \times \sqrt{SW28} + 0.36 \times \ln(CRP+1) + 0.014 \times SA + 0.96$$

With:

- TEN28: number of joints with tenderness upon touching
- SW28: number of swollen joints
- CRP: C-reactive Protein
- SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale betweenn 0 and 100 ("0":no activity, "100": highest activity possible)

The DAS-CRP provides an absolute indication of RA disease activity on a scale of 0.49 to 9.07

- A DAS-CRP value >5.1 corresponds to a high disease activity
- A DAS-CRP value between 3.2 and 5.1 corresponds to a moderate disease activity
- A DAS-CRP value between 2.6 and 3.2 corresponds to a low disease activity
- A DAS-CRP value < 2.6 corresponds to remission

Medical Care

Optimal care of patients with RA requires an integrated approach of pharmacologic and nonpharmacologic therapies.

Nonpharmacologic

Education is important in helping patients to understand their disease and to learn how to cope with its consequences. Physiotherapy and physical therapy are initiated to help improve and sustain range of motion, increase muscle strength, and reduce pain. Occupational therapy is initiated to help patients to use joints and tendons efficiently without stressing these structures, to help patients decrease

tension on the joints through the use of specially designed splints, and to help patients to cope with daily life through the use of adaptations to the patients' environment and the use of different aids. Orthopedic measures include reconstructive and replacement-type surgical measures.

Pharmacologic

The most important measure to successfully treat RA is the use of DMARDs. DMARDs can retard or prevent disease progression and, thus, joint destruction and subsequent loss of function. Successful DMARD therapy may eliminate the need for other anti-inflammatory or analgesic medications. Until the full action of DMARDs takes effect, anti-inflammatory or analgesic medications may be required as bridging therapy to reduce pain and swelling. DMARDs can be classified into xenobiotic and biologic agents. Current task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar DMARDs) and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).

Xenobiotic agents

The xenobiotic DMARDs, ie, gold salts (eg, aurothiomalate, auranofin, others), D-penicillamine, chloroquine and hydroxychloroquine, sulfasalazine (SSZ), methotrexate (MTX), azathioprine, and cyclosporin A, have been widely used to treat RA; some have been used for decades.

MTX and SSZ are the most active compounds in terms of frequency of remissions and time to onset of action and provide the best risk-benefit ratios. MTX alone or in combination with other agents has become the standard of care for moderate-to-severe RA.

Interest in the use of minocycline has recently been increasing because of its capacity to act as a DMARD. Leflunomide is the most recent addition to the xenobiotics and has an activity similar to that of SSZ and MTX. SSZ is dosed up to 2-4 g/d, while MTX is administered up to 25 mg once a week (PO, IV, IM, or SC). Both SSZ and MTX are started at low dosages and are increased to full dosages within approximately 4-6 weeks. Monitoring of CBC counts and liver enzymes is important because of the drugs' hematologic and hepatic toxicities. Approximately 1% of patients develop agranulocytosis to SSZ or pneumonitis to MTX. Leflunomide is usually initiated with a loading dose of 100 mg/d for 3 days and is then continued at 20 mg/d. CBC counts and liver enzymes also must be monitored.

Most of these drugs have been shown to improve signs and symptoms (as well as quality of life) and to significantly retard radiographic progression of RA.

The most important and most common adverse events relate to liver and bone marrow toxicity (MTX, SSZ, leflunomide, azathioprine, gold compounds, D-penicillamine), renal toxicity (cyclosporine A, parenteral gold salts, D-penicillamine), pneumonitis (MTX), allergic skin reactions (gold compounds, SSZ), autoimmunity (D-penicillamine, SSZ, minocycline) and infections (azathioprine, cyclosporine A). Antimalarials may cause ocular toxicity. Nevertheless, these drugs, when used with appropriate clinical and laboratory control monitoring, are usually tolerated well. Adverse events typically become more rare after the first 2-3 months. Most adverse events are reversible with cessation of the drugs or with reduction of the doses.

It has been shown that approximately 30-70% of patients using DMARDs, either alone or in combined therapy, achieve partial responses according to the American College of Rheumatology's disease activity score. Predicting which patients will not respond is impossible. In clinical practice, attempting to reduce disease activity as much as possible by increasing the dose of medication (eg, MTX), switching to other DMARDs in those who do not respond or in those with responses regarded as insufficient, or initiating combination therapy is important. Because patients may require 2-3 months to achieve a full response to DMARDs, decisions regarding changes in medication are often delayed until that time.

Biologic agents

The recognition of TNF-alpha and IL-1 as central proinflammatory cytokines has led to the development of agents that block these cytokines or their effects. The TNF blockers include etanercept, infliximab, and adalimumab. Etanercept, a bivalent p75–TNF receptor linked to the Fc portion of human IgG, is administered at 25 mg SC twice weekly or 50 mg SC weekly, with or without concomitant MTX. Infliximab, a chimeric monoclonal antibody against TNF-alpha, is administered at doses of 3 mg/kg IV at weeks 0, 2, and 6 and then every 4-8 weeks, usually with MTX. Adalimumab, a recombinant human IgG1 monoclonal antibody specific for human TNF monoclonal antibody, is administered 40 mg SC every 2 weeks.

These agents are expensive. Consensus statements do not recommend their use until at least one xenobiotic DMARD, usually MTX, has been administered without sufficient success. In clinical trials, up to 70% of patients achieve significant responses, but remissions are not usually observed.

These agents bind TNF and thus prevent its interaction with its receptors; infliximab binds to cells that express membrane TNF, while etanercept binds

lymphotoxin (formerly termed TNF-beta) in addition to soluble TNF-alpha. Failure to respond to one TNF blocker does not preclude response to another. As with xenobiotics, the decision to continue or stop biologic agents can often be made within 3 months after initiation of therapy.

Adverse effects associated with the biologic agents include the generation of antibodies against these compounds, emergence of antinuclear antibodies, occasional drug-induced lupus like syndromes, and infections (including tuberculosis). Rarely, demyelinating disorders and bone marrow suppression may occur. Acute and chronic infections, demyelinating disorders, and recent malignancies are contraindications for TNF blockers. Thoroughly searching for latent tuberculosis using chest x-ray films and/or purified protein derivative (PPD) testing is recommended before starting these agents.

Another biologic is anakinra (IL-1 receptor antagonist [IL-1ra]). IL-1ra occupies the IL-1 receptor without triggering it and prevents receptor binding of IL-1. It is given at a dose of 100 mg/d SC. In clinical trials, a significant response was observed in approximately 40% of patients with RA.

Abatacept is a selective costimulation modulator that inhibits T-cell activation by binding to CD80 and CED86, thereby blocking CD28 interaction. CD28 interaction provides a signal needed for full T-cell activation that is implicated in RA pathogenesis. It is dosed according to body weight (vida infra); after initial infusion, repeat on week 2 and week 4, then every 4 weeks following.

In addition to improving signs and symptoms and quality of life, all biologics significantly retard radiographic progression of joint erosions.

An algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on RA management is reported on Scheme 3.

Targeted synthetic DMARDs

Targeted synthetic DMARDs (the Janus kinase inhibitors -JAKs) include tofacitinib, baricitinib, filgotinib, and upadacitinib, which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA. Janus kinases consist of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor–receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity, including gene expression. JAK inhibitors modulate the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. These signals maintain the inflammatory condition in RA.

Inhibition of JAKs reduces production of and modulates proinflammatory cytokines central to RA.

Tofacitinib is an oral inhibitor of JAK-3 was approved by the FDA in November 2012 as second-line treatment for moderate to severe active RA. The indication is specific for patients who have had an inadequate response to or are intolerant of MTX. Tofacitinib may be given as monotherapy or in combination with MTX or other nonbiologic DMARDs. It should not be used in combination with biologic DMARDs or potent immunosuppressive agents (eg, azathioprine or cyclosporine). Tofacitinib has been associated with reductions in signs and symptoms of RA and improvement in physical function. Treatment with tofacitinib 5 mg twice daily was generally well-tolerated, with the most frequently reported adverse events and does not increase the risk for malignancies.

Baricitinib is a second JAK-1 and JAK-3 inhibitor was approved by FDA in June 2018 as a second-line treatment of moderately to severely active RA in adults who have had an inadequate response to one or more TNF antagonists. Baricitinib may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs. It should not be used in combination with biologic DMARDs or potent immunosuppressive agents (eg, azathioprine or cyclosporine). The dosage of baricitinib is one 2-mg tablet daily. The FDA declined to approve 4-mg tablets, citing safety concerns. The drug's prescribing information will contain a boxed warning about the risk for serious infections, malignancies, and thrombosis.

Another JAK inhibitor, upadacitinib, was approved in August 2019 for moderately to severely active RA in adults who have had an inadequate response or are intolerant to methotrexate. It may be used as monotherapy or in combination with methotrexate or other xenobiotic DMARDs.

Combination DMARD therapy

About 30-70% of patients using DMARDs, either as monotherapy or in combination therapy, achieve partial responses, as determined by the ACR disease activity score. Currently, it is not possible to predict which patients will not have a treatment response. In clinical practice, three strategies are employed to reduce disease activity as much as possible in patients whose disease does not respond or in those with clinical responses that are regarded as insufficient:

- Increasing the dose of medication
- Switching to other DMARDs
- Initiating combination therapy

Because patients may require 2-3 months to achieve a full response to DMARDs, decisions regarding changes in medication are often delayed until that time.

Combination therapy appears to be helpful in patients whose disease partly or completely fails to respond to DMARD monotherapy. One study found that in patients with early, active RA, combination DMARD therapy with downward titration or intensive triple-DMARD combination therapy is more cost-effective than DMARD monotherapy. Several combinations have proved successful without posing unexpected added risks; most include MTX (eg, MTX plus SSZ plus HCQ, MTX plus leflunomide, or MTX plus biologic DMARDs). Combination therapy appears to be helpful in patients who had RA insufficiently or completely fails to respond to monotherapy with a DMARD.

Phase I

Clinical diagnosis of Rheumatoid Arthritis[1]

No contraindication for methotrexate — *Contraindication for methotrexate*

Start methotrexate[3] + Combine with short-term glucocorticoids + Start leflunomide or sulfasalazine

Achieve improvement at 3 months and target at 6 months[2]

No → Failure phase I: go to phase II

Yes → Continue → Dose reduction in sustained remission

Phase II

Failure for lack of efficacy and/or toxicity in phase I

Prognostically unfavourable factors present — *such as RF/ACPA, esp. at high levels; high disease activity; early joint damage; failure of ≥2 csDMARDs*

Prognostically unfavourable factors absent

Change to or add a second conventional synthetic DMARD
Leflunomide, sulfasalazine, methotrexate alone or in combination[6] (ideally with addition of glucocorticoids as above)

Achieve improvement at 3 months and target at 6 months[2]

No → Add a bDMARD[4] (current practice) or a Jak-inhibitor[5]

Achieve improvement at 3 months and target at 6 months[2]

No → Failure phase II: go to phase III

Yes → Continue → Dose reduction / interval increase in sustained remission[7]

Phase III

Failure for lack of efficacy and/or toxicity in phase II

Change the bDMARD
Replace any first bDMARD by any other bDMARD [abatacept or IL-6-inhibitor[8] or rituximab or a (second) TNF-inhibitor[4]] or use a Jak-inhibitor[9]

Achieve improvement at 3 months and target at 6 months[2]

Yes → Continue → Dose reduction / interval increase in sustained remission[7]

No → Other bDMARD or tsDMARD

[1]2010 ACR-EULAR classification criteria can support early diagnosis. [2]The treatment target is clinical remission according to ACR-EULAR definition or, if remission is unlikely to be achievable, at least low disease activity; the target should be reached after 6 months, but therapy should be adapted or changed if no sufficient improvement is seen after 3 months. [3]"Methotrexate should be part of the first treatment strategy"; while combination therapy of csDMARDs is not preferred by the Task Force, starting with methotrexate does not exclude its use in combination with other csDMARDs. [4]TNF-inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab, including EMA/FDA approved bsDMARDs), abatacept, IL-6-inhibitors, or rituximab; in patients who cannot use csDMARDs as comedication, IL6-inhibitors and tsDMARDs have some advantages. [5]Current practice would be to start with a bDMARD (in combination with MTX or another csDMARD) because of the long-term experience compared with tsDMARDs (Jak-inhibitors). [6]The most frequently used combination comprises methotrexate, sulfasalazine and hydroxychloroquine. [7]Dose reduction or interval increase can be safely done with all bDMARDs with little risk of flares; stopping is associated with high flare rates; most but not all patients can recapture their good state upon re-institution of the same bDMARD. [8]Efficacy and safety of bDMARDs after Jak-inhibitor failure is unknown; also, efficacy and safety of an IL-6 pathway inhibitor after another one has failed is currently unknown. [9]Efficacy and safety of a Jak-inhibitor after insufficient response to a previous Jak-inhibitor is unknown.

Scheme 3. Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on RA management.

Abbreviations: ACPA, anticitrullinated protein antibody; ACR, American College of Rheumatology; bDMARD, biological DMARD; bsDMARD, biosimilar DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs; EMA, European Medicines Agency; FDA, Food and Drug Administration; IL, interleukin; MTX, methotrexate; RF, rheumatoid factor; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs

Several compounds have been successfully combined without unexpected added risks; these usually include MTX as one of the drugs, ie, MTX plus cyclosporine A, MTX plus SSZ plus an antimalarial, MTX plus leflunomide, or MTX plus biologics. In general, the same precautions are needed as with the single compounds, although liver and bone marrow toxicity may be increased if compounds affecting these organs are combined.

Early therapy

Many studies have revealed that early treatment of RA (ie, within 3-12 mo of onset) with DMARDs can not only more efficiently retard disease progression than later treatment, but also may induce more remissions. Thus, early therapy with DMARDs has become the standard of care. Importantly, note that patients with early forms of arthritis should be evaluated by, and if necessary, referred to physicians who are experienced in the diagnosis and treatment of this disease. It has beeb recommended to administer DMARD monotherapy in patient with early RA and low-high disease activity. If disease activity remains moderate / high despite DMARD monotherapy, use combination DMARDs or a TNF inhibitor or a non-TNF biologic drugs. If disease activity remains moderate or high despite DMARD monotherapy, ACR guidelines recommend one of the following:

- Combination DMARDs
- Add an anti-TNF biologic
- Non-TNF biologic
- Tofacitinib

If disease activity remains moderate or high despite use of a single anti-TNF biologic, switch to a non-TNF biologic with or without MTX over another anti-TNF inhibitor or tofacitinib.

If disease activity remains moderate or high despite use of one anti-TNF biologic and one non-TNF biologic, use another non-TNF biologic with or without MTX over tofacitinib, and if still uncontrolled use tofacitinib.

Complications of DMARD treatment

Patients with an established diagnosis of RA who are being treated with DMARDs, particularly those treated with combination therapy, including biologic agents such as TNF antagonists, may present with serious infections, malignancies, or both. Additionally, adverse events from RA medications may include liver toxicity, renal toxicity, bone marrow depression, lung inflammation, and skin manifestations.

TNF precautions and mortality

Patients taking anti-TNF agents must avoid live-virus vaccines (eg, measles-mumps-rubella, HZV, varicella-zoster virus, and bacillus Calmette-Guérin vaccines) to avoid the potential for serious infection. The evaluation of a risk of malignancy in patients with RA treated with TNF inhibitors showed that these DMARDs did not increase the risk of malignancy, particularly lymphoma; however, they did appear to increase the risk of skin cancer, including melanoma.

Glucocorticoids

Glucocorticoids are potent anti-inflammatory drugs and are commonly used in patients with RA to bridge the time until DMARDs are effective. Doses of up to 10 mg of prednisone per day are typically used, but some patients may require higher doses. Timely dose reductions and cessation are important because of the adverse effects associated with long-term steroid use. One study found that the use of corticosteroids was associated with heart failure in patients with RA, independent of cardiovascular risk factors and coronary heart disease. Those patients who currently used MTX showed a lower risk of heart failure.

Recommendations for Use of DMARDS and Biologic Agents 2019 EULAR Recommendations

Guidelines from the European League Against Rheumatism (EULAR) on the use of DMARDs in patients with rheumatoid arthritis (RA) were updated in 2019. Recommendations include the following:

- Therapy with DMARDs should be started as soon as the diagnosis of RA is made.
- Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
- Patients with active disease should have frequent monitoring (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.
- Methotrexate (MTX) should be part of the first treatment strategy.
- In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the first-line treatment strategy.

- Short-term glucocorticoids should be considered when initiating or changing the dose of a conventional synthetic DMARDs; different dose regimens and routes of administration may be used for glucocorticoids, but the drugs should be tapered as rapidly as clinically feasible.
- If the treatment target is not achieved with the first conventional synthetic DMARD strategy, in the absence of poor prognostic factors, other conventional synthetic DMARDs should be considered.
- If the treatment target is not achieved with the first conventional synthetic DMARD strategy, when poor prognostic factors are present, a biologic DMARD or a targeted synthetic DMARDs (currently, Janus kinase inhibitors) should be added.
- Biologic DMARDs or targeted synthetic DMARDs should be combined with a conventional synthetic DMARD; in patients who cannot use conventional synthetic DMARDs as co-medication, interleukin-6 pathway inhibitors and targeted synthetic DMARDs may have some advantages compared with other biologic DMARDs.
- If a biologic DMARD or targeted synthetic DMARD has failed, treatment with another biologic or targeted synthetic DMARD should be considered; if one tumor necrosis factor (TNF) inhibitor therapy has failed, patients may receive an agent with another mode of action or a second TNF inhibitor.
- If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering biologic or targeted synthetic DMARDs, especially if this treatment is combined with a conventional synthetic DMARD.
- If a patient is in persistent remission, tapering the conventional synthetic DMARD could be considered

Non-steroid anti-inflammatory drugs

NSAIDs interfere with prostaglandin synthesis through inhibition of the enzyme cyclooxygenase (COX), thus reducing swelling and pain. However, they do not retard joint destruction and thus are not sufficient to treat RA when used alone. Like corticosteroids, NSAIDs can be reduced in dose or discontinued with successful DMARD therapy. The several dozen NSAIDs are available can be classified into several different groups of compounds. Traditional NSAIDs are nonselective COX inhibitors, include ibuprofen, naproxen, ketoprofen, piroxicam, and diclofenac.

The coxibs (COX-2 inhibitors), a new group of compounds, have recently been developed. These compounds have a significant preference for COX-2 over COX-1. COX-1 has a protective role, particularly in the stomach, while COX-2 is

strongly up-regulated during inflammation. Coxibs, with their selectivity for COX-2, have been shown to be clinically efficacious and are accompanied by significantly reduced GI toxicity, the major adverse event related to the use of nonselective COX inhibitors (ie, NSAIDs). Other adverse effects, such as water retention, hypertension, and abnormal transaminase levels, are observed with both nonselective and COX-2–selective drugs. Whether and to what degree nonaspirin NSAIDs, coxibs, or both have cardiovascular toxicity has not been definitively settled.

Analgesics

Acetaminophen/paracetamol, tramadol, codeine, opiates, and a variety of other analgesic medications can also be employed to reduce pain. These agents do not affect swelling or joint destruction.

Experimental therapies

Despite significant advances over the past decades, RA continues to be an incurable disease. The disease remains active in many patients whose conditions partially or completely fail to respond to DMARDs. Therefore, a vigorous search is underway for new therapeutic agents. Although not truly experimental because it has been approved for use in RA, an immunoadsorbent column (Prosorba) is used on occasion to treat patients with resistant disease. Weekly exchanges are given for 12 weeks. New TNF blockers are in clinical trials and include CDP 870, a Fab fragment of a humanized monoclonal antibody; and a pegylated version of the p55 TNF receptor. Biologics capable of blocking IL-6 or interfering with T-cell/non–T-cell interactions may also be promising. Xenobiotics directed at molecules involved in transduction of TNF or IL-1–mediated signals could prove helpful. Inhibition of matrix metalloproteinases, although initially unsuccessful, could prove to be efficacious, as could agents that inhibit activation of osteoclasts. Apheresis procedures are being investigated. High-dose immunosuppression combined with autologous stem cell transplantation has been used in study protocols for patients whose conditions are resistant to other therapies.

Surgical Care

Cervical spine involvement usually affects C1-C2 and may potentially cause serious neurological consequences. Patients who are to undergo intubation or procedures that may involve manipulation of the neck should have careful evaluation of the cervical spine. Patients with RA often need multiple operations over time (eg, synovectomy, tendon corrections, joint replacements).

Consultations

- Orthopedists
- Physical and rehabilitative medicine specialists

Deterrence and Prevention

RA is a progressive inflammatory disease historically treated according to a pyramid or sequential strategy, beginning with NSAID therapy. The current approach to management emphasizes aggressive control of inflammation to prevent long-term damage using early DMARD therapy, including the use of single or combination DMARDs. Early use of DMARDs had traditionally been avoided until patients show signs of joint damage; however, this strategy has proved ineffective over several years. Patients experience poor long-term outcomes, including severe functional declines, radiographic progression of disease, work disability, and premature mortality.Two issues appear to be sources of confusion regarding long-term outcomes of treatment. First, a small percentage of patients who meet diagnostic criteria for RA have a self-limited process with spontaneous remission.

Thus, in the absence of signs of progression, some patients are diagnosed with, and subsequently treated for, other conditions. Second, measures of inflammatory activity, such as joint swelling or ESRs, are often used to assess inflammatory activity. However, these indices are less useful end points for evaluation than severe long-term outcomes such as work disability or joint deformity and radiographic changes, in which the latter two are irreversible. During a period in which inflammatory markers may be stable or even improved, radiographic progression and functional decline can occur.The traditional DMARDs, injectable gold salts and penicillamine, rarely induce sustained remission and are usually discontinued within 2 years. Because better agents are available, they are rarely used. Newer DMARDs, such as MTX and SSZ, have greater long-term effectiveness but still rarely induce true remission. Optimal control may require combination therapy. Recent studies have shown that MTX combined with other DMARDs is more effective and has acceptable toxicity when compared with use of a single agent. In combination with cyclosporine, MTX results in greater clinical improvement than MTX alone. Triple therapy with MTX, SSZ, and hydroxychloroquine provides substantially greater clinical improvement than MTX alone or SSZ plus hydroxychloroquine.1 In combination with infliximab, MTX provides a superior response to monotherapy.2 In combination with etanercept, MTX provides a higher rate of meaningful clinical response. Toxicities of these drug combinations are rarely more significant than those occurring with any of the individual agents used alone. The goal of contemporary management of RA should be complete remission or no evidence of disease activity. Achieving this goal likely requires ongoing drug therapy, probably using a combination of MTX with some other DMARD, although some patients may still respond satisfactorily to

monotherapy. More long-term studies are needed to evaluate potential important adverse effects associated with combination therapy before definite recommendations can be made.

Complications

RA is not fatal, but complications of the disease may shorten survival by a few years in some individuals. In general, RA is progressive and cannot be cured; in some, the disease gradually becomes less aggressive and symptoms may even improve. However, if bone and ligament destruction and any deformities have occurred, the effects are permanent.

Joint disability and pain with daily life are common. Affected joints can become deformed, and the performance of even ordinary tasks may be very difficult or impossible. According to one survey, 70% of patients with RA believe the disease prevents them from living a fully productive life. In 2000, a study in England found that approximately one third of individuals stop working within 5 years of the onset of disease. RA is a systemic disease that can affect other parts of the body in addition to joints. These effects include the following:

Peripheral neuropathy: This condition affects nerves, most often those in the hands and feet. It can result in tingling, numbness, or burning.

Anemia

Scleritis: This is an inflammation of the blood vessels in the eye that can result in corneal damage, scleromalacia, and, in severe cases of nodular scleritis, perforation.

Infections: Patients with RA have a higher risk for infections, particularly from some of the immunosuppressive drugs required for treatment.

GI problems: Although patients may experience stomach and intestinal distress, lower rates of stomach and colorectal cancers have been reported among patients with RA.

Osteoporosis: Osteoporosis is more common than average in postmenopausal women with RA. The hip is particularly affected. The risk for osteoporosis also appears to be higher than average in men with RA who are older than 60 years.

Lung disease: One small study found a very high prevalence of lung disease (pulmonary inflammation and fibrosis) in patients newly diagnosed with RA. However, the association between a history of smoking and a higher risk for RA may at least partially account for this finding. Cigarette smoking, in any case, may increase the severity of the disease.

Heart disease: RA can affect the blood vessels and increases the risk for coronary ischemic heart disease.

Sjögren syndrome: Keratoconjunctivitis sicca is a common complication of RA. Oral sicca and salivary gland enlargement are less common.

Felty syndrome: The combination of splenomegaly, leukopenia (neutropenia), and recurrent bacterial infections, this syndrome sometimes responds to DMARD therapy.

Lymphoma and other cancers: Alterations in the immune system associated with RA may play a role in the higher risk for lymphoma observed in patients with RA. Aggressive treatments for RA that suppress the immune system may help prevent this cancer, but more research is needed to evaluate this possibility. Other cancers that may occur with increased frequency in patients with RA include prostate and lung cancers.

Macrophage activation syndrome: This is a life-threatening complication of RA and requires immediate treatment with high-dose steroids and cyclosporin A. Patients should be aware of symptoms, which include persistent fever, weakness, drowsiness, and lethargy.

Prognosis

The clinical course is generally one of exacerbations and remissions. Approximately 40% of patients become disabled after 10 years, but outcomes are highly variable. Some patients experience a relatively self-limited disease, and others have a chronic progressive illness.

Improvements in the detection of early joint injury have provided a previously unappreciated view of the ubiquity and importance of early joint damage. Nonetheless, predicting the course of an individual case at the outset remains difficult, although the HLA-DRB1*04/04 genotype, a high serum titer of RF, extra-articular manifestations, a large number of involved joints, age younger than 30 years, female sex, and systemic symptoms all correlate with an unfavorable prognosis with joint damage and disability. Insidious onset is also an unfavorable sign.

Disease that remains persistently active for more than a year is likely to lead to joint deformities and disability. Cases in which periods of activity lasting only weeks or a few months are followed by spontaneous remission have a better prognosis.

The absence of RF does not necessarily portend a good prognosis. Outcome is compromised when diagnosis and treatment are delayed. Other laboratory markers of a poor prognosis include early radiologic evidence of bony injury, persistent anemia of chronic disease, elevated levels of the C1q component of complement, and the presence of anti-CCP antibodies.

The overall mortality rate for patients with RA is reportedly 2.5 times that of the general population. In those with severe articular and extra-articular disease, the mortality rate approaches that of patients with 3-vessel coronary disease or stage IV Hodgkin disease. Much of the excess mortality derives from infection, vasculitis, and poor nutrition. Mortality from cancer is unchanged.

Most data on rates of disability derive from specialty units caring for referred patients with severe disease. Little information is available on patients cared for in primary care community settings. Estimates suggest that more than half of these patients remain fully employed, even after 10-15 years of disease, with a third having only intermittent low-grade disease and another third experiencing spontaneous remission.

Patient Education

Patient education and counseling are well worth the time invested because they help to reduce pain, disability, and frequency of physician visits. They represent the most cost-effective intervention.

Informing the patient of the diagnosis

With a potentially disabling disease such as RA, the act of informing the patient of the diagnosis takes on major importance. The goal is to satisfy the patient's informational needs regarding the diagnosis, prognosis, and treatment without going into an overwhelming and excessive amount of detail. Careful questioning and empathic listening are required to understand the patient's perspective, requests, and fears.

Telling patients more than they are intellectually or psychologically prepared to handle (a common practice) risks making the experience so intense as to trigger withdrawal. Conversely, failing to address issues of importance to the patient compromises the development of trust. The patient needs to know that the primary physician understands the situation and is available for support, advice, and therapy as the need arises. Encouraging the patient to ask questions helps to communicate interest and caring.

Discussing prognosis and treatment

Patients and families do best when they know what to expect and can view the illness realistically. Uncertainty greatly contributes to the disease of RA. Many patients fear crippling consequences and dependency.

The most common disease manifestations should be described. Without building false hopes, the physician can point out that spontaneous remissions can occur and that more than two thirds of patients live independently without major disability. In addition, emphasize that much can be done to minimize discomfort and to preserve function. A review of available therapies and their efficacy helps to

overcome feelings of depression stemming from an erroneous expectation of inevitable disability. Even in patients with severe disease, guarded optimism is now appropriate, given the host of effective and well-tolerated disease-modifying treatments that are emerging.

Abandonment is a major fear. Patients are relieved to know that they will be closely observed by the primary physician and health care team, working in conjunction with a consulting rheumatologist and physical/occupational therapist, all of whom are committed to maximizing the patient's comfort and independence and to preserving joint function.

Dealing with misconceptions

Several common misconceptions deserve attention. A substantial proportion of patients and their families feel that they have done something to cause the illness. Explaining that no known controllable precipitants exist helps to eliminate much unnecessary guilt and self-recrimination.

Dealing in an informative, evidence-based fashion with a patient who expresses interest in alternative and complementary forms of therapy can help limit expenditures on ineffective treatments.

Another misconception is that a medication must be expensive to be helpful. Aspirin, generic NSAIDs, low-dose prednisone, and the first-line disease-modifying agents are quite inexpensive, yet remarkably effective, a point that bears emphasizing. The sense that one must be treated with the latest TNF inactivator can be addressed by a careful review of the overall treatment program and the proper role of such agents in the patient's plan of care.

The active participation of the patient and family in the design and implementation of the therapeutic program helps to boost morale and ensure compliance, as does explaining the rationale for the therapies used.

Preserving a sense of self-worth

A major goal is to preserve the patient's sense of worth and independence. However, when fatigue, morning stiffness, or specific joint disease interferes with a patient's capacity to carry out the usual responsibilities at work and at home, counseling will be necessary to recommend modification of work responsibilities and perhaps retraining. Recognition and treatment of concomitant depression is important. With the use of occupational therapy, the treatment effort is geared to helping the patient maintain a meaningful work role within the limitations of the illness. The family plays an important part in striking the proper balance between dependence and independence. Household members should avoid overprotecting the patient (eg, refraining from intercourse out of fear of hurting the patient) and

should work to sustain the patient's pride and ability to contribute to the family. Allowing the patient with RA to struggle with a task is sometimes constructive.

Supporting the patient with debilitating disease

Persons with long-standing severe disease who have already sustained much irreversible joint destruction benefit from an emphasis on comfort measures, supportive counseling, and attention to minimizing further debility. Such patients need help in grieving for their disfigurement and loss of function.

An accepting, unhurried, empathic manner allows the patient to express feelings. The seemingly insignificant act of touching does much to restore a sense of self-acceptance. Attending to pain with increased social support, medication, and a refocusing of attention to function are useful. A trusting and strong patient-doctor relationship can do much to sustain a patient through times of discomfort and disability.

PART 6: GOUT

Gout is a common disorder of uric acid metabolism that can lead to recurrent episodes of joint inflammation, tissue deposition of uric acid crystals, and joint destruction if left untreated. Unlike many other rheumatic diseases, gout is very treatable. A definitive diagnosis can be made using joint aspiration and synovial fluid analysis. Early diagnosis and treatment have made a significant impact in this disorder, as evidenced by the declining incidence of chronic tophaceous gout. However, tophaceous gout may occur due to misdiagnosis, poor management, and poor patient compliance.

Pathophysiology

High levels of uric acid circulating in the blood, which can cause needle-shaped urate crystals to settle in the tissues of the joints as well as the kidneys. These crystals are sodium urate crystals which are the end products of purine metabolism. This inherited gene causes an abnormality in the enzyme of purine metabolism (primary gout). Several X-linked mutations have been identified in the PRPP synthase gene which results in the enzyme having either:

- Increased V_{max} for the production of PRPP
- A lower K_m for ribose 5-phosphate
- Decreased sensitivity to its purine nucleotide inhibitors

Gout is caused by excess stores of uric acid that accumulate in tissues, including the synovium. Lowering serum uric acid levels can prevent attacks of gouty arthritis. However, urate crystals also can be found in synovial fluid in the absence of joint inflammation. Thus, the mere presence of intrasynovial urate

crystals is not sufficient to cause flares of gouty arthritis. Because urate crystals can be coated with apolipoprotein (apo) E or apo B, a reasonable hypothesis is that this protein coating prevents the crystals from triggering an inflammatory response. Therefore, situations that lead to exposure of bare areas of the crystals may trigger an inflammatory response. Clinically, gout flares can be triggered by fluxes in uric acid levels or by microtrauma, each of which can lead to shedding of uncoated crystals. When bare areas of the urate crystals are exposed, they can bind immunoglobulin G (IgG). Such binding stimulates neutrophils to engulf and phagocytose the crystals. Once this occurs, there is a brisk influx of neutrophils associated with elevated levels of interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor-alpha, prostaglandin E2, leukotriene B4, kinins, C5a, and other inflammatory mediators. It is also conceivable is that recoating of uric acid crystals by apo E or apo B could lead to the spontaneous resolution of attacks.

The overall result is increased purine production resulting in high levels of plasma uric acid (figure 7).


Figure 7: Pathogenesis of gout

Mortality and Morbidity

Gout is associated with considerable morbidity. During acute episodes, patients often are incapacitated. Untreated chronic tophaceous gout can develop and lead to severe joint destruction. Hyperuricemia is associated with increased all-cause mortality. This is not due to gout, per se, but to diseases associated with gout, such as insulin resistance, type 2 diabetes mellitus, abdominal obesity, hypercholesterolemia, and hypertension.

Race, sex and age particularities

Blacks have a slightly higher prevalence compared to whites. The prevalence for men is 13.6 cases per 1000 men, and the prevalence for women is 6.4 cases per 1000 women. This difference is largely a manifestation of age of onset because estrogenic hormones have a mild uricosuric effect; therefore, gout is unusual in premenopausal women. As a general rule, uric acid levels are elevated for 20 years before the onset of gout. In men, uric acid levels rise at puberty, and peak age of onset of gout is in the fourth to sixth decades. In women, uric acid levels rise at menopause, and peak age of onset is in the sixth to eighth decades. Gout is unlikely to present in premenopausal women or in men younger than 30 years unless renal insufficiency or a genetic abnormality of purine metabolism is present, such as hypoxanthine-guanine phosphoribosyltransferase deficiency or phosphoribosylpyrophosphate synthetase superactivity. The higher prevalence of gout in elderly persons may also reflect an increased prevalence of the metabolic syndrome, high rates of diuretic treatment for hypertension and congestive heart failure, and the use of low-dose acetylsalicylic acid. Typically, tophi may be clinically detected approximately 10 years after the first attack of gout. Cyclosporin A can cause an accelerated form of gout, even in premenopausal women, that can present after only a few years of hyperuricemia, particularly if the patient also is treated with diuretics.

History of gout

Acute monoarticular arthritis is the initial presentation of gout in 90% of patients. In early gout, usually only 1 or 2 joints are involved. Typically, they are the smaller, lower-extremity joints. Podagra (inflammation of the first metatarsophalangeal joint) is the initial joint manifestation involved in 50% of cases. Eventually, it is involved in 90% of cases. Podagra is not synonymous with gout. Podagra can be observed in patients with pseudogout, sarcoidosis, gonococcal arthritis, psoriatic arthritis, and reactive arthritis. The attacks begin abruptly and reach maximum intensity in 8-12 hours. The joints are red, hot, and exquisitely tender; even a bed sheet on the swollen joint is uncomfortable. Untreated, the first attacks resolve spontaneously in less than 2 weeks. Intermittent inflammatory arthritis, in which the joints return to normal between attacks, typically is caused by crystalline disorders and is true of gouty arthritis early in its course. Gout can initially present as a polyarticular arthritis in 10% of patients. Elderly women, particularly women with renal insufficiency and taking a thiazide diuretic, often develop polyarticular arthritis as their first manifestation of gout. These attacks may occur in coexisting Heberden and Bouchard nodes. Such patients also may develop tophi more quickly, occasionally without prior episodes of acute gouty arthritis. Untreated, the clinical characteristics of gout change over

time. The attacks become more polyarticular. Although more joints may become involved, inflammation in a given joint may become less intense. More proximal and upper-extremity joints become involved. Attacks occur more frequently and last longer.

Eventually, patients may develop a chronic polyarticular arthritis, sometimes nearly symmetrical, that can resemble rheumatoid arthritis. Indeed, if a patient presents with a chronic polyarticular arthritis that began as an intermittent arthritis, a crystalline disorder should be considered in the differential diagnosis.

While gout typically causes inflammation in a joint, it also can cause inflammation in other synovial-based structures such as bursas and tendons.

Tophi are collections of uric acid crystals in the soft tissues. They occur in more than half of untreated patients. While the classic location is along the helix of the ear, they can be found in multiple locations, including the fingers, toes, in the olecranon bursae, and along the olecranon, where they can resemble rheumatoid nodules. The finding of a rheumatoid nodule in a patient with a negative rheumatoid factor should prompt the clinician to consider gout in the differential diagnosis. Finding tophi during the first episode of gout is unusual; they tend to develop after 10 years in untreated patients who develop chronic gouty arthritis.

Acute flares of gout can occur in situations that lead to increased levels of serum uric acid, such as the use of alcohol, overindulgence of certain foods, trauma, hemorrhage, or the use of medications that elevate levels of uric acid. Situations that lead to the rapid depletion of adenosine triphosphate (ATP) can result in the accumulation of adenosine 5'-diphosphate, adenosine monophosphate (AMP), and, subsequently uric acid. Alcohol, for example, accelerates the conversion of ATP to AMP. Alcohol also increases lactate relative to pyruvate and thereby reduces the excretion of uric acid. Beer contains guanosine and thereby increases the purine load.

Acute flares of gout also can occur in situations that lead to decreased levels of serum uric acid, such as the use of radiocontrast dye or medications that lower the levels of uric acid.

Patients with gout have a 1000-fold increased incidence of renal stones and therefore may have a history of renal colic. Indeed, renal stones may precede the onset of gout in 40% of patients. While 80% of these patients may have stones composed entirely of uric acid, 20% may develop calcium oxalate or calcium phosphate stones with a uric acid core. Patients with gout also are prone to develop urate nephropathy, in which uric acid crystals are deposited in the medullary interstitium and pyramids. While patients with gout have a higher incidence of renal impairment, whether hyperuricemia is an independent risk factor for this

remains unclear because such patients have a higher incidence of hypertension, diabetes, and other risk factors for renal insufficiency.

Patients with gout often are clustered with the insulin resistance syndrome known as metabolic syndrome or syndrome X: diabetes, hypertension, hypertriglyceridemia, and low high-density lipoproteins. No evidence indicates that gout or hyperuricemia cause any of these other disorders. Because the presence of these associated disorders can lead to coronary artery disease, the incidence of which also is increased in patients with gout, these problems should be sought and treated in patients diagnosed with gout. However, no evidence indicates that gout is an independent risk factor for atherosclerosis.

Importantly, ask about a history of peptic ulcer disease, renal disease, or other conditions that may complicate the use of the medications to treat gout.

Physical examination findings

During an acute attack, examine all joints to determine if the patient's arthritis is monoarticular or polyarticular. Involved joints show all the signs of inflammation: swelling, warmth, erythema, and tenderness. The erythema over the joint can resemble cellulitis, and the skin may desquamate as the attack subsides. The joint capsule becomes quickly swollen, resulting in a loss of range of motion of the involved joint. During an acute gout attack, patients can have a fever, particularly if it is an attack of polyarticular gout. Look for sites of infection that could have potentially seeded the joint and caused an infectious arthritis that can resemble or coexist with acute gouty arthritis. The presence of tophi suggests long-standing hyperuricemia.

Causes of gout

Gout can develop when excessive stores of uric acid are present. Uric acid is a byproduct of purine metabolism. Lacking uricase, humans remove uric acid primarily by renal excretion. Of patients with primary gout, 90% develop excess stores of uric acid because they are unable to excrete sufficient amounts of uric acid in their urine (underexcretion). The remaining patients produce excessive amounts of uric acid (overproduction). When uric acid levels exceed 6.8 mg/dL, with some variability depending on temperature and pH, uric acid can crystallize.

Individual attacks of gout often are triggered by acute fluxes in uric acid levels that may lead to the exposure or shedding of crystals that are not coated with apo B or apo E. This can result from alcohol ingestion, overindulgence in certain foods, starvation, trauma, hemorrhage, or medications such as diuretics. It also can result from situations that lower levels of uric acid, including the use of radiocontrast dyes and medications such as allopurinol.

Rarely, overproduction of uric acid is due to genetic disorders. These include hypoxanthine-guanine phosphoribosyl transferase deficiency (Lesch-Nyhan syndrome), glucose-6-phosphatase deficiency (von Gierke disease), fructose1-phosphate aldolase deficiency, and PP-ribose-P synthetase variants.

Overproduction of uric acid also can occur secondary to disorders causing high cell turnover. These include myeloproliferative and lymphoproliferative disorders, psoriasis, chemotherapy (tissue lysis), hemolytic anemias, excessive exercise, and obesity.

More common causes of secondary gout include renal insufficiency, lead nephropathy (saturnine gout), starvation or dehydration, hypothyroidism, hyperparathyroidism, drugs (including diuretics and cyclosporine A), and ethanol abuse. These disorders should be identified and corrected if possible.

Lab Studies

- Synovial fluid: When a patient presents with acute inflammatory monoarticular arthritis, aspiration of the involved joint is critical to rule out an infectious arthritis and to attempt to confirm a diagnosis of gout or pseudogout by crystal identification.
- The critical and essential study is synovial fluid analysis to identify urate crystals. Finding intracellular urate crystals by polarizing light microscopy firmly establishes a positive diagnosis of gouty arthritis.

Urate crystals are shaped like needles or toothpicks with pointed ends.

Urate crystals are negatively birefringent. Pragmatically, this means that the crystals are yellow when aligned parallel to the slow ray of the compensator and that they are blue when they are perpendicular.

Pseudogout crystals (calcium pyrophosphate) are rod-shaped with blunt ends.

Pseudogout crystals are positively birefringent. Pragmatically, this means that the colors are the opposite of gout. Thus, pseudogout crystals are blue when aligned parallel to the slow ray of the compensator and yellow when they are perpendicular.

Crystals need to be distinguished from birefringent cartilaginous or other debris. Debris may have fuzzy borders and may be curved, whereas crystals have sharp borders and are straight.

Corticosteroids used to inject joints have a crystalline structure that can be either positively or negatively birefringent. Therefore, interpreting polarized microscopy from a joint that was recently injected with corticosteroids is difficult.

The sensitivity of a synovial fluid analysis for crystals is 84%, with a specificity of 100%. If gout remains a clinical consideration after a negative analysis, the procedure can be repeated in another joint or with a subsequent flare.

While the sensitivity is less, urate crystals can be identified from synovial fluid aspirated from previously inflamed joints that are not currently inflamed. These generally are extracellular.

Minute quantities of fluid in the shaft or hub of the needle are sufficient for synovial fluid analysis.

Once a crystal diagnosis of gout is established, joints do not need repeat aspiration with subsequent flares unless infection is suggested or the flare does not respond appropriately to therapy for acute gout.

For patients with acute monoarticular arthritis, send synovial fluid for Gram stain and culture and sensitivity. The culture also provides sensitivities for antibiotic management.

Synovial fluid also should be sent for cell count.

During acute attacks, the synovial fluid is inflammatory, with a WBC count greater than 2000/microliter (class II fluid) and possibly greater than 50,000/microliter with a predominance of polymorphonuclear neutrophils.

Synovial fluid glucose usually is normal, whereas in septic arthritis and occasionally rheumatoid arthritis, it may be depressed. Measurement of synovial fluid protein has no clinical value.

Crystalline arthritis and infectious arthritis can coexist. Indeed, infectious arthritis is more common in previously damaged joints, which may occur in chronic gouty arthritis.

Serum uric acid

This is the most misused test in the diagnosis of gout.

Five to eight percent of the population has elevated serum uric acid levels (>7 mg/dL), but only 5-20% of patients with hyperuricemia develop gout. Thus, the presence of an elevated level of serum uric acid does not mean the patient has gout or will develop gout. Gout is diagnosed by finding urate crystals in the synovial fluid or soft tissues. More importantly, a number of patients with infectious arthritis present with a hot swollen joint and an elevated serum uric acid level. These patients will be mismanaged if their synovial fluid is not aspirated to determine that they have septic arthritis.

Asymptomatic hyperuricemia should not be treated. However, patients with levels higher than 11 mg/dL and overexcretion of uric acid are at risk for renal stones and renal impairment; therefore, renal function should be monitored in these individuals.

The risk for developing gout increases with the level of serum uric acid. The 5-year risk for developing gout is approximately 0.6% if the level is less than 7.9 mg/dL, 1% if 8-8.9 mg/dL, and 22% if higher than 9 mg/dL.

As many as 10% of patients with gout have normal serum uric acid levels at the time of their attack. Thus, the correct diagnosis of gout can be missed if the joint is not aspirated because their uric acid level is normal. Remember that situations that lower uric acid levels can trigger attacks of gout. However, the patient's prior medical records should reveal prior elevations of uric acid. Elevated levels of serum uric acid can be observed in other disorders such as myeloproliferative disorders, polycythemia vera, psoriasis, sarcoidosis, hyperparathyroidism, hypothyroidism, pernicious anemia, and sickle cell anemia.

Uric acid in 24-hour urine sample.

If patients excrete more than 800 mg of uric acid in 24 hours on a regular diet, they are overexcretors and thus overproducers of uric acid. Patients who excrete more than 1100 mg in 24 hours should have renal function monitored closely because of the risk of stones and urate nephropathy. Patients who are overproducers of uric acid, only 10% of patients with gout, require allopurinol instead of probenecid to lower their uric acid. If the patient already has a contraindication for using probenecid, such as a history of renal stones or renal insufficiency, then a 24-hour urine test of uric acid excretion does not need to be performed because the patient clearly will need allopurinol.

Blood chemistry

Obtaining an estimate of the patient's renal function before deciding on therapy for gout is important. Remember that the serum creatinine alone can overestimate renal function in elderly patients or in patients with low muscle mass. Patients with gout have a higher incidence of diabetes mellitus. Abnormal liver function tests need to be considered when selecting therapy.CBC count: WBC count can be elevated in patients during the acute gouty attack, particularly if it is polyarticular.

Lipids: Hypertriglyceridemia and low high-density lipoproteins are associated with gout.

Urinalysis: Patients with gout have a high incidence of renal stones; therefore, patients may have or may have had hematuria.

Imaging Studies

Plain radiographs may show findings consistent with gout, but these findings are not diagnostic. Radiograph examination usually shows sharply "punched-out" bony defects of the distal radius, as indicated Figure 8.

Figure 8

Radiograph showing sharply "punched-out" bony defects of the distal radius and proximal phalange of the middle finger

The most common radiographic finding early in the disease is soft-tissue swelling or a normal radiograph.

- Haziness suggestive of tophi can be seen in late gout, and tophi may calcify.
- Erosions that are not typical of rheumatoid arthritis may suggest gout.
- Erosions with maintenance of the joint space
- Erosions without periarticular osteopenia
- Erosions outside the joint capsule
- Erosions with overhanging edges
- Erosions with sclerotic borders, sometimes called cookie-cutter or punched-out borders
- Erosions that are distributed asymmetrically among the joints, with strong predilection for distal joints, especially in the lower extremities

Procedures

Perform arthrocentesis to rule out an infectious arthritis and to establish a crystal-proven diagnosis of gout. Tophi also may be aspirated for crystal analysis under polarizing microscopy.

Histologic Findings

Tophi have been found in all tissues except the brain. However, uric acid dissolves in formalin; therefore, only the ghosts of uric acid crystals may be seen if formalin is used. Alcohol-fixed tissue is best for identification of uric acid crystals.

Medical Care

There are 3 stages in the management of gout: treating the acute attack, providing prophylaxis to prevent acute flares, and lowering excess stores of uric

acid to prevent flares of gouty arthritis and to prevent tissue deposition of uric crystals.

Management of acute gout: Options for treatment of acute gout include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or colchicine (a classic treatment but now rarely indicated). The choice is based primarily on the patient's other health problems, such as renal insufficiency and peptic ulcer disease.

Nonsteroidal anti-inflammatory drugs

NSAIDs are the drugs of choice in most patients without underlying health problems. Indomethacin is the traditional choice unless the patient is elderly, because of the potential for adverse CNS effects in this age group. However, most NSAIDs can be used. Select an agent with a quick onset of action, but do not use aspirin because it can alter uric acid levels and potentially prolong and intensify an acute attack. Cyclooxygenase-2 (COX-2) inhibitors have been used with success. Start with the highest dose for 2-3 days and taper down over approximately 2 weeks. Patients should be asymptomatic for at least 2 days before discontinuing the NSAID. Avoid NSAIDs in patients who have a history of peptic ulcer disease or GI bleeding, patients with renal insufficiency, patients with abnormal hepatic function, patients taking coumadin (selective COX-2 inhibitors can be used), and patients in the intensive care unit who are predisposed to gastritis.

Corticosteroids

Corticosteroids can be given to those patients who cannot use NSAIDs or colchicine. Some rheumatologists recommend corticosteroids over NSAIDs as the preferred choice for treatment of acute gout. Steroids can be given orally, intravenously, intramuscularly, intra-articularly, or indirectly via adrenocorticotropic hormone (ACTH). Prednisone can be given at a dose of approximately 40 mg for 1-3 days and then tapered over approximately 2 weeks. Tapering more rapidly can result in a rebound flare. Using parenteral corticosteroids confers no advantage unless the patient cannot take oral medications. Intra-articular corticosteroids are particularly useful in patients with a monoarticular flare to help reduce the systemic effect of oral steroids. Ensuring that the joint is not infected prior to injecting intra-articular corticosteroids is particularly important. ACTH at 40 IU IM can be given to induce corticosteroid production by the patient's own adrenal glands. Such a regimen does not depend on the patient to taper prednisone properly.

Colchicine

Colchicine is the classic medication for gout but is not the preferred medication for the treatment of acute gout. It is most effective during the first 12-24 hours of

an attack, but its effectiveness declines with the duration of inflammation. Moreover, when used to treat an acute attack, colchicine causes adverse GI effects, particularly diarrhea and vomiting, in 80% of patients. To treat an acute attack colchicine is given orally at 0.5-0.6 mg every hour until the patient has relief, has adverse GI effects, or takes 6 mg (ten 0.6-mg tabs). The total dose and the frequency need to be reduced in patients with renal or hepatic insufficiency, and colchicine generally is not recommended in these situations. Patients may be able to abort an attack by taking a single colchicine tablet at the first twinge of an attack. Colchicine should not be used if the glomerular filtration rate (GFR) is less than 10 mL/min, and the dose should be decreased by at least half if the GFR is less than 50 mL/min. Colchicine also should be avoided in patients with hepatic dysfunction, biliary obstruction, or an inability to tolerate diarrhea. A clinical response to colchicine is not pathognomonic for gout and can be seen with pseudogout, sarcoid arthropathy, psoriatic arthritis, and calcific tendonitis. Colchicine also can be administered intravenously. While this route of therapy can quickly abort an attack of gout, it should be employed only in unusual circumstances because it is potentially toxic. Indeed, this therapy is banned in some countries due to a 2% fatality rate. IV colchicine should be used cautiously, if at all, in patients with renal insufficiency or hepatic dysfunction. When given intravenously, 1 mg of colchicine is diluted in 20 mL of isotonic sodium chloride solution without glucose and pushed over 10-20 minutes in a secure IV line. A maximum of 4 mg is given over 24 hours, and no further colchicine should be given for the next week. If the medication extravasates, it can cause tissue necrosis. Within the vessels, it also can cause thrombophlebitis. Granulocytopenia is a prime complication of IV colchicine. The WBC count should be measured before infusion. Other complications include disseminated intravascular coagulopathy, renal failure, hepatocellular toxicity, seizures, and shock.

Prophylaxis to prevent acute flares

Lowering uric acid with either allopurinol or probenecid can precipitate attacks of gout. When used prophylactically, colchicine can reduce such flares by 85%. The standard dose for prophylaxis is colchicine at 0.6 mg bid. In patients with renal insufficiency, this dose may need to be decreased to daily or every-other-day administration. Compared with the 80% risk of adverse GI effects in patients using colchicine for the treatment of acute gout, the prophylactic dose of colchicine induces adverse GI effects in only 4% of patients. Long-term use of colchicine can lead to a muscle weakness associated with elevated levels of creatine kinase due to a drug-induced neuromyopathy, particularly in patients with renal insufficiency. In

patients who cannot take colchicine, NSAIDs can be used for prophylaxis, such as indomethacin at 25 mg bid.

Prophylaxis with colchicine can be started during the acute attack.

Lowering uric acid levels.

In many cases, patients who have a first attack of gout should undergo therapy with agents that lower uric acid, given the high risk for further inflammatory attacks and the potential for destructive tophaceous deposition in the bone and synovium, even without episodes of acute inflammation. Some rheumatologists advocate waiting for the second attack to begin therapy to lower uric acid levels because not all patients have a second attack and because some patients may need to be convinced they need life-long therapy. This decision is partly dependent on the baseline serum uric acid levels (a level > 9 mg/dL denoting higher risk for recurrent gouty arthritis and tophi). In all cases, the risks and benefits need to be judged based on the individual patient. For instance, in an elderly patient with multiple medical problems and renal insufficiency, the risks of therapy to lower uric acid levels may outweigh the benefits. The goal of therapy is to lower serum uric acid levels to approximately 5-6 mg/dL. The risk of a second attack of gout after the first attack is 62% after 1 year, 78% after 2 years, and 93% after 10 years. Treating patients with colchicine alone may help prevent flares of inflammatory arthritis but does not prevent the accumulation of uric acid in the joints, which can lead to further joint destruction. While using agents that lower uric acid is important, they should not be started during an acute attack. This may lead to a more intense and prolonged attack. Typically, they should be started a few weeks after the attack has resolved and with the protection of colchicine to prevent another attack. If the patient develops a flare of gout when starting on agents that lower uric acid, do not discontinue the agent because this will only cause another flux in the uric acid level that may prolong and intensify the attack.

Probenecid

Some rheumatologists prefer probenecid whenever possible because it has fewer significant adverse effects than allopurinol. Probenecid can be used in the majority of middle-aged, otherwise healthy men with gout. Indications for the use of allopurinol instead of probenecid include renal insufficiency (GFR <50 mL/min), renal stones, use of aspirin (blocks the effect of probenecid), overproduction of uric acid, and unresponsiveness to probenecid. Drug interactions may occur with probenecid. Patients using probenecid need to drink 2 L of fluid daily at the inception of therapy to ensure adequate diuresis to decrease the risk of renal stones.

Sulfinpyrazone: Sulfinpyrazone is an alternative uricosuric agent that has antiplatelet activity but is seldom used because of the added risk of bone marrow suppression.

Allopurinol

Allopurinol blocks xanthine oxidase and thus reduces the generation of uric acid. Therefore, it should be used in patients who are overproducers of uric acid and in patients at risk of tumor lysis syndrome to prevent renal toxicity during therapy for malignancies. It is the most effective agent to lower serum uric acid levels. However, alcohol can interfere with the effectiveness of allopurinol. Approximately 3-10% of patients taking allopurinol develop dyspepsia, headache, diarrhea, or pruritic maculopapular rash. More infrequently, patients can develop allopurinol hypersensitivity, which has a mortality rate of 20-30%. Features of allopurinol hypersensitivity include fever, toxic epidermal necrolysis, bone marrow suppression, eosinophilia, leukocytosis, renal failure, hepatic failure, and vasculitis. Corticosteroids often are used to treat allopurinol hypersensitivity. Allopurinol hypersensitivity is more likely to occur in patients with renal insufficiency, patients who are taking a diuretic, and patients begun on 300 mg of allopurinol. Allopurinol should be discontinued in patients who develop a rash. In patients with a history of drug eruptions due to allopurinol, both an oral and IV desensitization regimen are available that can be considered. In most patients, start at 100 mg per day and adjust the dose monthly according to the uric acid level until the goal of a uric acid level of 5-6 mg/dL is achieved.

Beware of drug interactions. For example, allopurinol prolongs the half-life of azathioprine and 6-mercaptopurine. It enhances the toxicity of cyclophosphamide. Patients taking concomitant ampicillin have an increased incidence of rash. Once the target level is achieved and maintained for 6 months, discontinue colchicine prophylaxis. Avoiding the use of medications that elevate uric acid in patients with gout is prudent. Thus, other agents are preferable to a thiazide diuretic to treat hypertension. However, if such a medication is needed, it can be used with appropriate adjustments of allopurinol or probenecid. Allopurinol can be used in combination with probenecid. However, note that allopurinol increases the half-life of probenecid, whereas probenecid increases the excretion of allopurinol.

Other drugs

Nonrecombinant urate-oxidase (uricase) is used in Europe to prevent severe hyperuricemia induced by chemotherapy in malignant patients, as well as for selected patients with treatment-refractory gout. Recently, the Food and Drug Administration (FDA) approved recombinant Aspergillus flavus uricase for the prevention of tumor lysis syndrome. However, it is highly immunogenic and may

cause anaphylaxis. Patients with allopurinol hypersensitivity can often tolerate oxypurinol, which is a metabolite of allopurinol. Benzbromarone is an effective uricosuric agent that may eventually become available. However, it can cause fulminant hepatotoxicity.

Febuxostat, a nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with gout. It is orally administered and metabolized mainly in the liver. In contrast, allopurinol and its metabolites are excreted primarily by the kidney. Therefore, febuxostat can be administered in patents with renal insufficiency, with no dosage adjustment. Its efficacy and side-effect profile otherwise appears similar to that of allopurinol.

Febuxostat, pegloticase and interleukin-1 inhibitors (anakinra, canakinumab, rilonacept) are recommended for frequent and poorly controlled flares in patients who have contraindications to colchicine, NSAIDs and corticosteroids, because of the high cost and an increased likelihood of infection.

The angiotensin receptor blocker losartan and the triglyceride-lowering agent micronized fenofibrate have moderately potent uricosuric effects. They should therefore be considered in patients with gout who also require treatment for hypertension and hypertriglyceridemia.

Vitamin C, with its uricosuric effect, may reduce the serum concentration of uric acid.

Surgical Care

If diagnosed and treated early, patients should not need orthopedic surgery. In patients who are untreated or in those who are treated late in the course of their disease, orthopedic repair may be necessary. Tophi should not be surgically removed unless they are in a critical location or drain chronically. In patients undergoing arthroscopy, the presence of white lesions, sometimes on an erythematous base, should prompt consideration for gout.

Consultations

Rheumatologists should be involved in the care of patients with gout. They can establish the diagnosis by arthrocentesis and synovial fluid analysis for crystals. They also are skilled in the management of this disorder.

Diet

Diet modifications can only improve the serum uric acid levels by 1 mg/dL and rarely are able to lower uric acid levels sufficiently to prevent further attacks and accumulation of uric acid. Patients should avoid alcohol because it elevates levels of uric acid and therefore can precipitate attacks of gout. Indeed, heavy drinkers are much more likely to have recurrent gout attacks, even with allopurinol therapy. Particularly because of the association of gout with atherosclerosis, the diagnosis

of gout may be a good time to advise a low-cholesterol, low-fat diet if otherwise appropriate for the patient. While such a diet may help uric acid levels, such advice should be given primarily to help prevent atherosclerosis. Weight reduction in patients who are obese can improve hyperuricemia.

Activity

Patients should avoid using the inflamed joint during the acute attack. Otherwise, they should be active.

Complications

Untreated, gout can lead to severe joint destruction. In those undergoing treatment, the primary problems are toxicity of the medications. Septic arthritis can occur in a gouty joint, and draining tophi can become secondarily infected.

Prognosis

If treated early and properly and if patient compliance is good, the prognosis is excellent.

PART 7: DERMATOMYOSITIS

Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) with characteristic cutaneous findings. In 1975, Bohan and Peter first suggested a set of criteria to aid in the diagnosis and classification of dermatomyositis and polymyositis (PM). Four of the 5 criteria are related to the muscle disease, as follows: progressive proximal symmetrical weakness, elevated muscle enzymes, an abnormal finding on electromyogram, and an abnormal finding on the muscle biopsy sample. The fifth criterion was compatible cutaneous disease. The association between dermatomyositis (and possibly polymyositis) and malignancy has been recognized for a long time. Dermatomyositis is a systemic disorder that frequently affects the esophagus and lungs and, less commonly, may affect the heart. Calcinosis is a complication that is observed most often in children or adolescents. Therapy of the muscle component involves the use of corticosteroids with or without an immunosuppressive agent. The skin disease is treated with sun avoidance, sunscreens, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil and/or intravenous immune globulin. Some of the newer biologic agents may prove useful for either component of the disease or for both components. The prognosis depends on the severity of the myopathy, the presence of a malignancy, and/or the presence of cardiopulmonary involvement.

Pathophysiology of dermatomyositis

The pathogenesis of the cutaneous disease is poorly understood. Bohan and Peter (1975) suggested 5 subsets of myositis, as follows: dermatomyositis,

polymyositis, myositis with malignancy, childhood dermatomyositis/polymyositis, and myositis overlapping with another collagen-vascular disorder. In a subsequent publication, Bohan et al (1975) noted that cutaneous disease may precede the development of the myopathy. The existence of another subset of patients with disease that only affects the skin (called amyopathic dermatomyositis [ADM] or dermatomyositis-sine myositis) was only recently recognized. Lastly, a group of patients exists whose myopathy is controlled but who continue to have severe and sometimes debilitating skin disease; these patients' conditions have been termed postmyopathic dermatomyositis. Recent studies of the pathogenesis of the myopathy have been controversial. Some suggest that the myopathy in dermatomyositis and polymyositis is pathogenetically different. Dermatomyositis is probably caused by complement-mediated (terminal attack complex) vascular inflammation, while polymyositis is caused by the direct cytotoxic effect of $CD8^+$ lymphocytes on muscle. However, other studies of cytokines suggest that some of the inflammatory processes may be similar. A recent report has linked tumor necrosis factor (TNF) abnormalities with dermatomyositis.

Frequency of dermatomyositis or polymyositis

The incidence of dermatomyositis/polymyositis has been estimated at 5.5 cases per million people, and the incidence is apparently increasing.

Mortality and morbidity of dermatomyositis or polymyositis

Dermatomyositis may cause death because of muscle weakness or cardiopulmonary involvement. Patients with an associated malignancy may die from the malignancy. Most patients with dermatomyositis survive, in which case they may develop residual weakness and disability. In children with severe disease, contractures can develop. Calcinosis may complicate dermatomyositis. It is very rare in adults, but is more common in children and has been linked to delay in diagnosis and to less aggressive therapy.

Race, sex and age particularities of dermatomyositis or polymyositis

No racial predilection exists for dermatomyositis or polymyositis. Women are affected twice as often as men. Dermatomyositis can occur in people of any age. Two peak ages of onset exist. In adults, the peak age of onset is approximately 50 years, and, in children, the peak age is approximately 5-10 years

History of dermatomyositis or polymyositis

Patients often present with skin disease as one of the initial manifestations. Sometimes, perhaps in as many as 40% of the patients, the skin disease may be the sole manifestation at the onset. Muscle disease may occur concurrently, may precede the skin disease, or may follow the skin disease by weeks to years. Patients often notice an eruption on exposed surfaces. The rash is often pruritic, and intense

pruritus may disturb sleep patterns. Patients may also report a scaly scalp or diffuse hair loss. Muscle involvement is manifested by proximal muscle weakness. Patients often begin to note fatigue of their muscles or weakness when climbing stairs, walking, rising from a sitting position, combing their hair, or reaching for items in cabinets that are above their shoulders. Muscle tenderness may occur, but tenderness is not a regular feature of the disease. Systemic manifestations may occur; therefore, the review of systems should assess for the presence of arthralgia, arthritis, dyspnea, dysphagia, arrhythmia, and dysphonia. Malignancy is possible in any patient with dermatomyositis, but it occurs more frequently in adults older than 60 years. Only a few children with dermatomyositis and malignancy have been reported. The history should include a thorough review of systems and an assessment for previous malignancy. Children with dermatomyositis may have an insidious onset that defies diagnosis until the dermatologic disease is clearly observed and diagnosed. Calcinosis is a complication of juvenile dermatomyositis but is rarely observed at the onset of disease. Ask questions about hard nodules of the skin during the initial examination.

Physical findings

Dermatomyositis is a disease that primarily affects the skin and the muscles but may affect other organ systems. The characteristic, and possibly pathognomonic, cutaneous features of dermatomyositis are heliotrope rash and Gottron papules. Several other cutaneous features, including malar erythema, poikiloderma (ie, variegated telangiectasia, hyperpigmentation) in a photosensitive distribution, violaceous erythema on the extensor surfaces, and periungual and cuticular changes, are characteristic of the disease even though they are not pathognomonic. Muscle findings typically include proximal weakness and, sometimes, tenderness. Other systemic features include joint swelling, changes associated with Raynaud phenomenon, and abnormalities on cardiopulmonary examination. The heliotrope rash consists of a violaceous-to-dusky erythematous rash with or without edema in a symmetrical distribution involving periorbital skin. Sometimes, this sign is subtle and may involve only a mild discoloration along the eyelid margin. A heliotrope rash is rarely observed in other disorders; thus, its presence is highly suggestive of dermatomyositis. The Gottron papules are found over bony prominences, particularly the metacarpophalangeal joints, the proximal interphalangeal joints, and/or the distal interphalangeal joints. Papules may also be found overlying the elbows, knees, and/or feet. The lesions consist of slightly elevated violaceous papules and plaques. A slight scale and, occasionally, a thick psoriasiform scale may be present. These lesions may resemble lesions of lupus erythematosus (LE), psoriasis, or lichen planus (LP). Nailfold changes consist of periungual

telangiectases and/or a characteristic cuticular change with hypertrophy of the cuticle and small hemorrhagic infarcts with this hypertrophic area. Periungual telangiectases may be apparent clinically or may be visible only on capillary microscopy. Poikiloderma may occur on exposed skin, such as the extensor surfaces of the arm, and may appear in a V-shaped distribution over the anterior neck and upper chest and back (ie, shawl sign). With the exception of the heliotrope rash, the eruption of dermatomyositis is photodistributed and photoexacerbated. Despite the prominent photodistribution of the rash, patients rarely report photosensitivity. Facial erythema may also occur in dermatomyositis. This change must be differentiated from LE, rosacea, seborrheic dermatitis, or atopic dermatitis. Scalp involvement in dermatomyositis is relatively common and is manifested by an erythematous-to-violaceous psoriasiform dermatitis. Clinical distinction from seborrheic dermatitis or psoriasis is occasionally difficult. Nonscarring alopecia may occur in some patients and often follows a flare of systemic disease. Dermatomyositis-sine myositis, also known as ADM, is diagnosed in patients with typical cutaneous disease, no clinical evidence of muscle weakness, and normal serum muscle enzyme levels for at least 2 years. Patients who have undergone disease-modifying therapies such as corticosteroids or immunosuppressive agents are not classified as having ADM. Some patients with ADM have abnormal findings on sonogram, MRI, or muscle biopsy sample. These patients have subclinical muscle involvement, but their condition still may be classified as ADM. Because many ADM patients are not evaluated beyond clinical and enzymatic studies, many think that ADM represents a systemic process requiring systemic therapies. Some patients have myositis that resolves following therapy, but the skin disease remains an active important feature of the disease. Although the skin disease is the major, and often only, manifestation of the disease, these patients are not diagnosed with ADM. In addition, a small subset of patients never develop myositis despite having prominent cutaneous changes. Rare cutaneous manifestations include vesiculobullous erosive lesions and exfoliative erythroderma. Biopsy tissue samples from these patients reveal an interface dermatitis (ie, inflammation at the dermal-epidermal junction) similar to biopsy tissue samples from heliotrope rash, Gottron papules, poikiloderma, or scalp lesions. These cutaneous manifestations may be more common in patients with an associated malignancy. Various other cutaneous lesions have been described in patients with dermatomyositis or polymyositis that do not reflect the interface changes observed histopathologically with the pathognomonic or characteristic lesions. Panniculitis, urticaria, and hyperkeratosis of the palms (known as mechanic's hands) are examples of these cutaneous lesions. Other findings include

cutaneous mucinosis, follicular hyperkeratosis, hyperpigmentation, ichthyosis, white plaques on the buccal mucosa, cutaneous vasculitis, and flagellate erythema. Muscle disease manifests as a proximal symmetrical muscle weakness. Patients may have difficulty rising from a chair or squatting and raising themselves from this position. In an effort to rise, patients sometimes use other muscles that are not as affected. The careful examiner may note this finding. Testing of the muscle strength is part of each assessment of the patient. Often, the extensor muscles of the arms are more affected than the flexors. Distal strength is almost always maintained. Muscle tenderness is a variable finding. Calcinosis of the skin or muscle is unusual in adults but may occur in as many as 40% of children or adolescents with dermatomyositis. Calcinosis cutis is manifested by firm, yellow- or flesh-colored nodules, often over bony prominences. Occasionally, the nodules can extrude through the surface of the skin, in which case secondary infection may occur. Joint swelling occurs in some patients with dermatomyositis. The small joints of the hands are most frequently involved. The arthritis associated with dermatomyositis is not erosive or deforming. Patients with pulmonary disease may have abnormal breath sounds (crackles from interstitial fibrosis or pneumonitis). Patients with an associated malignancy may have physical findings relevant to the affected organs.

Causes

The cause of dermatomyositis is unknown; however, the following factors have been implicated:

- A genetic predisposition may exist. Dermatomyositis rarely occurs in multiple family members, but it may be linked to certain human leukocyte antigen (HLA) types (eg, DR3, DR5, DR7). In addition, polymorphisms of TNF-alpha have been linked to photosensitity in patients with dermatomyositis.

- Immunological abnormalities are common in patients with dermatomyositis. Patients frequently have circulating autoantibodies. Abnormal T-cell activity may be involved in the pathogenesis of both the skin and the muscle disease. In addition, family members may have other diseases associated with autoimmunity.

- Autoantibodies to nuclear antigens (ANA) and cytoplasmic (ie, antitransfer RNA synthetases) antigens may be present. Although their presence may help to define subtypes of dermatomyositis and polymyositis, their role in pathogenesis is uncertain.

- Infectious agents, including viruses (eg, coxsackievirus, parvovirus, echovirus, human T-cell lymphotrophic virus type 1 [HTLV-1], HIV) and Toxoplasma and Borrelia species, have been suggested as possible triggers of the disease.

- Several cases of drug-induced disease have been reported. Dermatomyositislike skin changes have been reported with hydroxyurea in patients with chronic myelogenous leukemia or essential thrombocytosis. Other agents that may trigger the disease include penicillamine, statin drugs, quinidine, and phenylbutazone.
- Dermatomyositis may be initiated or exacerbated by silicon breast implants or collagen injections, but the evidence for this is anecdotal and has not been verified in case-control studies. A recent report detailed HLA differences among women in whom inflammatory myopathy develops after they received silicone implants.

Lab Studies

Muscle enzyme levels are often abnormal during the course of dermatomyositis, except in patients with the amyopathic variant. The most sensitive/specific enzyme is an elevated creatine kinase (CK), but aldolase levels and other tests (eg, aspartate aminotransferase [AST], lactic dehydrogenase [LDH]) may also yield abnormal results. At times, the elevation of the enzymes precedes clinical evidence of myositis. Thus, if a patient who is presumably stable develops an elevation of an enzyme previously within the reference range, the clinician should assess the possibility of a flare of the muscle disease. Several serologic abnormalities have been identified and may be helpful in the classification of subtypes for prognosis, but they are not used for routine diagnosis. As a group, these antibodies have been termed myositis-specific antibodies (MSAs). These autoantibodies occur in about 30% of all patients with dermatomyositis or polymyositis.

- A positive ANA finding is common in patients with dermatomyositis.
- Anti–Mi-2 antibodies are highly specific for dermatomyositis but lack sensitivity because only 25% of the patients with dermatomyositis demonstrate them. They are associated with acute-onset classic dermatomyositis with the V-shaped and shawl rash (poikiloderma) and a relatively good prognosis.
- Anti–Jo-1 (antihistidyl transfer RNA [t-RNA] synthetase) is more frequent in patients with polymyositis than in patients with dermatomyositis. It is associated with pulmonary involvement (interstitial lung disease), Raynaud phenomenon, arthritis, and mechanic's hands.
- Other MSAs include antisignal recognition protein (anti-SRP), associated with severe polymyositis, and anti–PM-Scl and anti-Ku, which are associated with overlapping features of myositis and scleroderma.

Imaging Studies

- Magnetic resonance imaging
  - MRI may be useful for assessing the presence of an inflammatory myopathy in patients without weakness.
  - MRI is useful in differentiating a steroid myopathy from continued inflammation.
  - MRI imaging may serve as a guide in selecting a muscle biopsy site.
- Chest radiographs should be obtained at the time of diagnosis and when symptoms develop.
- A barium swallow allows evaluation of esophageal dysmotility.
- Ultrasonography of the muscles has been suggested for evaluation, but it has not been widely accepted.
- Electromyography is a means of detecting muscle inflammation and damage and, at times, has been useful in selecting a muscle biopsy site. This test is obtained less commonly since the introduction of MRI of muscle.
- CT scans are useful in the evaluation of potential malignancy that might be associated with inflammatory myopathy.

Other Tests

- Pulmonary function studies
- Electrocardiography
- Esophageal manometry - May be obtained in select patients

Procedures

A muscle biopsy sample, obtained either open or by a needle, may enhance the clinician's ability to diagnose dermatomyositis. The results of this biopsy may be useful in differentiating steroid myopathy from active inflammatory myopathy when patients have been on corticosteroid therapy but are still weak.

Histologic Findings

A skin biopsy sample reveals an interface dermatitis that is difficult to differentiate from LE. Vacuolar changes of the columnar epithelium and lymphocytic inflammatory infiltrates at the dermal-epidermal junction basement membrane can occur. Muscle biopsy samples in patients with dermatomyositis reveal perivascular and interfascicular inflammatory infiltrates with adjoining groups of muscle fiber degeneration/regeneration. This contrasts with polymyositis infiltrates, which are mainly intrafascicular (endomysial inflammation) with scattered individual muscle fiber necrosis.

Medical Care

The therapy of dermatomyositis involves general measures and measures to control both the muscle disease and the skin disease. In addition, some patients may need treatment for other systemic manifestations or complications.

General treatments

Bedrest is often valuable for those patients with severe muscle inflammation. In patients with muscle weakness, especially children, a program of physical therapy is useful to help prevent contractures that can complicate the disease when patients do not fully move their joints. For patients with dysphagia, recommending elevating the head of their bed and not eating before bedtime is useful, possibly preventing aspiration pneumonitis. Occasionally, nasogastric tube feeding may be needed to increase caloric input.

Treatments for muscle disease

The mainstay of therapy for the muscle disease is systemically administered corticosteroids. Traditionally, prednisone (1-2 mg/kg/d) is administered as initial therapy. Taper slowly to avoid relapse of the disease. Because most patients develop steroid-related toxic effects, many authorities begin an immunosuppressive or cytotoxic agent early in the course. Most clinical and published experience is with the use of methotrexate as a steroid-sparing agent, but azathioprine and mycophenolate mofetil have been used. Results with cyclophosphamide in severe cases have been disappointing. In patients for whom these measures fail, the use of monthly high-dose intravenous immunoglobulin (IVIG) for 6 months has proved beneficial in the short term. A recent report has suggested that rituximab, a chimeric antibody directed against $CD20^+$ B cells, may be effective. However, other reports have failed to produce positive results.

Treatments for skin disease

Therapy of the cutaneous disease is often difficult. Some patients present primarily with skin disease (ie, amyopathic dermatomyositis), while other patients present with a muscle component that is controlled but with significant ongoing skin disease. First-line therapy is to recognize that the patient is photosensitive and to prescribe sun avoidance and sun protective measures, including broad-spectrum sunscreens. Hydroxychloroquine and chloroquine have been beneficial in small, open-label case studies; however, roughly 20% of patients with dermatomyositis who are treated with an antimalarial agent develop a drug eruption. Methotrexate is useful. Recently, mycophenolate mofetil has been reported to be useful. Sirolimus may also be of use in some patients. IVIG not only benefits the muscle but also clears the skin lesions.

Calcinosis

This complication of the disease affects children and adolescents. Some believe that aggressive early treatment of the myositis may aid in preventing this complication. Once established, the process is debilitating in many patients. Although spontaneous remission is a possibility, it often occurs after many years. The use of the calcium channel blocker diltiazem (240 mg bid) is reportedly associated with gradual resolution of calcinosis in a small number of cases.

Surgical Care

Surgical care is usually not necessary. Some patients may request surgical removal of local areas of calcinosis.

Consultations

- Rheumatologist
- Dermatologist
- Neurologist
- Medical or surgical oncologist (for patients with cancer)
- Internal medicine specialist or pediatrician (depending on patient age)
- Pulmonologist

Diet

A well-balanced diet is useful. Patients with severe muscle inflammation may need extra protein to balance their loss. Patients with dysphagia should avoid eating before bedtime. They may require a special diet depending on the severity of the esophageal dysfunction.

Activity

Activity should be maintained as much as possible; however, avoid vigorous physical training when the myositis is active. Use exercises to maintain the patient's range of motion. Recommend sun avoidance and sun protective measures in patients with skin lesions.

Further Inpatient Care

Inpatient care is needed for patients with fulminant disease.

Further Outpatient Care

Monitoring disease activity is necessary at least on a monthly basis. Repeat measurements of muscle enzymes may aid in assessment of the activity of the myositis, along with clinical assessment of patients' strength. Machines are available that can aid in the quantification of strength, but they are not used widely. Skin disease is assessed with physical examination in conjunction with history. A system for judging the activity and damage associated with dermatomyositis is being developed. Annual physical examinations are useful to monitor for potential toxicity from therapy or for the presence of a malignancy. Malignancy evaluations should be conducted for at least the first 3 years following diagnosis. A report by

Hill et al (2001) suggested that the risk of malignancy never returns to baseline, even after 3 years; thus, vigilance is still warranted. The testing selected should be chosen based upon the patient's age, sex, race, and other symptoms or findings. Female patients should be screened for ovarian cancer. After 3 years, patients should be monitored as any other person of their same age, race, and sex.

In/Out Patient Meds

Prednisone is a first-line therapy. The dose is altered depending on the response of the patient's condition. Immunosuppressive/cytotoxic agents are used as steroid-sparing agents for the muscle disease. Methotrexate has been demonstrated to be useful for the skin disease even in the absence of significant muscle disease. Mycophenolate mofetil may also be useful for cutaneous disease. Antimalarials, particularly hydroxychloroquine, may be useful for the cutaneous disease. An increased risk of drug eruptions may exist in patients with dermatomyositis.

Intravenous immunoglobulin is used in patients for whom therapy with corticosteroids and immunosuppressives fails. This agent is useful for both the skin and the muscles. Biologic therapies including rituximab and TNF antagonists might be useful. However, their widespread use is discouraged until adequate, preferably controlled studies demonstrate efficacy and safety.

Transfer

Patients may be served better by a physician or a team of physicians who have experience in managing this relatively rare disorder. Transfer to a tertiary center is often warranted for initial care and even for follow-up care.

Deterrence/Prevention

Skin disease is exacerbated by sunlight and other sources of ultraviolet light. In addition, the muscle disease may be exacerbated. Sunscreens and sun protective measures are helpful in avoiding flares of the disease.

Complications

Calcinosis may complicate dermatomyositis in children and adolescents. Contractures can occur if the patient is immobile.

Prognosis

Patients with dermatomyositis who have malignancy, cardiac involvement, or pulmonary involvement or who are elderly (ie, >60 y) have a poorer prognosis. The disease may spontaneously remit in as many as 20% of the patients. About 5% of patients have a fulminant progressive course with eventual death. Therefore, many patients require long-term therapy.

PART 8: SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic lupus erythematosus (SLE) is a chronic, multifaceted inflammatory disease that can affect every organ system of the body. SLE is protean in its manifestations and follows a relapsing and remitting course. This article addresses what is known regarding the etiology, pathophysiology, clinical features, and treatment of SLE.

Pathophysiology

SLE is an autoimmune disorder that involves multisystem microvascular inflammation with the generation of autoantibodies. Although the specific cause of SLE is unknown, multiple factors are associated with the development of the disease. These include genetic, racial, hormonal, and environmental factors. Many immune disturbances, both innate and acquired, occur in SLE. One proposed mechanism for the development of autoantibodies involves a defect in apoptosis that causes increased cell death and a disturbance in immune tolerance. The redistribution of cellular antigens during apoptosis leads to a display of plasma and nuclear antigens on the cell surface. Thus, dysregulated (intolerant) lymphocytes begin targeting normally protected intracellular antigens. Immune complexes form in the microvasculature, leading to complement activation and inflammation. Moreover, antibody-antigen complexes deposit on the basement membranes of skin and kidneys. In active SLE, this process has been confirmed based on the presence of complexes of nuclear antigens such as DNA, immunoglobulins, and complement proteins at these sites. Antinuclear antibodies (ANAs) are present in the serum in virtually all patients with active SLE, and antibodies to native double-stranded DNA (dsDNA) are relatively specific for the diagnosis of SLE.

Frequency

Worldwide, the prevalence of SLE is variable, from 12 cases per 100,000 population in Britain to 39 cases per 100,000 population in Sweden. Although African Americans have a high prevalence of this disease, SLE is exceedingly rare among blacks who live in Africa. In New Zealand, disease prevalence is 50 cases per 100,000 population among Polynesians, compared with only 14.6 cases per 100,000 in the white population. The prevalence of SLE in US is approximately 1 case per 2000 population. The annual incidence averages 1 case per 10,000 population. Frequency varies with ethnicity.

Mortality and morbidity

The natural history of SLE varies from relatively benign disease to rapidly progressive and even fatal disease. Most patients are diagnosed at ages 14-64 years, and the disease often waxes and wanes in individual patients throughout life. Patients with isolated skin and musculoskeletal involvement have higher survival rates than those with renal and central nervous system (CNS) disease. Despite

improvements in overall survival rates, patients with SLE still have a death rate that is 3 times that of the general population.

The 10-year survival rate now approaches 90%; prior to 1955, the 5-year survival rate was less than 50%. Decreased mortality rates can be attributed to earlier diagnosis (including milder cases), improvement in disease-specific treatments, and advances in general medical care. One third of SLE-related deaths in the United States occur in patients younger than 45 years, making this a serious issue despite declining overall mortality rates.

Specific SLE-related deaths, such as those due to nephritis, usually occur within the first 5 years of symptom onset. Infectious complications related to active SLE and immunosuppressive treatment are now the most common cause of death in early active SLE. Cardiovascular disease and malignancy, which may be related to chronic inflammation and cytoxic therapies, are common etiologies of late mortality.

The Framingham Offspring Study demonstrated that women aged 35-44 with SLE had a 50-fold greater risk of myocardial infarction than healthy women. Causes of accelerated coronary artery disease (CAD) are likely multifactorial, including endothelial dysfunction, inflammatory mediators, corticosteroid-induced atherogenesis, and dyslipidemia related to renal disease. Active lupus (34%), infection (22%), cardiovascular disease (16%), and cancer (6%) accounted for deaths in 144 of 408 patients with SLE who were monitored over 11 years.

Race

Worldwide, different races appear to have varying rates of disease. However, because of different prevalence rates among people of the same race in different geographical locations, a clear conclusion cannot yet be drawn. A higher prevalence of SLE occurs in African American women (2.5- to 6-fold higher relative risk) in the United States than in white women. Black women in the United States tend to have a higher frequency of antibodies to dsDNA, with an associated higher rate of renal involvement. The influence of race on prognosis has been widely debated because black and Hispanic patients often have a poorer prognosis in the United States than whites do. However, links between socioeconomic status and prognosis suggest this association may be confounded. The essential nonexistence of SLE in West and Central Africa in contrast to high prevalence of the disease among African American women provides strong support for the importance of environmental influences.

Sex

SLE occurs predominantly in women of childbearing age, suggesting a role for hormonal factors in the pathogenesis of the disease. A hormonal influence

hypothesis is supported by the 6- to 10- fold higher incidence of SLE in women of reproductive age and a higher prevalence of SLE in men with Klinefelter disease. Additionally, pregnancy and administration of exogenous estrogen often precipitate exacerbations of SLE. Men at all ages have a risk of disease similar to that of women who are prepubertal or postmenopausal.

Age

A correlation between age and incidence of SLE mirrors peak years of female sex hormone production. Disease incidence is highest among women aged 14-64 years. Males do not have an age-related peak in incidence.

History

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect almost any organ system. Its presentation and course is highly variable, ranging from indolent to fulminant.

- Constitutional

Nonspecific fatigue, fever, arthralgia and weight changes are the most frequent symptoms in new cases or recurrent active SLE flares. Fatigue, the most common constitutional symptom, can be due to active SLE, medications, lifestyle habits, or affective disorders. Fatigue due to active SLE generally occurs in concert with other clinical and laboratory markers. Fever, another common yet nonspecific symptom, may also be due to many causes. Active SLE, infection, and drug fever are the most common etiologies. Careful history taking may help to differentiate these. Weight loss may occur with active disease. Weight gain may also be due to corticosteroid treatment or active disease such as nephrotic syndrome anasarca.

- Musculoskeletal

Arthralgia, myalgia, and arthritis represent the most common presenting symptoms in SLE. Small joints of the hands, wrists, and knees are involved most frequently. Migratory asymmetrical pain is often out of proportion with swelling.

- Dermatologic

Cutaneous manifestations of SLE comprise 3 diagnostic criteria and multiple other clues to a potential diagnosis of lupus. Malar rash describes an erythematous rash over the cheeks and nasal bridge that lasts from days to weeks and is occasionally painful or pruritic. A report of a photosensitive rash may be elicited from patients if they are asked if they have any unusual rash or symptom exacerbation after sun exposure. Discoid lesions often also develop in sun-exposed areas but are plaquelike lesions with follicular plugging and scarring. They may be part of systemic lupus or may represent discoid lupus without organ involvement, which is a separate diagnostic entity. Alopecia is a common yet less specific feature of SLE that often affects the temporal regions or creates a patchlike pattern of hair loss.

Asking patients if they note any hand color change or pain with cold exposure may yield a history of Raynaud phenomenon. A painful triphasic blue, white, and red color change is a classic description. Although it is not a specific finding for SLE, Raynaud phenomenon may be seen in up to 20-30% of patients with SLE. Other skin lesions related to but not specific to SLE include livedo reticularis, panniculitis (lupus profundus), bullous lesions, vasculitic purpura, and urticaria.

- Renal

The kidney is the most commonly involved visceral organ in SLE. Although only approximately 50% of patients develop clinically evident renal disease, biopsy studies demonstrate some degree of renal involvement in almost all patients. Glomerular disease usually develops within the first few years after onset and is usually asymptomatic. Acute nephritic disease may manifest as hypertension and hematuria. Nephrotic syndrome may cause edema, weight gain, or hyperlipidemia. Acute or chronic renal failure may cause symptoms related to uremia and fluid overload.

- Neuropsychiatric

Widely varying nomenclature has been used to describe SLE-related CNS manifestations, although broader syndromes are commonly reported. Headache is the most common neurological symptom, often with migraine or complex migraine features, although a clear association with SLE is debated. Mood disorders such as anxiety and depression are frequently reported. Cognitive disorders may be variably apparent in patients with SLE. Formal neuropsychiatric testing reveals deficits in 21-67% of patients with SLE. Whether this represents true encephalopathy, neurological damage, medication effects, depression, or some other process is unclear. Psychosis related to SLE may manifest as paranoia or hallucinations. Delirium represents a spectrum of fluctuating altered consciousness characteristic of SLE. Delirium may be caused by CNS vasculitis, encephalopathy, or the manifestations previously called organic brain syndrome. Seizures related to SLE may be generalized or partial and may precipitate status epilepticus. Stroke and transient ischemic attack (TIA) may be related to antiphospholipid antibody syndrome or vasculitis. Movement disorders include chorea and parkinsonism; additionally, transverse myelitis with spastic paraparesis is a rare but serious complication of SLE. Myelopathy, optic neuropathy, or other demyelinating disorders may occur. Mononeuritis may result in focal peripheral deficits such as foot drop. Sensory neuropathy or mixed polyneuropathy may also be reported. Aseptic meningitis may occur.

- Pulmonary

Pulmonary manifestations of SLE may manifest acutely or indolently, representing many different complications. Pleurisy with pleuritic chest pain with or without pleural effusions is the most common feature of acute pulmonary involvement. Shortness of breath or dyspnea may be due to many causes. Serositis due to pericardial or pulmonary effusions, pulmonary embolism, lupus pneumonitis, chronic lupus interstitial lung disease, complement-mediated pulmonary leukoaggregation, or infection may be related to lupus disease. Pulmonary hypertension without underlying parenchymal lung disease rarely occurs with symptomatic dyspnea or right heart failure. Hemoptysis may herald diffuse alveolar hemorrhage, a rare, acute, life-threatening pulmonary complication of SLE.

- Gastrointestinal

Gastrointestinal symptoms secondary to primary SLE and adverse effects of medication are common among persons with SLE. Abdominal pain in SLE is significant because it may be directly related to active lupus, including peritonitis, pancreatitis, mesenteric vasculitis, and bowel infarction. Nausea and dyspepsia are frequent symptoms in patients with active SLE and are sometimes difficult to correlate with objective evidence of gastrointestinal involvement. Jaundice due to autoimmune hepatitis may be reported.

- Cardiac

Heart failure or chest pain symptoms must be carefully examined in patients with SLE. Pericarditis that manifests as chest pain is the most common cardiac manifestation of SLE and may occur with or without a detectable pericardial effusion. Libman-Sacks endocarditis is noninfectious but may manifest with symptoms similar to those of infectious endocarditis. Myocarditis may occur in SLE with heart failure symptomatology. Accelerated ischemic CAD is associated with SLE and may present as atypical anginal equivalents in this predominantly female population. Coronary vasculitis that manifests as angina or infarction is rarely reported. Coronary thrombosis related to antiphospholipid antibodies is also rare.

- Hematologic

History of multiple cytopenias such as leucopenia, lymphopenia, anemia, or thrombocytopenia may suggest SLE, among other etiologies. Leukopenia and, more specifically, lymphopenia are common in SLE; this and hypocomplementemia may predispose persons with SLE to frequent infections. Thrombocytopenia may be mild or part of a thrombotic thrombocytopenic purpura (TTP)–like syndrome. Anemia is occasionally overlooked in young menstruating women.

- Other

History of recurrent early miscarriages or a single late pregnancy loss may be clues to lupus, or isolated antiphospholipid antibody syndrome. Family history of autoimmune disease should also raise further suspicion of SLE.

Physical

As discussed above, almost any organ system can be involved in active SLE. The constellation of several physical findings may suggest a diagnosis of SLE. For the American College of Rheumatology (ACR) diagnostic criteria.

- Constitutional
  - Fever may signal infection or an acute SLE flare.
  - Lymphadenopathy or splenomegaly may be found.
- Skin
  - Malar rash describes an erythematous rash over the cheeks and nasal bridge with classic nasolabial fold sparing, as seen in Image 2.
  - Photosensitive rash is often macular or diffusely erythematous in sun-exposed areas of the face, arms, or hands, as in Image 3.
  - Discoid lesions are plaquelike lesions with follicular plugging, which may create scarring. Again, these may represent limited discoid lupus or systemic SLE.
  - Erythema annular centrifugum describes unique nonscarring erythematous papules or plaques with central sparing or a more confluent appearance similar to that of psoriasis or lichen planus.
  - Alopecia in SLE often affects the temporal regions or creates a patchy pattern.
  - Livedo reticularis describes a lacy, mottled, erythematous skin pattern that develops in some patients with SLE or antiphospholipid antibody syndrome.
  - Raynaud phenomenon may be observed with blue, white, and red color change at the distal digital tips. Capillaroscopy can be performed with an ophthalmoscope to look for dilated capillary nailfold loops.
  - Oral ulcers may be noted, with palatal ulcers being most specific for SLE.
  - Panniculitis, bullous lesions, vasculitic purpura, and urticaria are other skin lesions that are sometimes seen in SLE.
- Musculoskeletal
    - Jaccoud arthropathy is the term for the nonerosive hand deformities due to chronic arthritis and tendonitis that develop in 10% of patients with SLE. This may mimic rheumatoid arthritis (RA) ulnar deviation and phalangeal subluxations.

- Small-joint arthritis of the hands and wrists is most frequent, followed by arthritis of the knees. Pain reports may be out of proportion to synovitis or swelling upon examination.
- Myositis that manifests as weakness rarely occurs and is more commonly related to overlap syndromes or corticosteroid-induced myopathy.
- Fibromyalgia may be concomitant with SLE, causing generalized widespread pain, arthralgia, and myalgia.

- Renal
  - Hypertension or hematuria may signal nephritic disease.
  - Edema of periorbital or peripheral regions and anasarca are common physical findings related to nephrotic syndrome or volume overload with renal failure.

- Neuropsychiatric
  - Altered mental status may be secondary to aseptic meningitis, seizures, psychosis, or organic brain syndrome.
  - Focal neurological deficits may represent stroke, TIA, or mononeuritis.
  - Mononeuritis manifests with the functional loss of one or a few isolated peripheral nerves. Mononeuritis is observed in some patients with SLE vasculitis or antiphospholipid disease.

- Cardiopulmonary
  - Pleuropericardial friction rubs and signs of effusions may be found.
  - Hypoxia, tachypnea, crackles, or gross hemoptysis may be signs of pneumonitis or diffuse intrapulmonary hemorrhage.
  - Hemodynamic instability and hypoxia may suggest pulmonary embolism.
  - Heart failure signs or arrhythmias may point to ischemia or inflammatory myocarditis.
  - Murmurs may represent Libman-Sacks endocarditis, superimposed infectious endocarditis, or thromboembolic disease.
  - Ischemic chest pain due to CAD may be observed in a patient with lupus with otherwise inactive disease.

- Gastrointestinal
  - Abdominal tenderness and pain may be observed in peritonitis, pancreatitis, mesenteric vasculitis, or non–lupus-related processes.
  - Lupus peritonitis is a less common serositis that may be present, even in the absence of ascites.

Causes

Although the specific cause of SLE is unknown, immune system dysregulation and immune complex tissue damage at sites such as the skin and kidneys, as well as direct antibody-mediated cytotoxicity that causes thrombocytopenia and hemolytic anemia, are suspected causes. Multiple immune disturbances may predispose to SLE.

- At least 10 different gene loci are known to increase the risk for SLE.
    - A genetic predisposition is supported by the 10-fold increase in concordance among monozygotic twins versus dizygotic twins.
    - Studies of the human leukocyte antigens (HLA) reveal that HLA-DR2 and HLA-DR3 occur more often in people with SLE than in the general population.
    - The presence of the null complement alleles and congenital deficiencies of complement (especially C4, C2, and other early components) are also associated with an increased risk of SLE.
    - The multitude of distinct genetic associations suggests a complex genetic predisposition for the disease, perhaps explaining the variable clinical courses and organ system involvement

Lab Studies

Systemic lupus erythematosus (SLE) is a diagnosis that must be based on the proper constellation of clinical findings and laboratory evidence. Familiarity with the diagnostic criteria helps clinicians to recognize SLE and to subclassify patients with this complex disease based on their pattern of target organ manifestations. The American College of Rheumatology (ACR) criteria summarize features necessary to diagnose SLE; they are summarized below with a useful mnemonic. The presence of 4 of the 11 criteria holds a sensitivity of 85% and a specificity of 95%. Keep in mind that individual features are variably sensitive and specific. Patients may present with any combination of clinical features and serologic evidence of lupus, ranging from indolent mild disease to fulminant acute initial presentations. The following is the ACR diagnostic criteria in SLE, presented in the "SOAP BRAIN MD" acronym:

- Serositis - Pleurisy, pericarditis
- Oral ulcers - Oral or nasopharyngeal, usually painless; palate is most specific
- Arthritis - Nonerosive Jaccoud type
- Photosensitivity - Unusual skin reaction to light exposure
- Blood disorders - Leukopenia, lymphopenia, thrombocytopenia, Coombs test–positive anemia

- o Renal involvement - Proteinuria (>0.5 g/d or positive on dipstick testing; cellular casts)
- o Antinuclear antibodies (ANAs) - Higher titers generally more specific (>1:160)
- o Immunologic phenomena - Lupus erythematosus (LE) cells; anti–double-stranded DNA (dsDNA); anti-Smith (Sm) antibodies; antiphospholipid antibodies (anticardiolipin immunoglobulin G [IgG] or immunoglobulin M [IgM] or lupus anticoagulant); biologic false-positive serologic test results for syphilis
- o Neurologic disorder - Seizures or psychosis
- o Malar rash - Fixed erythema over the cheeks and nasal bridge
- o Discoid rash - Raised rimmed lesions with keratotic scaling and follicular plugging
- In patients with high clinical suspicion or high ANA titers, additional testing is indicated. This may commonly include evaluation of antibodies to dsDNA, complement, and ANA subtypes such as Sm, SSA, SSB, and ribonucleoprotein (RNP) (often called the ENA panel). Screening laboratory studies to diagnose possible SLE should include a CBC count with differential, serum creatinine, urinalysis with microscopy, ANA, and, perhaps, basic inflammatory markers. The following are autoantibody tests used in SLE diagnosis:
  - o ANA - Screening test; sensitivity 95%; not diagnostic without clinical features
  - o Anti-dsDNA - High specificity; sensitivity only 70%; level variable based on disease activity
    - o Anti-Sm - Most specific antibody for SLE; only 30-40% sensitivity
    - o Anti-SSA (Ro) or Anti-SSB (La) - Present in 15% of patients with SLE and other connective tissue diseases such as Sjögren syndrome; associated with neonatal lupus
    - o Anti-ribosomal P - Uncommon antibodies that may correlate with lupus cerebritis
    - o Anti-RNP - Included with anti-Sm, SSA, and SSB in the ENA profile; may indicate mixed connective tissue disease with overlap SLE, scleroderma, and myositis
    - o Anticardiolipin - IgG/IgM variants measured with enzyme-linked immunoassay (ELISA) among the antiphospholipid antibodies used to screen for antiphospholipid antibody syndrome

- o Lupus anticoagulant - Multiple tests (eg, Direct Russell Viper Venom test) to screen for inhibitors in the clotting cascade in antiphospholipid antibody syndrome
- o Coombs test - Coombs test–positive anemia to denote antibodies on RBCs
- o Anti-histone - Drug-induced lupus (DIL) ANA antibodies often this type (eg, with procainamide or hydralazine; perinuclear antineutrophil cytoplasmic antibody [p-ANCA]–positive in minocycline-induced DIL)

- Other laboratory tests include the following:
  - o Inflammatory markers: Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels may be elevated in any inflammatory condition, including SLE; CRP levels change more acutely, and ESR lags behind disease changes.
  - o Complement levels: C3 and C4 levels are often depressed in patients with active SLE because of consumption by immune complex–induced inflammation. In addition, some patients have congenital complement deficiency that predisposes them to SLE.
  - o Complete blood count: Including differential diagnoses, CBC count may help to screen for leucopenia, lymphopenia, anemia, and thrombocytopenia.
  - o Urinalysis/urine protein: Screening tests are used to evaluate for proteinuria (>0.5 g/d or positive on dipstick testing), hematuria, casts, or pyuria.
  - o Creatinine: Creatinine evaluation is useful to monitor kidney disease activity.
  - o Liver function tests: These may be mildly elevated in acute SLE or in response to therapies such as azathioprine or nonsteroidal anti-inflammatory drugs (NSAIDS).
  - o Creatinine kinase: Creatinine kinase levels may be elevated in myositis or overlap syndromes.

Imaging Studies

Joint radiography often provides little evidence of SLE given the absence of erosions, even in the presence of Jaccoud arthropathy with deformity or subluxations. The most common radiographic changes include periarticular osteopenia and soft tissue swelling. Chest radiography and chest CT scans can be

used to monitor interstitial lung disease and to assess for pneumonitis, pulmonary emboli, and alveolar hemorrhage. Brain MRI/magnetic resonance angiography (MRA) is used to evaluate CNS lupus for white-matter changes, vasculitis, or stroke, although findings are often nonspecific. Echocardiography is used to assess for pericardial effusion, pulmonary hypertension, or verrucous Libman-Sacks endocarditis.

Procedures

Lumbar puncture may be performed to exclude infection with fever or neurologic symptoms. Nonspecific elevations in cell count and protein level and decrease in glucose level may be found in the cerebrospinal fluid of patients with CNS lupus. Renal biopsy is used to identify the specific type of glomerulonephritis, to aid in prognosis, and to guide treatment. Another benefit of renal biopsy is to distinguish renal lupus from renal thrombosis, which may complicate antiphospholipid antibody syndrome and require anticoagulation rather than immunomodulatory therapy. Skin biopsy can help to diagnose SLE or unusual rashes in patients with SLE. Many different rashes may herald SLE, making review by a dermatopathologist important.

Histologic Findings

Renal biopsy confirms the presence of lupus nephritis, aids classification of SLE nephritis, and guides therapeutic decisions. The World Health Organization classification for lupus nephritis is based on light microscopy, electron microscopy, and immunofluorescence findings. The following is the International Society of Nephrology 2003 revised classification of SLE nephritis (Table 10):

Table 10

Classification of SLE nephritis accordingly International Society of Nephrology (2003)

Class	Stage	Microscopy findings
Class I	Minimal mesangial	Normal light microscopy findings; abnormal electron microscopy findings
Class II	Mesangial proliferative	Hypercellular on light microscopy
Class III	Focal proliferative	<50% of glomeruli involved
Class IV	Diffuse proliferative	>50% of glomeruli involved; classified segmental or global; aggressively treated

| Class V | Membranous | Predominantly nephrotic disease |
| Class VI | Advanced sclerosing | Chronic lesions and sclerosis |

Lupus skin rash often demonstrates inflammatory infiltrates at the dermoepidermal junction and vacuolar change in the basal columnar cells. Discoid lesions demonstrate more significant skin inflammation, with hyperkeratosis, follicular plugging, edema, and mononuclear cell infiltration at the dermoepidermal junction. In many SLE rashes, immunofluorescent stains demonstrate immunoglobulin and complement deposits at the dermoepidermal basement membrane.

Medical Care

Care of patients with systemic lupus erythematosus (SLE) depends on disease severity. Periodic follow-up and laboratory testing, including urinalyses, are imperative to detect signs and symptoms of new organ system involvement and to monitor response or adverse reactions to therapies. CBC count with differential, creatinine, and urinalyses aid in detection of new organ system involvement and in monitoring response to therapies. At least quarterly visits are recommended in most cases. Fever, skin, musculoskeletal, and serositis represent milder disease manifestations, which may wax and wane with disease activity. These are often controlled with low-potency medications or short steroid courses. CNS involvement and renal disease must be recognized as more severe disease manifestations and are often treated with more aggressive immunosuppression.

Acute emergencies in SLE include severe neurologic involvement, systemic vasculitis, profound thrombocytopenia with a TTP-like syndrome, rapidly progressive glomerulonephritis, or diffuse alveolar hemorrhage. Rare serious manifestations such as TTP, diffuse alveolar hemorrhage, or profound steroid-refractory thrombocytopenia may require plasma exchange or intravenous immunoglobulin (IVIG), respectively.

Preventative care measures are necessary to minimize the risks of steroid-induced osteoporosis and accelerated atherosclerotic disease. The ACR Guidelines for the prevention of glucocorticoid-induced osteoporosis suggest traditional steps and the consideration of prophylactic bisphosphonate therapy. Recently, numerous authors have also advocated drafting cardiovascular prevention guidelines that equate SLE as a "CAD risk-equivalent" similar to diabetes mellitus. This is based on a 10-year coronary event rate of 13-15% in patients with active SLE compared with a 10-year event rate of 18.8% in patients with known pre-existing coronary heart disease. The European League Against Rheumatism (EULAR) recently released new recommendations for the treatment of SLE.

Consultations

The multisystemic nature of this chronic disease often requires involvement of consultants, depending on the organ system involved. Consultation with any of the following specialists may be necessary:

- Rheumatologist
- Infectious disease specialist
- Neurologist
- Pulmonologist
- Cardiologist
- Gastroenterologist
- Nephrologist
- Dermatologist
- Hematologist

Diet

No diet-based treatment of SLE has been proven effective.

Activity

Patients should be reminded that activity may need to be modified as tolerated. Specifically, stress such as physical illness may precipitate SLE flares. Additionally, persons with SLE should wear sunscreen and protective clothing or avoid sun exposure to limit photosensitive rash or disease flares.

Further Inpatient Care

Fever in patients with systemic lupus erythematosus (SLE) is grounds for inpatient admission because of the difficulty of distinguishing a disease flare from infection in these immunocompromised hosts. Patients with SLE are often complement deficient and at risk for encapsulated organisms. For example, meningococcemia in young females with lupus may be catastrophic. Stress-dose steroid protocols should be used in patients receiving maintenance corticosteroids who are admitted with infectious or perioperative stress.

Further Outpatient Care

Periodic follow-up and laboratory testing, including urinalyses, are imperative to detect signs and symptoms of new organ system involvement and to monitor response and adverse reactions to therapies. Perform at least 1 screening urinalysis per year to assess for nephritis. Immunization against encapsulated organisms is advised. This may include meningococcal vaccination, Pneumovax, and routine Haemophilus influenzae childhood vaccination. Annual influenza vaccine is also encouraged.

Transfer

TTP should prompt transfer to a center capable of offering plasma exchange therapy. CNS lupus with depressed consciousness may prompt ICU transfer and consideration of protective intubation.

Deterrence/Prevention

Avoid ultraviolet light and sun exposure to minimize worsening symptoms due to photosensitivity. Antimalarial therapy (hydroxychloroquine) has been shown to prevent relapses and to improve mortality. Estrogen therapies have typically been avoided to prevent disease flares; progesterone contraception has been encouraged. However, recent literature suggests that oral contraceptives may not be associated with disease flares or thrombosis risk in mild lupus without antiphospholipid antibodies. High rates of sulfa allergy and anecdotal reports of disease flares have also led to avoidance of sulfa-based medications in patients with SLE. Aggressive blood pressure and lipid goals may help to prevent CAD or renal disease progression. Angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers may be useful in patients with chronic renal disease. Calcium, vitamin D, and prophylactic bisphosphonates may reduce the risk of glucocorticoid-induced osteoporosis.

Complications

Opportunistic infections can develop, most often in patients receiving chronic immunosuppressive therapy. Osteonecrosis, especially of the hips and knees, is not uncommon and is related to prolonged high-dose corticosteroid usage. Premature atherosclerotic disease and myocardial infarction are possible complications.

Prognosis

Prognosis for SLE is highly variable. Renal and CNS involvement tend to be associated with a poorer prognosis.

PART 9: SYSTEMIC SCLEROSIS

Systemic sclerosis (SSc) is a systemic connective tissue disease. Characteristics of systemic sclerosis include essential vasomotor disturbances; fibrosis; subsequent atrophy of the skin, subcutaneous tissue, muscles, and internal organs (eg, alimentary tract, lungs, heart, kidney, CNS); and immunologic disturbances accompany these findings.

Definition.

The term systemic sclerosis is used to describe a systemic disease characterized by skin induration and thickening accompanied by various degrees of tissue fibrosis

and chronic inflammatory infiltration in numerous visceral organs, prominent fibroproliferative vasculopathy, and humoral and cellular immune alterations.

The American College of Rheumatology (ACR) criteria for the classification of systemic sclerosis require one major criterion or two minor criteria, as follows:

- Major criterion: Proximal scleroderma is characterized by symmetric thickening, tightening, and induration of the skin of the fingers and the skin that is proximal to the metacarpophalangeal or metatarsophalangeal joints. These changes may affect the entire extremity, face, neck, and trunk.
- Minor criteria
  - Sclerodactyly includes the above major criterion characteristics but is limited to only the fingers.
  - Digital pitting scars or a loss of substance from the finger pad: As a result of ischemia, depressed areas of the fingertips or a loss of digital pad tissue occurs.
  - Bibasilar pulmonary fibrosis includes a bilateral reticular pattern of linear or lineonodular densities most pronounced in basilar portions of the lungs on standard chest roentgenograms. These densities may assume the appearance of diffuse mottling or a honeycomb lung and are not attributable to primary lung disease.

Pathophysiology

Excessive collagen deposition causes skin and internal organ changes. Many factors, including environmental factors, can lead to immunologic system disturbances and vascular changes. Endothelial alterations may lead to a cascade of stimulatory changes that involve many cells, including fibroblasts, T lymphocytes, macrophages, and mast cells. In turn, the activated cells secrete a variety of substances, including cytokines and their soluble receptors and enzymes and their inhibitors. These substances lead to changes in the extracellular matrix compounds, including fibronectin; proteoglycans; and collagen types I, III, V, and VII. Increased collagen deposition in tissues is a characteristic feature of systemic sclerosis. Increased collagen production or disturbances in its degradation can cause excessive collagen deposition in tissues.

Fibrosis can be caused by profibrotic cytokines, including transforming growth factor-beta (TGF-beta), interleukin-4 (IL-4), platelet-derived growth factor (PDGF), and connective-tissue growth factor. The vasculopathy may be linked to TGF-beta and PDGF, while the diminution of lesional cutaneous blood vessels can be attributed to antiendothelial cell autoantibodies. The activation of the immune system is of paramount importance in the pathogenesis of systemic sclerosis. Antigen-activated T cells, activated infiltrate early, infiltrate the skin, and produce

the profibrotic cytokine IL-4. B cells may contribute to fibrosis, as deficiency of CD19, a B-cell transduction molecule, results in decreased fibrosis in animal models.

Different factors, including genetic, environmental, vascular, autoimmunologic, and microchimeric factors are involved in systemic sclerosis pathogenesis. One theory states that antigens from the human leukocyte antigen (HLA) histocompatability complex, including HLA-B8, HLA-DR5, HLA-DR3, HLA-DR52, and HLA-DQB2, are involved in systemic sclerosis. Some data suggest that apoptosis and the generation of free radicals may be involved in the pathogenesis of systemic sclerosis. In systemic sclerosis, affected organs and systems include the skin, lungs, heart, digestive system, kidneys, muscles, joints, and nervous system.

Frequency

Systemic sclerosis is estimated to occur in 2.3-10 people per 1 million. Systemic sclerosis is rare in the resident population of Japan and China. Systemic sclerosis is a rare disease. Systemic sclerosis is diagnosed in approximately 67 male patients and 265 female patients per 100,000 people each year.

Mortality and morbidity

The mortality rate is increasing in the United States and Europe; as many as 3.08 persons are affected per 1 million. Generally, renal and lung changes are responsible for death in patients with systemic sclerosis. Pulmonary hypertension leads to 12% of systemic sclerosis–related deaths. Lung fibrosis and heart changes are responsible for 9% of systemic sclerosis – related deaths.

Race, sex and age particularities

No apparent racial predominance exists. However, systemic sclerosis is rare in the resident population of Japan and China. Diffuse systemic sclerosis (dSSc) occurs more often in black women than in white women. Overall, a substantial female predominance exists, with a female-to-male ratio of 3-6:1. However, dSSc occurs equally in males and females. The limited form of systemic sclerosis (lSSc) has a strong female predominance, with a female-to-male ratio of 10:1. Systemic sclerosis usually appears in women aged 30-40 years, and it occurs in slightly older men. In approximately 85% of cases, systemic sclerosis develops in individuals aged 20-60 years. Cases also are observed in children and in the elderly population.

History of Systemic sclerosis

Systemic sclerosis can have many different presentations. It involves the skin and many internal organs. Therefore, the presenting symptoms may differ among patients.

- Cutaneous pruritus is common.

- [Raynaud phenomenon](#), or whitening of the hands on exposure to cold, is a common finding. Pain in the affected digits, blanching, cyanosis, and hyperemia can follow.
- Difficulty in swallowing solid foods can be followed by difficulty with swallowing liquids and subsequent nausea, vomiting, weight loss, abdominal cramps, blotting diarrhea, and fecal incontinence.
- The patient can have shortness of breath on exertion and, subsequently, at rest.
- Palpitations may occur without characteristic pain in thoracic cavity.
- The patient may have a nonproductive cough.
- Atypical chest pain, fatigue, dyspnea, and hypertension may be present.
- Joint pain, limitation of movement, joint swelling, and muscle pain may be present. Systemic sclerosis begins as joint pain in 15% of patients. It begins as inflammatory myopathy in 10% of patients.
- Weakness is present in 80% of patients.
- Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis were assessed. In one study, 114 patients underwent examination, including a determination of skin thickening. Signs and symptoms were a significant correlate of all outcomes. Patient-reported dependent edema significantly correlated with all outcomes. For disability, significant correlates were physician-determined joint tenderness and number of tender points and patient-reported joint pain with motion, joint contracture, extremity ulcers other than digital, and dyspnea.

Physicalexamination findings
- According to the American College of Rheumatology (ACR), features characteristic for scleroderma are divided into 2 groups:
- Major features include centrally located skin sclerosis that affects the arms, face, and/or neck.
- Minor features include sclerodactyly, erosions, atrophia of the fingertips, and bilateral lung fibrosis.
- Systemic sclerosis is diagnosed when a patient has 1 major and 2 minor criteria.

Cutaneous involvement has 3 phases: edematous, indurative, and atrophic. Skin becomes thickened and tight. Systemic sclerosis is divided into 5 forms: dSSc, lSSc, transitory form (dSSc/lSSc), systemic scleroderma sine scleroderma, and malignant scleroderma. The principal forms are dSSc and lSSc. In addition to the

following features, dSSc is characterized by Raynaud phenomenon that precedes the development of skin changes by approximately 1 year:
- Generalized skin fibrosis of the chest and limbs
- Areas of skin hyperpigmentation and hypopigmentation
- Tendon friction rubs
- Early involvement of the lungs, kidneys, digestive system, and heart
- Antibodies against topoisomerase I DNA (Scl 70) in approximately 30% of patients
- Nail-fold capillary dilatation and capillary destruction

lSSc is characterized by sclerotic changes of the hands, face, feet, and forearms in addition to the following features:
- Atrophic changes of the ala nasi and lips, facial amimia
- Telangiectasia of the skin
- Late involvement of the lungs and late development of pulmonary hypertension
- Anticentromere antibodies in approximately 70-80% of patients
- Dilated capillary loops in nail folds
- Cutaneous calcification
- dSSc and/or lSSc are described in a few cases in which internal organ changes preceded or simultaneously occurred with cutaneous changes.
- Systemic scleroderma sine scleroderma is difficult to diagnose because only internal organs are involved. Systemic scleroderma sine scleroderma usually is diagnosed after the patient's death.
- Malignant scleroderma most often occurs in men, usually in elderly men. An accelerated course of malignant scleroderma leads to death.

Causes

Systemic sclerosis is an autoimmunologic disease, but the pathogenesis is only partially understood. Certain factors are well known to trigger occurrence of the disease or create a similar clinical appearance. Environmental factors include exposure to the following:
- Vibration injury (similar vascular changes)
- Silica
- Organic solvents (eg, toluene, benzene, xylene)
- Aliphatic hydrocarbons (eg, hexane, vinyl chloride, trichloroethylene)
- Epoxy resin
- Amino acid compound L-5-hydroxytryptophan
- Pesticides

- Drugs (eg, bleomycin, carbidopa, pentazocine, cocaine, penicillamine, vitamin K): A limited form of cutaneous systemic sclerosis has been described with paclitaxel in with the setting of breast cancer.
- Appetite suppressants (eg, phenylethylamine derivatives)
- Substances used in cosmetic procedures (eg, silicone or paraffin implants)

Lab Studies

The role of the immune system in the pathogenesis of systemic sclerosis remains unclear; however, patients have specific humoral and cell-mediated immunity abnormalities. Antinuclear antibodies are present in about 95% of the patients, usually with a speckled or homogenous pattern. A nucleolar pattern, although less common, is more specific for systemic sclerosis. Cell-mediated abnormalities involve lymphocytes, mononuclear phagocytes, and mast cells. Topoisomerase I antibodies (formerly Scl-70) are present in approximately 30% of patients with diffuse disease (absent in limited disease) and are associated with pulmonary fibrosis. Anticentromere antibodies are present in about 60-90% of patients with limited disease and are rare in patients with diffuse disease. Fibrillarin antibodies and antibodies to U3 ribonucleoprotein (RNP) may be present. Anti-U3RNP is present mostly in patients with diffuse disease with overlap syndromes. In addition, these antibodies are more common in patients with skeletal muscle involvement and pulmonary disease. Anti-ThRNP is present mostly in limited disease and is associated with more extensive visceral disease. Anti-PM-Scl is present in limited and overlap states and is associated with myositis and renal involvement. A microangiopathic hematologic picture may precede renal crisis. Current studies report new autoantibodies in systemic sclerosis that may play a role in its pathogenesis; these autoantibodies include antiendothelial cell (AECA), anti-fibrillin (FBN1), anti–matrix metalloproteinase (MMP)–1 and anti–MMP-3, and anti–platelet-derived growth factor receptor (PDGFr).

Imaging Studies

CT scan: HRCT scan is required to evaluate pulmonary fibrosis. Imaging may reveal a ground-glass appearance, possibly indicating active alveolitis. Ground-glass appearance on HRCT scan is the first abnormality observed during the development of lung fibrosis and is subsequently replaced by honeycombing and traction bronchiectasis or bronchiolectasis. HRCT scanning should be performed every 6 months if active alveolitis or interstitial pulmonary fibrosis is present and every year if these abnormalities are not present.

Radiography: Chest radiography is a very insensitive imaging procedure that shows only late findings of pulmonary fibrosis, such as increased interstitial

markings. Extremity radiography should be performed to reveal calcinosis and resorption of the distal tufts of the digits.

Echocardiography: Conduct this test to evaluate the patient's pulmonary artery pressure and to assess septal fibrosis or pericardial effusions. Roughly 30% of patients have asymptomatic pericardial effusions.

Right-heart catheterization: This remains the standard criterion for diagnosing pulmonary hypertension and is performed after an elevated pulmonary artery pressure is found on echocardiographic screening.

Esophagraphy: Perform this test to document esophageal dysmotility and incompetent LES.

Other Tests

- Pulmonary function testing (every 6 months)

Conduct this test to evaluate the DLCO, forced vital capacity (FVC) and total lung capacity (TLC). A FVC/DLCO of greater than 1.6 increases the likelihood of pulmonary hypertension. This is a very sensitive technique for detecting early fibrotic changes, alveolitis, and pulmonary hypertension. An isolated reduction in the DLCO is the best predictor of pulmonary hypertension.

Serum N-terminal pro-brain natriuretic peptide (NT-proBNP): Elevation of NT-proBNP levels may correlate with early pulmonary hypertension.

Cardiac rhythm monitoring: Perform 24-hour ambulatory Holter monitoring to evaluate arrhythmias and serious conduction defects. Esophagogastroduodenoscopy, esophageal manometry, and pH monitoring studies: Conduct these studies to survey and evaluate the upper GI system.

Procedures

- Nail fold capillary microscopy.
- Bronchoscopy with bronchoalveolar lavage to assess active lung inflammation

Histologic Findings

Systemic sclerosis is characterized by excessive fibrosis in the skin and other affected organs. The skin and lungs also show prominent T-lymphocyte infiltration. A severe fibroproliferative vasculopathy that affects small arteries and arterioles is universally present in affected organs. Platelet microthrombi are often found in the lumen of the narrowed vessels.

Medical Care

Skin thickening can be treated with D-penicillamine and other experimental drugs or interventions (interferon-gamma, mycophenolate mofetil, cyclophosphamide, photopheresis, allogeneic bone marrow transplantation). However, the US Food and Drug Administration (FDA) has not approved any

therapies for systemic sclerosis. No placebo-controlled studies have demonstrated superiority, although some large uncontrolled series suggest beneficial effect from D-penicillamine. Interferon-gamma is effective, but its use is limited because it activates inflammatory and endothelial cells.

Pruritus can be treated with moisturizers, histamine 1 (H1) and histamine 2 (H2) blockers, tricyclic antidepressants, and trazodone.

Raynaud phenomenon can be treated with calcium channel blockers (to tolerance), prazosin, prostaglandin derivatives such as prostaglandin E1, dipyridamole, aspirin, and topical nitrates. In the event of thrombosis and vascular flow compromise, a tissue plasminogen activator, heparin, and urokinase may be necessary. In very severe cases, patients may benefit from a pharmacologic cervical sympathectomy or from surgical digital sympathectomy. Bosentan, a dual endothelin receptor antagonist, is under investigation and may decrease new digital ulcer formation. Sildenafil has also been shown to be effective and tolerated in patients with primary Raynaud and is currently approved to treat pulmonary hypertension.

GI symptoms may be treated with antacids, H2 blockers, reflux and aspiration precautions, proton pump inhibitors, prokinetic agents, octreotide, smaller meals, and laxatives.

Pulmonary fibrosing alveolitis may be treated with cyclophosphamide, either orally or in intravenous pulses. Pulmonary hypertension may require supplemental oxygen. Bosentan is effective in treating primary (idiopathic) pulmonary hypertension, as well as pulmonary hypertension associated with systemic sclerosis, and has demonstrated substantial clinical and hemodynamic improvement in patients with systemic sclerosis–associated pulmonary hypertension. Numerous newer agents are available to treat pulmonary hypertension or are currently being tested in open and randomized controlled trials. These newer agents include other endothelin receptor antagonists such as sitaxsentan and ambrisentan; prostaglandin derivatives such as epoprostenol, treprostinil, beraprost and iloprost; and phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil. Preliminary nonrandomized studies have also shown benefit from mycophenolate mofetil.

Renal crisis episodes are best prevented and treated with the aggressive use of ACE inhibitors at the earliest signs of hypertension.

Myositis may be treated cautiously with steroids (first choice), methotrexate, and azathioprine. Doses of prednisone greater than 40 mg/d are associated with a higher incidence of sclerodermal renal crisis.

Arthralgias can be treated with acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs).

Proteinuria is not uncommon in patients with scleroderma who are receiving D-penicillamine.

Surgical Care

Digital sympathectomy may be used in patients with severe Raynaud phenomenon who have an unrelenting acute attack and who are threatened by digital loss. Debridement or amputation may be required in severe ischemic or infected digital lesions. Hand surgery may be performed to correct severe flexion contractures. Removal of severely painful or draining of infected calcinotic deposits is occasionally required.

Consultations

Ensure that all patients with systemic sclerosis are treated in conjunction with an experienced rheumatologist who has a full understanding of the disease, the complications of the therapies, and the frequently serious adverse effects.

Diet

Instruct the patient to avoid large does of vitamin C (>1000 mg/d) because it stimulates collagen formation and may enhance its deposition.

Activity

Ensure that the patient maintains a core body temperature to try to minimize the Raynaud phenomenon. Assist the patient in avoiding contamination of any skin wound caused by ischemic lesions or calcinosis. Digital ulcers must be kept clean and dry. Instruct the patient to perform continuous physical and occupational therapy to maintain range of motion and to minimize or delay contractures.

Further Inpatient Care

Patients may need to be treated by other subspecialists depending on their symptoms (eg, cardiologist, pulmonologist, gastroenterologist, nephrologist, hand surgeon). The value of serology testing is for initial diagnosis and assessment of associated conditions, but it is of little use for monitoring disease activity. Instruct the patient to maintain a core body temperature to minimize the risk of Raynaud phenomenon flare. Renal and lung transplantation are performed in specialized centers for patients with end-stage renal or lung involvement. Current studies of autologous stem cell transplantation are ongoing and may lead to disease remission.

Further Outpatient Care

Instruct the patient to avoid digital or skin trauma, cold exposure to the skin, and smoking and follow up for other complications. Evaluate the patient every 3-6 months, depending on the disease activity and progression. Serial skin scoring

(also known as modified Rodnan skin score) is useful for monitoring skin changes over time. New techniques such as durometry, a technique for objectively measuring skin involvement, are currently being studied.

Deterrence/Prevention

Instruct the patient to stop smoking, to avoid cold exposure, and to treat skin ulcerations prior to tissue breakdown.

Complications

- Digital infarctions
- Pulmonary hypertension
- Myositis
- Renal failure
- Wound infections

Prognosis

For patients with limited involvement, 10-year survival rates are roughly 60-70%. For patients with diffuse disease, 10-year survival rates are 20%. Factors that imply a more severe prognosis are as follows:

- Youth
- African descent
- Rapid progression of skin symptoms
- Extent of skin involvement
- Anemia
- Elevated erythrocyte sedimentation rate (ESR)
- Pulmonary and renal involvement

List of References

1. Arvikar SL, Crowley JT, Sulka KB, Steere AC. Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease. Arthritis Rheumatol. 2017;69(1):194-202.

2. Bonafede M, Oko-Osi H, Gharaibeh M, et al. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept. J Manag Care Spec Pharm. 2020; 26(2):211-220.

3. Braun J., Landewe R., Hermann K.G. et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006; 54(5): 1646-1652.

4. Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nat Rev Rheumatol. 2019;15(6):364-381.

5. Chen J., Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006; 33(4): 722-731.

6. Chen J., Liu C., Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006;CD004524.

7. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017; 17(1):65-70

8. Davis J.C., Van Der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48(11): 3230-6.

9. Gharaibeh M, Bonafede M, McMorrow D, Hernandez EJM, Stolshek BS. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data. J Manag Care Spec Pharm. 2020; 26(8):1039-1049. doi: 10.18553/jmcp.2020.26.8.1039. Erratum in: J Manag Care Spec Pharm. 2020;26(10):1256.

10. Grader-Beck T., Wigley F.M. Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am. 2005; 31(3): 465-481.

11. Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019;15(5):541-552.

12. Hoffman R.W. Mixed connective tissue disease, overlap syndromes and Sjogren's syndrome. In: Lahita RG, ed. Systemic Lupus Erythematosus. 4th ed. San Diego, Calif: Academic Press; 2004.

13. Hoffman R.W. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol. 2004;113(1):4-13.

14. Jenks K, Treharne GJ, Garcia J, Stebbings S. The ankylosing spondylitis quality of life questionnaire: validation in a New Zealand cohort. Int J Rheum Dis. 2010; 13(4): 361-6.

15. Khare S.D., Luthra H.S., David C.S. Animal models of human leukocyte antigen B27-linked arthritides. Am. Rheum Dis Clin North Am. 1998; 24(4): 883-894.

16. Lockshin M.D. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis. 2006; 64(1-2):57-59.

17. Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016;16(2):129-34.

18. Mathew AJ, Ravindran V. Infections and arthritis. Best Pract Res Clin Rheumatol. 2014;28(6):935-59.

19. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4(2):295-306.

20. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516-28.

21. Nielsen MA, Lomholt S, Mellemkjaer A, Andersen MN, Buckley CD, Kragstrup TW. Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune-Mediated Inflammatory Arthritis. ACR Open Rheumatol. 2020; 2(1):3-10.

22. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778.

23. Reveille J.D., Arnett F.C. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005;118(6):592-603.

24. Richette P, Doherty M, et al. "2016 updated EULAR evidence-based recommendations for the management of gout," Annals of the Rheumatic Diseases., 2016. DOI:10.1136/annrheumdis-2016-209707

25. Sampaio-Barros P.D., Bertolo M.B., Kraemer M.H. et al. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin. Rheumatol. 2001; 20(3): 201-206.

26. Schmalzing M, Behrens F, Schwaneck EC, Koehm M, Greger G, Gnann H, Burkhardt H, Tony HP. Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab. Medicine (Baltimore). 2020 May;99(19):e20201.

27. Singh JA, Hossain A, Mudano AS, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017; 5(5):CD012657.

28. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016-210715. [Epub ahead of print]

29. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.

30. Sudoł-Szopińska I, Schueller-Weidekamm C, Plagou A, Teh J. Ultrasound in Arthritis. Radiol Clin North Am. 2017;55(5):985-996.

31. Tkacz J, Gharaibeh M, DeYoung KH, Wilson K, Collier D, Oko-Osi H. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate. J Manag Care Spec Pharm. 2020; 26(3):285-294.

32. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005; 52(7): 2103-2108.

33. van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2): 582-591

34. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2): 582-591.

35. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54(7): 2136-2146.

36. Wanders A., Heijde D., Landewe R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6): 1756-1765.

37. Zochling J.Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011; 63 Suppl 11:S47-58.